[go: up one dir, main page]

HK40028776B - Heterocyclic compounds as pad inhibitors - Google Patents

Heterocyclic compounds as pad inhibitors Download PDF

Info

Publication number
HK40028776B
HK40028776B HK62020018519.2A HK62020018519A HK40028776B HK 40028776 B HK40028776 B HK 40028776B HK 62020018519 A HK62020018519 A HK 62020018519A HK 40028776 B HK40028776 B HK 40028776B
Authority
HK
Hong Kong
Prior art keywords
alkyl
radical
aryl
heteroaryl
hydrogen
Prior art date
Application number
HK62020018519.2A
Other languages
Chinese (zh)
Other versions
HK40028776A (en
Inventor
古鲁林加帕·哈勒
瓦米 阿提萨亚曼尼·杰亚拉杰·杜赖斯
布基·雷迪·普拉
N·V·S·K·拉奥
斯里德哈兰·拉贾格帕兰
Original Assignee
朱比兰特埃皮帕德有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朱比兰特埃皮帕德有限公司 filed Critical 朱比兰特埃皮帕德有限公司
Publication of HK40028776A publication Critical patent/HK40028776A/en
Publication of HK40028776B publication Critical patent/HK40028776B/en

Links

Description

Heterocyclic compounds as PAD inhibitors
Technical Field
The present disclosure relates to novel heterocyclic compounds of formula (I), (II) and (III) and polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, which act as PAD4 inhibitors.
Also described herein are processes for preparing the heterocyclic compounds of formulas (I), (II), and (III) above, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, and metabolites thereof, which are useful for preparing such compounds.
The compounds described herein are PAD4 inhibitors and are useful in the treatment of a variety of disorders, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, cutaneous lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis, and psoriasis.
Background
PAD (protein arginine deiminase) consists of a family of enzymes that convert peptidyl arginine to peptidyl citrulline. The process of this transformation is known as citrullination (j.e. jones, et al. Curr. Opin. Drug discov. Devel.,2009,12, 616-627). Five isoenzymes of the PAD family are found in mammals, namely PAD1, PAD2, PAD3, PAD4 and PAD6. The amino acid sequences of these isozymes share 70% to 95% sequence similarity with mammals. Citrullination is a post-translational modification of arginine to citrulline by a closely related enzyme of the PAD family, which affects many physiological and pathological processes.
Citrullination is involved in a variety of diseases (ailment), such as cell differentiation (k.nakashima et al., j.biol.chem.,1999,274, 27786-27792), stem cell pluripotency (m.a.christophorou et al., nature,2014,507, 104-108), apoptosis (g.y.liu, apoptosis,2006,11, 183-196), neutrophil Extracellular Trap (NET) formation (y.wang et al, j.cell biol.,2009,184, 205-213), transcriptional regulation (p.li et al., mol.cell l.,2008,28, 4745-4758), antigen processing in autophagy (j.m.ireland et al, j.irel et al, k.chem., 1999, chem. J.exp. Med.,2011,208, 2625-2632), inflammation (d.makrygiannakis et al, ann.rheum.dis.,2006,65, 1219-1222), keratinization of the skin (e.canti et al, nat.rev.mol.cell biol.,2005,6, 328-340), demyelination in multiple sclerosis (f.g.masternardi et al, j.neurosci.,2006,26, 11387-11396), chemokine modulation (t.loos et al, blood,2008,112, 2648-2656), spinal cord injury repair (s.lange et al, dev.biol.,2011,355, 205-214), and a variety of normal cellular processes.
The role of PAD in the pathogenesis of many diseases is becoming more and more pronounced, as the enzymes that catalyze citrullination also produce autoantibodies that recognize citrullinated proteins. The introduction of citrulline, a product of PAD activity, alters both the structure and function of proteins. At the physiologically active level, PAD regulates many cell signaling pathways, such as cell differentiation, apoptosis, and gene transcription: (et al int.J.biochem.cell biol.,2006,38, 1662-1677). Over the last decade it has become increasingly apparent that abnormal PAD activity has been implicated in many human inflammatory diseases, such as Rheumatoid Arthritis (RA), alzheimer's disease and multiple sclerosis (n.k.achharya, j.autoimmun.,2012,38, 369-380).
PAD4 is also known for deamination or citrullination of a variety of proteins both in vitro and in vivo, as a result of which different functional responses are elicited in a variety of diseases, such as Rheumatoid Arthritis (RA), diseases in which neutrophils contribute to pathogenesis (e.g., vasculitis, systemic lupus erythematosus, ulcerative colitis), and oncology indications (j.e. jones, et al. Curr. Opin. Drug discovery. Device., 2009,12, 616-627). PAD4 has been found to be involved in the formation of the Neutrophil Extracellular Trap (NET), more specifically in histone citrullination occurring during NETosis (j.cederval, a. -k.olsson, oncoscience,2015,2 (11), 900-901). Thus, the PAD4 enzyme is associated with a disease characterized by abnormal levels of Neutrophil Extracellular Trap (NET). The proposed role of PAD4 in NETosis is associated with Rheumatoid Arthritis (RA) because NET is absent in the absence of PAD4 and PAD4 is released extracellularly in the RA joint, probably due to the pathological state of RA neutrophils.
Given the fact that NET is involved in many diseases, the therapeutic potential of PAD inhibitor drugs would be enormous. Through epigenetic mechanisms, PAD4 inhibitors may also have broader applicability as tools and therapeutics for human diseases.
In the literature, a number of PAD inhibitors are known that are selective for PAD4 (h.d. lewis et al, nature Chemical Biology,2015,11, 189-191). Some of these compounds are chloroaerolysins (chloro-amidines), fluorosulfacloridine (fluorosulfadiazines) and related analogs that act as mechanism-based inhibitors, reversibly inactivating PAD4 and other PAD isoenzymes. PAD4 inhibitor compounds are useful against Rheumatoid Arthritis (RA). PAD4 detected in synovial tissue was found to cause citrullination of various joint proteins. These citrullinated protein substrates produce anti-citrullinated antibodies that cause disease pathogenesis (y. Kochi et al, ann. Rheum. Dis.,2011,70, 512-515).
PAD4 inhibitors are also known to alleviate the pathological activity of various diseases. Some specific studies have shown that the defense mechanism of neutrophils to eliminate pathogens (also known as NET formation) is associated with histone citrullination (i.neeli et al, j.immunol.,2008,180, 1895-1902). Thus, PAD4 inhibitor compounds are useful in injury and disease pathology where NET formation occurs in tissues. In addition, PAD4 inhibitors have broader applicability to neutrophil diseases.
US20170105971 discloses the reduction, treatment and/or prevention of autoimmune diseases, such as rheumatoid arthritis, osteoarthritis and joint pain, by using amylin as a PAD inhibitor compound. Another application of US20050159334 also discusses the treatment of Rheumatoid Arthritis (RA) by administering a suitable PAD inhibitor.
PAD inhibitor compounds chloroamyllysin have been extensively studied to show their efficacy in several animal disease models, such as collagen-induced arthritis (v.c. willis et al, j.immunol.,2011,186 (7), 4396-4404), dextran Sulfate Sodium (DSS) induced experimental colitis (a.a.chumanevich et al, am.j.physiol.gastrointest.lever physicol., 2011.300 (6), G929-G938), lupus-prone l/lpr mouse atherosclerosis and arterial thrombosis (j.s.knight et al, circ.res.,2014,114 (6), 947-956), spinal cord injury repair (s.lange.biol., dev.biol.,2011, experimental encephalomyelitis (2011-355), experimental myeloencephalitis, 214). Studies with DSS colitis have shown that chloroaamylin can drive apoptosis of inflammatory cells in vitro and in vivo, indicating the efficacy of PAD4 inhibitors in the treatment of inflammatory diseases.
PAD4 is expressed primarily in granulocytes and is closely associated with a variety of diseases. In a variety of tumors, PAD4 was found to be overexpressed, affecting p53 function and downstream pathways. The binding of calcium to PAD promotes the bioactive conformation, which increases PAD4 activity ten thousand-fold.
Slack et al show the use of PAD4 inhibitors in cancer treatment (J.L. Slack et al, cellular and Molecular Life Sciences,2011,68 (4), 709-720). Overexpression of PAD4 has been shown in a variety of cancers (x. Chang et al, BMC Cancer,2009,9, 40). PAD4 inhibitors are also proposed to have antiproliferative effects. PAD4 deiminates arginine residues in histones at the promoter of a p53 target gene (e.g., p 21) that is involved in Cell cycle arrest and apoptosis induction (p.li et al, molecular & Cell Biology,2008,28 (15), 4745-4758).
PAD inhibition is a viable strategy for the treatment of many of the diseases mentioned above. The use of PAD inhibitors in a variety of other diseases involving dysregulation of PAD activity remains to be explored. Although the exact role of dysregulation of PAD activity in these diseases has not been established, a direct link appears to be reasonable. However, there remains an unmet need to identify and develop PAD4 inhibitors that can effectively treat PAD 4-mediated disorders.
Disclosure of Invention
The present disclosure discloses compounds of formula (I), polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof,
wherein:
x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution;R 10 is hydrogen; r 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl group having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl group are optionally substituted by 1 to 5 heteroatoms selected from Substituent group substitution: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
The present disclosure also discloses compounds of formula (II), polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts thereof, and metabolites thereof,
Wherein:
x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a D is selected from N or CR 5 (ii) a E is selected from N or CR 6 (ii) a F is selected from N or CR 7 (ii) a G is selected from N or CR 8 (ii) a n is 0 to 2; r 1 、R 2 、R 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl radical、C(O)NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 10 Is hydrogen; r 11 Selected from the group consisting of: c 1-6 Alkylamino, and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
The present disclosure also discloses compounds of formula (III), polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof,
wherein:
x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a n is 0 to 2; r 1 、R 2 、R 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 10 Is hydrogen; r is 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
The present disclosure also describes methods of making compounds of formula (I), formula (II), and formula (III) or their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof.
The present disclosure also discloses pharmaceutical compositions comprising compounds of formula (I), formula (II), and formula (III), or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
The present disclosure also discloses methods for inhibiting one or more PAD families in a cell with an effective amount of a compound of the present disclosure.
The present disclosure also discloses methods of treating a disorder mediated by one or more PAD families, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition of formula (I), formula (II), and formula (III) of the present disclosure and other clinically relevant agents or biological agents.
The present disclosure also discloses compounds of formula (I), formula (II) and formula (III) for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus and psoriasis.
These and other features, aspects, and advantages of the present subject matter will become better understood with reference to the following description. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the disclosure, nor is it intended to be used to limit the scope of the subject matter.
Detailed Description
Those skilled in the art will appreciate that variations and modifications of the present disclosure may be made in addition to those specifically described. It is to be understood that the present disclosure includes all such variations and modifications. The present disclosure also includes all such steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any or more such steps or features.
Definition of
For convenience, certain terms and examples employed in the specification are collected here before the disclosure is further described. These definitions should be read in light of the remainder of this disclosure and understood by those skilled in the art. Terms used herein have meanings that are recognized and known by those skilled in the art, but specific terms and their meanings are set forth below for convenience and completeness.
Nouns without quantitative recitation mean one or more than one (i.e., at least one).
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers but not the exclusion of any other integer or step or group of integers or steps.
The term "including" is used to mean "including but not limited to". "include/include" and "include/include but not limited to" are used interchangeably.
In the structural formulae given herein and throughout this disclosure, the following terms have the meanings indicated, unless specifically stated otherwise.
Further, the compounds of formula (I), formula (II) and formula (III) may be derivatives, analogs, stereoisomers, diastereomers, geometric isomers, polymorphs, solvates, co-crystals, intermediates, metabolites, prodrugs or pharmaceutically acceptable salts and compositions thereof.
The compounds according to formula (I), formula (II) and formula (III) contain one or more asymmetric centers (also known as chiral centers) and may therefore exist as individual enantiomers, diastereomers or other stereoisomeric forms, or mixtures thereof. Chiral centers, such as chiral carbon atoms, may also be present in substituents such as alkyl groups. When the stereochemistry of the chiral centers present in formula (I), formula (II) and formula (III) or in any of the chemical structures illustrated herein is not specified, the structure is intended to encompass any stereoisomer and all mixtures thereof. Thus, compounds according to formula (I), formula (II) and formula (III) containing one or more chiral centers may be used as racemic variants (including racemic mixtures and racemates), enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers.
Individual stereoisomers of compounds according to formula (I), formula (II) and formula (III) comprising one or more asymmetric centers may be resolved by methods known to those skilled in the art. For example, such a resolution can be performed by: (1) By formation of diastereomeric salts, complexes or other derivatives; (2) By selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support (support) such as silica with bound chiral ligands, or in the presence of a chiral solvent. It will be appreciated that where the desired stereoisomer is converted to another chemical entity by one of the separation procedures described above, an additional step is required to liberate the desired form.
Alternatively, a particular stereoisomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts, or solvents, or by converting one enantiomer into the other via asymmetric transformation.
It will be understood that reference herein to compounds of formula (I), (II) and (III) and salts thereof encompasses compounds of formula (I), (II) and (III) as the free base or as a salt thereof, for example as a pharmaceutically acceptable salt thereof. Thus, in one embodiment, the present disclosure relates to compounds of formula (I), formula (II), and formula (III) as free bases. In another embodiment, the invention relates to compounds of formula (I), formula (II) and formula (III) and salts thereof. In another embodiment, the present invention relates to compounds of formula (I), formula (II) and formula (III) and pharmaceutically acceptable salts thereof.
It will be appreciated that pharmaceutically acceptable salts of the compounds according to formulas (I, II and III) may be prepared. Indeed, in certain embodiments of the present disclosure, pharmaceutically acceptable salts of the compounds according to formula (I), formula (II) and formula (III) may be preferred over the respective free bases, as such salts confer greater stability or solubility to the molecule, thereby facilitating its formulation into a dosage form. Accordingly, the present invention also relates to compounds of formula (I), formula (II) and formula (III) and pharmaceutically acceptable salts thereof.
"enantiomeric excess" (ee) is the excess of one enantiomer over the other, expressed as a percentage. In the racemic variants, since both enantiomers are present in equal amounts, the enantiomeric excess is zero (0% ee). However, if one enantiomer is enriched such that it constitutes 95% of the product, the enantiomeric excess will be 90% ee (amount of enriched enantiomer (95%) minus the amount of the other enantiomer (5%)).
"enantiomerically enriched" refers to a product whose enantiomeric excess (ee) is greater than zero. For example, "enantiomeric enrichment" refers to products whose enantiomeric excess is greater than 50% ee, greater than 75% ee, and greater than 90% ee. "enantiomerically pure" refers to a product having an enantiomeric excess of 99% or greater.
Included within the scope of "compounds of the present disclosure" are all solvates (including hydrates), complexes, polymorphs, prodrugs, radiolabeled derivatives and stereoisomers of the compounds of formula (I), (II) and (III), and salts thereof.
The compounds of the present disclosure may be present in solid or liquid form. In the solid state, the compounds of the present disclosure may be present in crystalline or amorphous form or mixtures thereof. For the compounds of the present disclosure in crystalline form, the skilled artisan will appreciate that pharmaceutically acceptable solvates may be formed, wherein solvent molecules are incorporated into the crystal lattice during crystallization. Solvates may involve non-aqueous solvents such as ethanol, isopropanol, N-dimethyl sulfoxide (DMSO), acetic acid, ethanolamine and ethyl acetate, or they may involve water as the solvent incorporated into the crystal lattice. Solvates in which water is the solvent incorporated into the crystal lattice are commonly referred to as "hydrates". Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The present disclosure includes all such solvates.
It will also be appreciated that certain compounds of the present disclosure, including various solvates thereof, in crystalline form may exhibit polymorphism (i.e., the ability to exist in different crystal structures). These different crystalline forms are often referred to as "polymorphs". The present disclosure includes such polymorphs. Polymorphs have the same chemical composition, but differ in packing, geometric arrangement, and other descriptive aspects of the crystalline solid state. Thus, polymorphs can have different physical properties, such as shape, density, hardness, deformability, stability, and solubility properties. Polymorphs typically exhibit different melting points, IR spectra and X-ray powder diffraction patterns, which can be used for identification. It is understood that different polymorphs can be produced, for example, by changing or adjusting the reaction conditions or reagents used to manufacture the compound. For example, changes in temperature, pressure or solvent can result in multiple polymorphs. Additionally, under certain conditions, one polymorph may spontaneously convert to another polymorph.
The present disclosure also includes isotopically-labeled compounds, which are identical to the compounds of formulae (I, II, and III) and salts thereof, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature. Some examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, and fluorine, e.g. 3 H、 11 C、 14 C and 18 F。
the term "co-crystal" refers to a solid, which is a crystalline single phase material composed of two or more different molecular and/or ionic compounds, usually in stoichiometric ratios, that is neither a solvate nor a simple salt.
The term "substituted" with respect to a group means replacing a hydrogen atom within the group to which one member atom is attached. It is to be understood that the term "substituted" includes implicit indications that such substitution is according to the allowed valencies of the substituted atom or group and that the substitution results in a stable compound (i.e., a compound that does not spontaneously undergo transformation (e.g., rearrangement, cyclization, or elimination)). In certain embodiments, a single atom may be substituted with more than one substituent, so long as such substitution is in accordance with the allowed valences of the atom. Suitable substituents for each substituted or optionally substituted group are defined herein.
The term "polymorph" refers to multiple crystal forms of the same molecule, and different polymorphs can have different physical properties, e.g., melting temperature, heat of fusion, solubility, dissolution rate, and/or vibrational spectrum, due to the arrangement or conformation of the molecules in the crystal lattice.
The term "prodrug" refers to a precursor of the compounds of formula (I, II and III) which undergoes a chemical transformation by metabolic processes upon administration and then becomes the active pharmacological substance. Typically, such prodrugs will be functional derivatives of the compounds of the present disclosure that are readily convertible in vivo into the compounds of the present disclosure.
The term "alkyl" refers to a saturated hydrocarbon chain having the indicated number of carbon atoms. Such as, but not limited to, C 1-6 Alkyl refers to alkyl groups having 1 to 6 carbon atoms or 1 to 3 carbon atoms. The alkyl group may be a straight chain or branched group. Representative branched alkyl groups have one, two or three branches. Preferred alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, and isobutyl.
The term "C (O) alkyl" refers to an alkyl group as defined above attached to the rest of the molecule via a carbonyl linkage. For example, C (O) C 1-6 Alkyl refers to an alkyl group having 1 to 6 carbon atoms or 1 to 3 carbon atoms attached to the rest of the molecule via a carbonyl linkage. Preferred C (O) alkyl groups include, but are not limited to, -C (O) CH 3 、-C(O)CH 2 CH 3 And so on.
The term "SO 2 Alkyl "means an alkyl group as defined above attached to the rest of the molecule via a sulfonyl linkage. For example, SO 2 C 1-6 Alkyl refers to an alkyl group having 1 to 6 carbon atoms or 1 to 3 carbon atoms bonded to the rest of the molecule via a sulfonyl linkage. Preferred SO 2 Alkyl includes but is not limited to-SO 2 CH 3 、-SO 2 CH 2 CH 3 And so on.
The term "alkoxy" refers to an alkyl group attached to the rest of the molecule via an oxygen linkage. E.g. C 1-6 Alkoxy means via an oxygen bondAn alkyl group having 1 to 6 carbon atoms or 1 to 3 carbon atoms attached to the remainder of the molecule. Preferred alkoxy groups include, but are not limited to-OCH 3 (methoxy), -OC 2 H 5 (ethoxy) and the like.
The term "alkylamino" refers to an alkyl group as defined above attached to the rest of the molecule via an amino linkage. E.g. C 1-6 Alkylamino refers to an alkyl group having 1 to 6 carbon atoms or 1 to 3 carbon atoms that is attached to the rest of the molecule via an amino linkage. Preferred alkylamino groups include, but are not limited to-NHCH 3 、-N(CH 3 ) 2 And so on.
The term "C (O) NR" refers to an alkylamino group as defined above attached to the rest of the molecule via a carbonyl linkage. Preferred C (O) NR groups include C (O) NCH 3 、C(O)NCH 2 CH 3 And the like.
The term "SO 2 NR "refers to an alkylamino group as defined above attached to the rest of the molecule via a sulfonyl linkage. Preferred SO 2 The NR groups comprising SO 2 NCH 3 、SO 2 NCH 2 CH 3 And so on.
The term "C (O) alkylamino" refers to an alkylamino group as defined above attached to the rest of the molecule via a carbonyl linkage. For example, C (O) C 1-6 Alkylamino refers to alkylamino groups having 1 to 6 carbon atoms or 1 to 3 carbon atoms attached to the rest of the molecule via a carbonyl linkage. Preferred C (O) alkylamino groups include, but are not limited to-C (O) NHCH 3 、-C(O)N(CH 3 ) 2 And so on.
The term "SO 2 Alkylamino "refers to an alkylamino group as defined above attached to the rest of the molecule via a sulfonyl linkage. For example, SO 2 C 1-6 Alkylamino refers to alkylamino groups having 1 to 6 carbon atoms or 1 to 3 carbon atoms attached to the rest of the molecule via a sulfonyl linkage. Preferred SO 2 Alkylamino includes, but is not limited to, -SO 2 NHCH 3 、-SO 2 N(CH 3 ) 2 And so on.
The term "acylamino" refers to a linkage to a molecule via an amino groupThe remainder is an attached acyl group. For example, C 1-6 Acylamino refers to an acyl group having 1 to 6 carbon atoms or 1 to 3 carbon atoms attached to the rest of the molecule via an amino linkage. Preferred acylamino groups include, but are not limited to- (CO) NHCH 3 、-(CO)N(CH 3 ) 2 And the like.
The term "haloalkyl" refers to an alkyl group as defined above attached to the rest of the molecule via a halo linkage. For example, C 1-6 Haloalkyl refers to an alkyl group having 1 to 6 carbon atoms or 1 to 3 carbon atoms attached to the rest of the molecule via a halo linkage. Preferred haloalkyl groups include, but are not limited to, -CH 2 Cl、-CHCl 2 And the like.
The term "C (O) haloalkyl" means a haloalkyl group as defined above attached to the remainder of the molecule via a carbonyl linkage. For example, C (O) C 1-6 Haloalkyl refers to haloalkyl groups having 1 to 6 carbon atoms or 1 to 3 carbon atoms attached to the remainder of the molecule via a carbonyl linkage. Preferred C (O) haloalkyl groups include, but are not limited to- (CO) CH 2 Cl、-C(O)CHCl 2 And the like.
The term "SO 2 Haloalkyl "means a haloalkyl group as defined above attached to the remainder of the molecule via a sulfonyl linkage. For example, SO 2 C 1-6 Haloalkyl refers to haloalkyl groups having 1 to 6 carbon atoms or 1 to 3 carbon atoms that are linked to the remainder of the molecule via a sulfonyl linkage. Preferred SO 2 Haloalkyl includes, but is not limited to, -SO 2 CH 2 Cl、-SO 2 CHCl 2 And so on.
The term "haloalkoxy" refers to an alkoxy group, as defined above, attached to the rest of the molecule via an oxygen linkage of the haloalkoxy group. E.g. C 1-6 Haloalkoxy refers to an alkoxy group having 1 to 6 carbon atoms or 1 to 3 carbon atoms that is attached to the rest of the molecule via an oxygen linkage. Preferred haloalkoxy groups include, but are not limited to, -OCH 2 Cl、-OCHCl 2 And the like.
The term "halogen" refers to a halogen group, such as fluorine, chlorine, bromine or iodine. "haloalkyl" refers to an alkyl group as defined herein aboveWherein at least one hydrogen atom has been replaced by a halogen group. ' C 1-6 Haloalkyl "refers to C wherein at least one hydrogen atom has been replaced by a halogen group 1-6 An alkyl group. An example of "haloalkyl" is trifluoromethyl or 2, 2-trifluoroethyl.
The term "cycloalkyl" refers to a saturated hydrocarbon ring having the indicated number of carbon atoms. Such as, but not limited to, C 3-6 Cycloalkyl refers to cycloalkyl having 3 to 6 member atoms or 3 member atoms. Preferred cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
The term "SO 2 C 3-6 Cycloalkyl "refers to a cycloalkyl group as defined above attached to the rest of the molecule via a sulfonyl linkage. For example, SO 2 C 3-6 Cycloalkyl refers to cycloalkyl groups having 3 to 6 carbon atoms attached to the rest of the molecule via a sulfonyl linkage. Preferred SO 2 Cycloalkyl groups include, but are not limited to, -SO 2 C 3 Cycloalkyl groups, and the like.
The term "aryl" refers to an aromatic ring having the indicated number of carbon atoms. E.g. C 5-6 Aryl refers to an aryl group having 5 or 6 member atoms or 6 atoms. Preferred aryl groups include, but are not limited to, phenyl and the like.
The term "C (O) aryl" refers to an aryl group as defined above attached to the rest of the molecule via a carbonyl linkage. For example, C (O) C 5-6 Aryl means an aryl group having 5 to 6 carbon atoms attached to the rest of the molecule via a carbonyl linkage. Preferred C (O) aryl groups include, but are not limited to-C (O) C 6 H 5 、-C(O)C 5 H 5 And the like.
The term "SO 2 Aryl "refers to an aryl group as defined above attached to the rest of the molecule via a sulfonyl linkage. For example, SO 2 C 5-6 Aryl means an aryl group having 5 to 6 carbon atoms linked to the rest of the molecule via a sulfonyl linkage. Preferred SO 2 Aryl groups include, but are not limited to, -SO 2 C 6 H 5 、-SO 2 C 5 H 5 And the like.
The term "heteroaryl" refers to a group in the ringAn aromatic ring containing 1 to 5 heteroatoms. A "heteroaryl" group, if so defined herein, may be substituted with one or more substituents. "C having 1 or 6 carbons as a member atom 1-6 Heteroaryl "ring. "heteroaryl" includes pyridyl, tetrazolyl, and pyrazolyl. "heteroatom" means a nitrogen, sulfur or oxygen atom, such as a nitrogen atom or an oxygen atom.
The term "C (O) heteroaryl" refers to a heteroaryl group as defined above attached to the rest of the molecule via a carbonyl linkage. For example, C (O) C 1-6 Heteroaryl refers to an alkyl group having 1 to 6 carbon atoms attached to the rest of the molecule via a carbonyl linkage. Preferred C (O) heteroaryl groups include, but are not limited to, -C (O) pyridyl, -C (O) pyrazolyl, and the like.
The term "SO 2 Heteroaryl "refers to an aryl group as defined above attached to the rest of the molecule via a sulfonyl linkage. For example, SO 2 C 1-6 Heteroaryl refers to an aryl group having 1 to 6 carbon atoms linked to the rest of the molecule via a sulfonyl linkage. Preferred SO 2 Heteroaryl includes, but is not limited to, -SO 2 Pyridyl, -SO 2 Pyrazolyl, and the like.
The terms "heterocycle" and "heterocyclyl" refer to a saturated or unsaturated monocyclic aliphatic ring comprising 5, 6, or 7 ring members, which contains 1 to 5 heteroatoms; or a saturated or unsaturated bicyclic aliphatic ring comprising 5, 6 or 7 ring members, each containing 1 to 5 heteroatoms. In certain embodiments, a "heterocyclyl" group is saturated. In other embodiments, a "heterocyclyl" group is unsaturated. A "heterocyclyl" group that contains more than one heteroatom may contain different heteroatoms. A "heterocyclyl" group may be substituted by one or more substituents as defined herein. "Heterocyclyl" includes piperidinyl, tetrahydropyranyl, azepinyl, oxaazepinyl, azabicyclo [3.1.0] hexyl.
The phrase "pharmaceutically acceptable" refers to compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, the term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the compounds of the present invention and exhibits minimal undesirable toxicological effects. These pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with an appropriate acid. Selected pharmaceutically acceptable salts derived from inorganic bases (such as, for example, li, na, K, ca, mg, fe, cu, zn and Mn); salts of organic bases such as N, N' -diacetylethylenediamine, glucosamine, triethylamine, choline, dicyclohexylamine, benzylamine, trialkylamine, thiamine, guanidine, diethanolamine, α -phenylethylamine, piperidine, morpholine, pyridine, hydroxyethylpyrrolidine, hydroxyethylpiperidine; ammonium; a substituted ammonium salt; aluminum salts, and the like. Salts also include amino acid salts such as glycine, alanine, cystine, cysteine, lysine, arginine, phenylalanine, and guanidine. Salts may include acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, pamates, methanesulphonates, toluenesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulphonates, ascorbates, glycerophosphates, ketoglutarates.
Salts and solvates with non-pharmaceutically acceptable counterions or related solvents are within the scope of the disclosure, e.g., as intermediates for preparing other compounds of formula (I), formula (II), and formula (III) and pharmaceutically acceptable salts thereof. Accordingly, one embodiment of the present disclosure includes compounds of formula (I), formula (II), and formula (III) and salts thereof. The compounds according to formula (I), formula (II) and formula (III) comprise basic functional groups and can therefore form pharmaceutically acceptable acid addition salts by treatment with an appropriate acid. Suitable acids include pharmaceutically acceptable inorganic acids and pharmaceutically acceptable organic acids. Representative pharmaceutically acceptable acid addition salts include the hydrochloride, hydrobromide, nitrate, methyl nitrate, sulphate, bisulphate, sulphamate, phosphate, acetate, hydroxyacetate, phenylacetate, propionate, butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate, fumarate, malate, tartrate, citrate, salicylate, glycolate, lactate, heptanoate, phthalate, oxalate, succinate, benzoate, o-acetoxybenzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, naphthoate, hydroxynaphthoate, mandelate, tannate, formate, stearate, ascorbate, palmitate, oleate, pyruvate, pamoate, malonate, laurate, glutarate, glutamate, laurate (estolate), methanesulphonate (methanesulphonate), ethanesulphonate (ethanesulphonate), 2-hydroxyethanesulphonate, benzenesulphonate (benzenesulphonate), aminobenzenesulphonate, p-toluenesulphonate (p-toluenesulphonate) and naphthalene-2-sulphonate.
The term "PAD inhibitor" or "PAD inhibitor" is used to identify compounds capable of interacting with the neutrophil extracellular capture NET, more specifically in histone citrullination occurring during NETosis. By inhibiting PAD4 enzyme activity is meant the ability to decrease the PAD4 enzyme, thereby inhibiting the formation of citrulline through the citrullination process. Preferably, this inhibition is specific for the PAD4 enzyme.
Once a term is described, it has the same meaning throughout the patent.
As described in the background section, PAD4 inhibitors have broad utility. However, despite the wide utility of PAD4 inhibitor compounds, its identification and development remains a problem. Thus, there is a need for new PAD4 inhibitor compounds for the treatment of PAD4 mediated disorders.
In one embodiment of the present disclosure, there is provided a compound of formula (I), polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, wherein:
x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r is 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 HalogenatedAlkyl radical, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogenElement, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 (ii) a heteroaryl group, wherein,wherein C is 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r is 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 Can be combined togetherForm = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O or N; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r is 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is O; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical、C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is N; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from the group consisting of: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic aryl areThe bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is N; a is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical、C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r is 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and having 1 to 3 substituents selected from N,5-to 10-membered monocyclic or bicyclic saturated heterocycle of a heteroatom of S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substitutedQuilt C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S or O, wherein 5A to 10 membered monocyclic or bicyclic aryl and a 5 to 10 membered monocyclic or bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxyl,Cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r is 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from the group consisting of: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy optionallyIs selected from one or more of hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 1; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyanoRadical, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen and C 1-4 An alkyl group; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally substitutedSelected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group,C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyanoRadical substitution of radicals and hydroxyl radicals; r is 3 Absent or selected from hydrogen, C 1-4 Alkyl radical, C 3-5 Cycloalkyl, C 1-4 Alkylamino radical, C 1-4 Haloalkyl, C (O) C 1-4 Alkyl, C (O) C 1-4 Haloalkyl, C (O) NR 18 、C(O)C 1-4 Alkylamino, SO 2 C 1-4 Alkyl, SO 2 C 1-4 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-4 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-4 Alkyl, (CO) C 1-4 Alkyl, C (O) C 1-4 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-4 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic ringOr a bicyclic saturated or unsaturated heterocycle, wherein said 5 to 10 membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O or S; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Is absent; r 10 Is hydrogen; r 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and having 1 to 3 substituents selected from N,5-to 10-membered monocyclic or bicyclic saturated heterocycle of a heteroatom of S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Selected from hydrogen, C 1-4 Alkyl radical, C 3-5 Cycloalkyl radical, C 1-4 Alkylamino radical, C 1-4 Haloalkyl, C (O) C 1-4 Alkyl, C (O) C 1-4 Haloalkyl, C (O) NR 18 、C(O)C 1-4 Alkylamino, SO 2 C 1-4 Alkyl, SO 2 C 1-4 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-4 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-4 Alkyl, (CO) C 1-4 Alkyl, C (O) C 1-4 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-4 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r is 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxySubstituted with the substituent(s); r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy radical, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 And R 11 May together form a 5 to 10 membered monocyclic or bicyclic saturated or unsaturated heterocycle wherein said 5The up to 10 membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 HalogenatedAlkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r is 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-4 Alkyl radical, C 1-4 Haloalkyl, C 1-4 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; r 16 Selected from: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic aryl areMonocyclic or bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r is 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl radical(ii) a And a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen and C 1-4 An alkyl group; r is 16 Selected from: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 A cycloalkyl group, a,C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen; r 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and has 1 to 5 substituents selected from N, S orA 5 to 10 membered monocyclic or bicyclic heteroaryl of a heteroatom of O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0To 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5-to 10-membered bicyclic aryl; and a 5-to 10-membered bicyclic heteroaryl having 1 to 2 heteroatoms selected from N or S, wherein the 5-to 10-membered bicyclic aryl and the 5-to 10-membered bicyclic heteroaryl are optionally substituted with 1 to 3 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halo, hydroxy, -COOH, and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O; y is O or N; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from the group consisting of: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is S; y is O or N; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein X is O or S; y is selected from O or N; z is N; a is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical,C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r is 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl is substituted, orR 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from the group consisting of: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently of each otherSelected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O; y is selected from O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein the 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O or S; y is selected from O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein the 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl and combination thereof
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O; y is selected from O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein the 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O; y is O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 1; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein the 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy、C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O or S; y is O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r 1 And R 2 Independently selected from hydrogen; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein the 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r is 16 Selected from hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic aryl areHeteroaryl is optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O or S; y is O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r 1 And R 2 Independently selected from hydrogen; r 3 Absent or selected from hydrogen, C 1-4 Alkyl, C (O) C 1-4 Alkyl radical, C 3-6 Cycloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Aryl radical, wherein C 1-4 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r is 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein the 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; and R is 16 Selected from hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acyl radicalAmino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano groups.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O or S; y is O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r 1 And R 2 Independently selected from hydrogen; r 3 Absent or selected from hydrogen, C 1-4 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-4 Alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Aryl radical, wherein C 1-4 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 And R 11 Together form a 5-to 6-membered monocyclic saturated heterocycle, wherein the 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino and NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s); r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; and R is 16 Selected from hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano groups.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O or S; y is O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r 1 And R 2 Independently selected from hydrogen; r 3 Absent or selected from hydrogen, C 1-4 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-4 Alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Aryl radical, wherein C 1-4 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 And R 11 Together form a 5-to 6-membered monocyclic saturated heterocycle, wherein the 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino and NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s); r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen and C 1-6 An alkyl group; and R is 16 Selected from hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano groups.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O; y is O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r is 1 And R 2 Independently selected from hydrogen; r 3 Absent or selected from hydrogen, C 1-4 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Aryl radical, wherein C 1-4 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 And R 11 Together form a 5-to 6-membered monocyclic saturated heterocycle, wherein the 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino and NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s); r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen and C 1-6 An alkyl group; r 16 Selected from hydrogen; 5-to 10-membered bicyclic aryl; and a 5-to 10-membered bicyclic heteroaryl having 1 to 2 heteroatoms selected from N or S, wherein the 5-to 10-membered bicyclic aryl and the 5-to 10-membered bicyclic heteroaryl are optionally substituted with 1 to 3 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -COOH and cyano.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 1; r is 1 And R 2 Independently selected from hydrogen, hydroxy, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl and C 1-6 Halogenoalkoxy, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 Is hydrogen; r 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 An alkyl group,C(O)C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S;
R 16 selected from hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r is 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C (O) C 1-6 Alkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 10 And R 11 Together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 2-4 Alkylamino radical, C 2-4 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 2-4 Alkyl, halogen, C 2-4 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radicals、C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 1; r 1 And R 2 Independently selected from hydrogen, hydroxy, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl and C 1-6 Halogenoalkoxy, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 HalogenatedAlkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 And R 11 Together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 2-4 Alkylamino radical, C 2-4 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 2-4 Alkyl, halogen, C 2-4 Alkoxy and hydroxy; r 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5 to 10 membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5 to 10 membered monocyclic or bicyclic aryl and the 5 to 10 membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl and C 1-6 Halogenoalkoxy, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) as described herein, wherein: x is O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r is 1 And R 2 Independently selected from hydrogen; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Aryl radical, in which SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 And R 11 Taken together form a 5-to 6-membered monocyclic saturated heterocycle, wherein the 5-to 6-membered monocyclic saturated heterocycle is optionally substituted with one or more substituents selected from amino, NHC (O) CH = CHCH 2 N(CH 3 ) 2 Or C 1-6 Substituted with alkyl amino; r is 12 、R 13 、R 14- And R 15 Independently selected from hydrogen or C 1-6 An alkyl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from hydrogen; 5 to 10 yuanA bicyclic aryl group; and a 5-to 10-membered bicyclic heteroaryl having 1 to 2 heteroatoms selected from N or S, wherein the 5-to 10-membered bicyclic aryl and the 5-to 10-membered bicyclic heteroaryl are optionally substituted with 1 to 3 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halo, hydroxy, -COOH, and cyano; r 17 Selected from hydrogen or C 1-6 An alkyl group; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present invention, there is provided a compound of formula (II), polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts thereof, and metabolites thereof,
/>
wherein: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a D is selected from N or CR 5 (ii) a E is selected from N or CR 6 (ii) a F is selected from N or CR 7 (ii) a G is selected from N or CR 8 (ii) a n is 0 to 2; r 1 、R 2 、R 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radicalBase, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 10 Is hydrogen; r 11 Is selected from C 1-6 Alkylamino and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (II) as described herein, which isThe method comprises the following steps: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a D is selected from N or CR 5 (ii) a E is selected from N or CR 6 (ii) a F is selected from N or CR 7 (ii) a G is selected from N or CR 8 (ii) a n is 1 to 2; r is 1 、R 2 、R 8 And R 9 Independently selected from hydrogen, halogen, hydroxy, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl and C 1-6 Haloalkoxy, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 5 、R 6 And R 7 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 10 Is hydrogen; r 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 CycloalkanesBase, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (II) as described herein, wherein: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a D is selected from N or CR 5 (ii) a E is selected from N or CR 6 (ii) a F is selected from N or CR 7 (ii) a G is selected from N or CR 8 (ii) a n is 0 to 2; r 1 、R 2 、R 8 And R 9 Independently selected from hydrogen, halogen, hydroxy, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl and C 1-6 Halogenoalkoxy, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r is 5 、R 6 And R 7 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 10 Is hydrogen; r is 11 Selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocyclic ring is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (II) as described herein, wherein: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is CR 1 (ii) a B is CR 2 (ii) a D is selected from N or CR 5 (ii) a E is CR 6 (ii) a F is CR 7 (ii) a G is CR 8 (ii) a n is 0 to 2; r 1 、R 2 、R 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 A halogenated alkoxy group,C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 10 And R 11 Together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 2-4 Alkylamino radical, C 2-4 Acylamino, -NHC (NH) CH 2 Cl、NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 2-4 Alkyl, halogen, C 2-4 Alkoxy and hydroxy; r is 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (II) as described herein, wherein: x is O; y is selected from O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a D is selected from N or CR 5 (ii) a E is CR 6 (ii) a F is CR 7 (ii) a G is CR 8 (ii) a n is 1 to 2; r 1 、R 2 、R 8 And R 9 Independently selected from hydrogen or halogen; r is 5 、R 6 And R 7 Independently selected from hydrogen, halogen, C 1 Alkyl radical, C 1 Alkoxy radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 A heteroaryl group; r 3 Absent or selected from hydrogen, C 1-6 Alkyl, C (O) C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl radical, C 3-6 Cycloalkyl, and SO 2 C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl radical, wherein SO 2 C 1-6 Alkyl and SO 2 C 5-6 Aryl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl is optionally substituted with one or more groups selected from: hydrogen, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, hydroxy, -CH 2 OH, -COOH and halogen; r 10 And R 11 Together form a 5-to 6-membered monocyclic saturated heterocycle, wherein said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s); and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (III), polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts thereof, and metabolites thereof,
wherein: x is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a n is 0 to 2; r 1 、R 2 、R 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r is 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino radical、SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 10 Is hydrogen; r 11 Selected from: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment of the present disclosure, there is provided a compound of formula (I) or its polymorph, stereoisomer, prodrug, solvate, co-crystal, intermediate, pharmaceutically acceptable salt, and metabolite thereof, selected from:
1) (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
2) (R) - (3-Aminopyrrolidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
3) (R) - (3-aminopiperidin-1-yl) (2- (1-ethyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
4) (2- (aminomethyl) piperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
5) (R) - (3-aminopiperidin-1-yl) (2- (1-ethyl-1H-pyrrolo [2,3-b ] pyridin-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
6) (R) - (3-aminopiperidin-1-yl) (1- (1- (cyclopropylmethyl) -1H-indol-2-yl) -8, 9-dihydro-7H-6-oxa-2, 9 a-diaza-benzo [ cd ] azulen-4-yl) methanone,
7) (R) - (3-Aminopyrrolidin-1-yl) (1- (1- (cyclopropylmethyl) -1H-indol-2-yl) -8, 9-dihydro-7H-6-oxa-2, 9 a-diazabenzo [ cd ] azulen-4-yl) methanone,
8) (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -7-methyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
9) (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
10 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-4-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
11 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
12 (R) - (3-aminopiperidin-1-yl) (2- (3-ethylbenzo [ b ] thiophen-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
13 (R) - (3-aminopiperidin-1-yl) (2- (1- (4-chlorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
14 (R) - (3-aminopiperidin-1-yl) (2- (1- (2-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
15 (R) - (3-aminopiperidin-1-yl) (2- (1- (4-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
16 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
17 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-dimethoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
18 (R) - (3-aminopiperidin-1-yl) (2- (1-benzyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
19 (R) - (3-aminopiperidin-1-yl) (2- (1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
20 (R) - (3-aminopiperidin-1-yl) (2- (1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
21 (R) - (3-aminopiperidin-1-yl) (2- (6-methoxy-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
22 (R) - (3-aminopiperidin-1-yl) (2- (1- (2-hydroxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
23 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
24 (R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
25 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyrazin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
26 (R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
27 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyrimidin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
28 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
29 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
30 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyridazin-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
31 (R) - (3-aminopiperidin-1-yl) (2- (1-isobutyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
32 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-difluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
33 (R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-2-yl) methyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
34 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
35 (R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
36 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
37 (R) - (3-aminopiperidin-1-yl) (2- (1- (4- (hydroxymethyl) benzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone trifluoroacetate,
38 (R, E) -N- (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) -4- (dimethylamino) but-2-enamide trifluoroacetate,
39 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
40 (R) - (3-aminopiperidin-1-yl) (2- (1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
41 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclobutylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
42 (R) -2- (2- (7- (3-aminopiperidine-1-carbonyl) -3, 4-dihydro-5-oxa 1,2a diazacenaphthen-2-yl) -1H-indol-1-yl) acetic acid,
43 (R) - (3-aminopiperidin-1-yl) (2- (1- (piperidin-4-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
44 (R) - (3-aminopiperidin-1-yl) (2- (1- (oxetan-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
45 (R) - (3-aminopiperidin-1-yl) (2- (1- ((1-methylpiperidin-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
46 (R) - (3-aminopiperidin-1-yl) (2- (5-fluoro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
47 (R) - (3-aminopiperidin-1-yl) (2- (1- (2, 2-difluoroethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
48 (R) - (3-aminopiperidin-1-yl) (2- (5-fluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
49 (R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- (4-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
50 (R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
51 (R) - (3-aminopiperidin-1-yl) (2- (1- (4-fluorobenzyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
52 3-aminopiperidin-1-yl) (2- (6-fluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
53 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclobutylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
54 (R) - (3-aminopiperidin-1-yl) (2- (5, 6-difluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
55 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1-isobutyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
56 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (2, 2-difluoroethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
57 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
58 (R, E) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-styryl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
59 (R) - (3-aminopiperidin-1-yl) (2- (1- ((4-methylthiazol-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
60 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
61 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
62 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
63 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
64 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
65 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
66 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-3-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
67 (R) - (3-aminopiperidin-1-yl) (2- (5-bromo-1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
68 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5- (pyridin-3-yl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
69 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-2-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
70 (R) - (3-aminopiperidin-1-yl) (2- (1- (2-fluorobenzyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
71 (R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-4-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
72 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
73 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
74 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
75 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
76 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (methylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
77 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-difluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
78 (R) - (3-aminopiperidin-1-yl) (6-cyclopropyl-2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
79 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (phenethylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
80 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -4-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
81 (R) - (3-aminopiperidin-1-yl) (6- ((4-chlorophenyl) sulfonyl) -2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
82 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (cyclopropylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
83 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- ((2-ethoxy) sulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
84 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -7-methyl-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
85 (R) -1- (8- (3-aminopiperidine e-1-carbonyl) -2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -4, 5-dihydro-6H-imidazo [1,5,4-de ] quinoxalin-6-yl) ethan-1-one,
86 (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanethione.
87 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone, and
88 (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
In one embodiment, the present disclosure relates to a process for preparing a compound of formula (I), formula (II), and formula (III) or polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof.
In one embodiment, the present disclosure relates to a process for preparing a compound of formula (I) or its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, comprising reacting formula (IV) with R 16 C (O) H reaction:
wherein R of formula (IV) 19 Selected from nitro and C 1-6 An alkoxy group; r 16 R of C (O) H 16 Selected from the group consisting of: hydrogen; 5 to 10 membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; x in formula (I) is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a n is 0 to 2; r 1 And R 2 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; r is 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 10 Is hydrogen; r is 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 12 、R 13 、R 14 And R 15 Independently selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 A heteroaryl group; or R 12 And R 13 May together form = O or = S; or R 14 And R 15 May together form = O or = S; r 16 Selected from: hydrogen; 5-to 10-membered monocyclic or bicyclic aryl; and a 5-to 10-membered monocyclic or bicyclic heteroaryl having 1 to 5 heteroatoms selected from N, S, or O, wherein the 5-to 10-membered monocyclic or bicyclic aryl and the 5-to 10-membered monocyclic or bicyclic heteroaryl are optionally substituted with 1 to 5 substituents selected from: hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In one embodiment, the present disclosure relates to a process for preparing a compound of formula (II) or its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts and metabolites thereof, comprising reacting formula (IV) with formula (V):
wherein R of formula (IV) 19 Selected from nitro and C 1-6 An alkoxy group; x of formula (II) is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a A is selected from N or CR 1 (ii) a B is selected from N or CR 2 (ii) a D is selected from N or CR 5 (ii) a E is selected from N or CR 6 (ii) a F is selected from N or CR 7 (ii) a G is selected from N or CR 8 (ii) a n is 0 to 2; r 1 、R 2 、R 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 Heteroaryl, wherein: c 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r is 10 Is hydrogen; r is 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5-to 10-membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, whereinSaid 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl of which C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof; d of formula (V) is selected from N or CR 5 (ii) a E is selected from N or CR 6 (ii) a F is selected from N or CR 7 (ii) a G is selected from N or CR 8 ，R 9 Is H; and R is 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl group, wherein C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano.
In one embodiment, the present disclosure relates to a process for preparing a compound of formula (III) or its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts and metabolites thereof, comprising reacting formula (IV) with formula (VI):
wherein R of formula (IV) 19 Selected from nitro and C 1-6 An alkoxy group; x of formula (III) is selected from O or S; y is selected from O, N, S (O), SO 2 Or C; z is selected from N or CR 17 (ii) a n is 0 to 2; r is 1 、R 2 、R 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 A heteroaryl group, wherein: c 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Halogenated alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substitution; r 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; r 10 Is hydrogen; r 11 Selected from the group consisting of: hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-6 Alkylamino radical, C 1-6 Haloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 C 3-6 Cycloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 A heteroaryl group; and a 5 to 10 membered monocyclic or bicyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S or O, wherein C 1-6 Alkyl, (CO) C 1-6 Alkyl, C (O) C 1-6 Halogenated alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen, C 5-6 Aryl and C 1-6 Heteroaryl substituted, or R 10 And R 11 May together form a 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle, wherein said 5-to 10-membered monocyclic or bicyclic saturated or unsaturated heterocycle is optionally selected from amino, C 1-6 Alkylamino radical, C 1-6 Acylamino, -NHC (NH) CH 2 Cl、-NHC(O)CH＝CHCH 2 N(CH 3 ) 2 、C 1-6 Alkyl, halogen, C 1-6 Alkoxy and hydroxy; r 17 Selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted with one or more substituents selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano, and hydroxy; and is provided withR 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof; and R is 5 、R 6 、R 7 、R 8 And R 9 Independently selected from hydrogen, hydroxy, cyano, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Acylamino group, C 1-6 Alkylamino radical, C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 Heteroaryl group, wherein C 1-6 Alkoxy and C 1-6 Haloalkoxy is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxy, cyano and hydroxy; r 4 Selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl, C (O) NR 18 、C(O)C 1-6 Alkylamino, SO 2 C 1-6 Alkyl, SO 2 C 1-6 Haloalkyl, SO 2 NR 18 、SO 2 NC 1-6 Alkylamino radical, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl group, C 1-6 alkyl-C 1-6 Heteroaryl, C (O) C 5-6 Aryl, C (O) C 1-6 Heteroaryl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-6 Cycloalkyl, C 5-6 Aryl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 Heterocyclic group, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl, C 1-6 alkyl-C 1-6 Heteroaryl, (CO) C 1-6 Alkyl, C (O) C 1-6 Haloalkyl and SO 2 C 1-6 Alkyl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH, -COOH and cyano; and R is 18 Independently selected from hydrogen, C 1-6 Alkyl groups and combinations thereof.
In another embodiment, the present disclosure relates to pharmaceutical compositions comprising a compound of formula (I), formula (II), and formula (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
In another embodiment, the present disclosure relates to a pharmaceutical composition as described herein, wherein the composition is in a form selected from the group consisting of a tablet, a capsule, a powder, a syrup, a solution, an aerosol, and a suspension.
In one embodiment of the present disclosure, there is provided a compound of formula (I), formula (II) and formula (III) as described herein, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is selected from salts derived from inorganic bases, such as, for example, li, na, K, ca, mg, fe, cu, zn and Mn; organic bases, such as, for example, salts of N, N' -diacetylethylenediamine, glucosamine, triethylamine, choline, dicyclohexylamine, benzylamine, trialkylamine, thiamine, guanidine, diethanolamine, alpha-phenylethylamine, piperidine, morpholine, pyridine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, ammonium salts, substituted ammonium salts, aluminum salts, and the like. Salts also include amino acid salts such as glycine, alanine, cystine, cysteine, lysine, arginine, phenylalanine, and guanidine. Salts may, where appropriate, comprise acid addition salts which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmitates, methanesulphonates, toluenesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulphonates, ascorbates, glycerophosphates, ketoglutarates.
In one embodiment of the present disclosure, there is provided a compound of formula (I), formula (II) and formula (III), or a pharmaceutically acceptable salt thereof, as described herein, wherein said pharmaceutically acceptable salt thereof is for use in the manufacture of a medicament for inhibiting one or more PAD in a cell.
In one embodiment, the present disclosure relates to methods for inhibiting one or more PAD families in a cell with an effective amount of a compound of formula (I), formula (II), and formula (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
In one embodiment, the present disclosure relates to a method of treating a disorder mediated by one or more PAD families, the method comprising administering a therapeutically effective amount of a compound of formula (I), formula (II), and formula (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions, to a subject having a disorder mediated by one or more PAD families.
In one embodiment, the present disclosure relates to a method for treating and/or preventing a PAD-mediated disorder associated with PAD activity, comprising administering to a subject having a PAD-mediated disorder associated with PAD activity a therapeutically effective amount of a compound of formula (I), formula (II), and formula (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with one or more additional pharmaceutical compositions.
In one embodiment the disclosure relates to a method for the treatment and/or prevention of a PAD-mediated disorder associated with PAD, said disorder being selected from rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus and psoriasis.
In one embodiment, the present disclosure relates to a method for treating a PAD-mediated disorder, comprising administering to a subject in need thereof a combination of a compound of formula (I), formula (II), and formula (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions, and/or with other clinically relevant agents or biological agents.
In one embodiment, the present disclosure relates to a method for the treatment and/or prevention of PAD-mediated disorders associated with PAD selected from acid-induced lung injury, respiratory distress syndrome, allergen-induced asthma, allergic bronchopulmonary disease, aspergillosis, allergic conjunctivitis, alopecia, amyotrophic lateral sclerosis, inflammation, arthritis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, bone pain, bronchiolitis, chronic lung disease in premature infants, chronic obstructive pulmonary disease, colitis, complex local pain syndrome, crohn's disease, cystic fibrosis, familial cold urticaria, gout, gouty arthritis, GVHR disease, intestinal diseases, inflammatory bowel disease, inflammatory lung diseases, inflammatory neuropathies, inflammatory pain, insect bite induced inflammation, irritation induced inflammation, juvenile rheumatoid arthritis, kidney disease, kidney injury caused by parasitic infection, kidney transplant rejection prevention, lung injury, lupus nephritis, multiple sclerosis, muscle wasting, muscular dystrophy, non-allergen induced asthma, osteoarthritis, periodontitis, peritoneal endometriosis, plant irritation induced inflammation, psoriasis, lung disease, pulmonary fibrosis, purulent aseptic arthritis, kidney disease, rheumatic whole heart disease, rheumatic disease, rheumatoid arthritis, sepsis, severe pain, and ulcerative colitis.
In one embodiment, the present disclosure relates to the use of compounds of formula (I), formula (II) and formula (III), or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, optionally in combination with one or more other pharmaceutical compositions, in combination with other clinically relevant or biological agents, for: treating a disorder mediated by one or more PAD families; or treating and/or preventing a PAD-mediated disorder; or for the treatment of PAD mediated disorders.
In one embodiment, the present disclosure relates to a method for treating and/or preventing a disorder mediated by one or more PAD families or proliferative disorders or cancer, the method comprising administering a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition of the present disclosure to a subject having a disorder mediated by one or more PAD families or a PAD-mediated disorder.
In one embodiment, the present disclosure relates to methods comprising administering a compound or pharmaceutical composition of formula (I), formula (II), and formula (III) in combination with other clinically relevant or biological agents to a subject in need thereof.
In one embodiment, the present disclosure relates to methods for treating cancer comprising administering to a subject in need thereof a compound of formula (I), formula (II), and formula (III), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier and other clinically relevant or biological agents, optionally in combination with one or more other pharmaceutical compositions.
As used herein, the symbols and conventions used in these methods, schemes, and examples are consistent with those used in the contemporary scientific literature, e.g., the journal of the american chemical society. All starting materials were purchased from commercial suppliers and used without further purification unless otherwise noted. In particular, the following abbreviations may be used in the examples and throughout the specification:
abbreviations:
AcOH acetic acid
BOC 2 Di-tert-butyl O dicarbonate
nBuLi n-butyl lithium
BuOH Butanol
Bz benzyl group
Cbz Carboxybenzyl radical
cHex cyclohexane
Cs 2 CO 3 Cesium carbonate
DCM/CH 2 Cl 2 Methylene dichloride
DIAD diisopropyl azodicarboxylate
Dioxane 1, 4-Dioxane
DIPEA N, N-diisopropylethylamine
DMSO dimethyl sulfoxide
DMF N, N-dimethylformamide
Et 3 N-Triethylamine
Ether
EtOAc ethyl acetate
HATU O- (7-azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate
HPLC high performance liquid chromatography
IPA isopropyl alcohol
K 2 CO 3 Potassium carbonate
KOH potassium hydroxide
LiOH lithium hydroxide
LCMS or LC/MS liquid chromatography-mass spectrometry
MeOH methanol
Min minute
Na 2 SO 4 Sodium sulfate
NaHCO 3 Sodium bicarbonate
NH 4 Cl ammonium chloride
Palladium tetrakistriphenylphosphine Palladium
Pd/C palladium on carbon
PTSA para-toluenesulfonic acid
Rb round bottom (flask)
r.t/rt. Room temperature
Rt Retention time
TFA trifluoroacetic acid
TFAA trifluoroacetic anhydride
THF/THF tetrahydrofuran
TLC/tic thin layer chromatography
TMEDA Tetramethylethylenediamine
The following examples provide detailed information on the synthesis, activity and use of the compounds of the present disclosure. It should be understood that the following is representative only, and that the disclosure is not limited by the details shown in these examples.
The compounds of the present disclosure can be prepared by a variety of methods, including standard chemical methods. Any previously defined variables will continue to have the previously defined meanings unless otherwise specified. Illustrative general synthetic methods are set forth in the schemes below and can be readily adapted to prepare other compounds of the present disclosure.
Also provided are general processes for preparing compounds of formula (I, II and III) as shown in scheme-1 below, wherein all groups are as previously defined.
Scheme 1
The process for the preparation of compounds of formulae (I, II and III) comprises the steps of:
step 1: using CH 3 COOH and HNO 3 (reaction conditions a) Compound 1 was converted to Compound 2 under standard conditions.
Step 2: treatment of compound 2 with oxalyl chloride (reaction condition b) affords intermediate 3.
And step 3: using tert-butyl carbamate, cs 2 CO 3 And X-Phos (reaction condition c) converts intermediate 3 to Compound 4.
And 4, step 4: by BBr 3 (reaction Condition d) treatment of Compound 4 affords intermediate 5.
And 5: by reaction with 1, omega-dibromoalkane and K 2 CO 3 (reaction condition e) reaction to convert intermediate 5 into compound 6.
And 6: compound 6 is coupled with substituted indole-2-carbaldehyde 7 (reaction condition f) to afford compound 8.
And 7: compound 8 is hydrolyzed (reaction conditions g) to give compound 9.
And 8: coupling of compound 9 with tert-butyl (R) -piperidin-3-ylcarbamate (reaction condition h) affords intermediate 10.
And step 9: compound 10 was converted to final compound 11 by Boc deprotection (reaction condition i).
The examples given below are provided by way of illustration only and therefore should not be construed to limit the scope of the present disclosure.
Example-1:
synthesis of ((R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone (example-1)
Scheme 2
Step 1: preparation of methyl 4-hydroxy-3-methoxy-5-nitrobenzoate (2)
To a stirred solution of methyl 4-hydroxy-3-methoxybenzoate (1, 20g, 109.7mmol) in CH at 0 deg.C 3 HNO was added dropwise to a solution in COOH (100 mL) 3 (5.9mL, 94.4mmol), and then the reaction mixture is stirred at room temperature for 4 to 5 hours (reaction condition a). Ice-cold water was added to the reaction mixture and the reaction mixture was filtered to give a precipitate, which was dried using high vacuum to give the product as a yellow solid (18g, 75% yield). MS (ESI): c 9 H 9 NO 6 A calculated mass value of 227.04; measured value of m/z is 228[ m ] +H] + 。
Step 2: preparation of methyl 4-chloro-3-methoxy-5-nitrobenzoate (3)
To a stirred solution of methyl 4-hydroxy-3-methoxy-5-nitrobenzoate (2, 18g, 79.29mmol) in DMF (100 mL) at 0 ℃ was slowly added oxalyl chloride (14.27mL, 113.28 mmol) and the reaction mixture is then refluxed at 80 ℃ for about 12 hours (reaction condition b). Ice-cold water was added to the reaction mixture, and the resulting solid was filtered. The solid was dried under high vacuum to obtain the product as a brown solid (17.5g, 90% yield). MS (ESI): c 9 H 8 CINO 5 The calculated mass value of (a) is 245.01; the measured value of m/z is 246[ m ] +H] + 。
And step 3: preparation of methyl 4- ((tert-butoxycarbonyl) amino) -3-methoxy-5-nitrobenzoate (4)
In N 2 Next, to a stirred solution of methyl 4-chloro-3-methoxy-5-nitrobenzoate (3,6g, 24.42mmol) in t-butanol (50 mL) was added tert-butyl carbamate (2.86g, 24.42mmol, cs) 2 CO 3 (9.5g, 29.31mmol) and X-Phos (1.116g, 2.44mmol). Addition of Pd 2 (dba) 3 (0.44g, 0.48mmol) and stirred at room temperature for about 10 minutes and then the resulting mixture was heated to 100 ℃ for 12 hours (reaction conditions c). The reaction mixture was cooled to room temperature and diluted with ethyl acetate (100 mL × 3), the organic phase was washed with water and brine, dried over sodium sulfate and concentrated under reduced pressure to give the crude compound purified by column chromatography (silica gel, 0% to 20% EtOAc in hexanes) to give methyl 4- ((tert-butoxycarbonyl) amino) -3-methoxy-5-nitrobenzoate (2.5 g,75% yield) as a colorless liquid. MS (ESI): c 14 H 18 N 2 O 7 A mass calculated value of 325.0; m/z found value of 326.3[ m ] +H] + 。
And 4, step 4: preparation of methyl 4-amino-3-hydroxy-5-nitrobenzoate (5)
4- ((tert-butyl) under stirring at-78 deg.C Butoxycarbonyl) amino) -3-methoxy-5-nitrobenzoic acid methyl ester (4,3.5 g, 10.74mmol) in DCM (30 mL) was added BBr 3 (3.5 mL) and the resulting mixture was stirred at room temperature for 3 hours (reaction condition d). The progress of the reaction was monitored by TLC. The reaction mixture was quenched with ice and sodium bicarbonate solution (30 mL) and extracted with DCM (50 mL × 3). The combined organic extracts were washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give methyl 4-amino-3-hydroxy-5-nitrobenzoate as a brown solid (0.7g, 35% yield). MS (ESI): c 8 H 8 N 2 O 5 A calculated mass value of 212.1; measured value of m/z is 213[ m ] +H] + 。
And 5: preparation of 5-nitro-3, 4-dihydro-2H-benzo [ b ]][1,4] Oxazine-7-carboxylic acid methyl ester (6) />
To a stirred solution of methyl 4-amino-3-hydroxy-5-nitrobenzoate (5,1.1g, 5.12mmol) in DMF (10 mL) was added 1, 2-dibromoethane (0.44 mL) and K 2 CO 3 (0.86g, 2.38mmol), and the resulting mixture was heated to 80 ℃ for 12 hours (reaction condition e). The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to give the crude compound purified by column chromatography (SiO 2, 0% to 20% EtOAc in hexanes) to give 5-nitro-3, 4-dihydro-2H-benzo [ b ] as a brown solid ][1,4]Oxazine-7-carboxylic acid methyl ester (0.45g, 89% yield). MS (ESI): c 10 H 10 N 2 O 5 A mass calculated value of 238.2; measured value of m/z is 239.1[ m + H ]] + 。
And 6: preparation of 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2-diaza Acenaphthene-7-carboxylic acid methyl ester (8)
5-Nitro-3, 4-dihydro-2H-benzo [ b ] with downward stirring][1,4]A solution of a mixture of oxazine-7-carboxylic acid methyl ester (6,0.2g, 0.84mmol) and 1- (cyclopropylmethyl) -1H-indole-2-carbaldehyde (7,0.18g, 0.92mmol) in EtOH (10 mL) was added to water (5 mL) Na 2 S 2 O 4 (0.73g, 4.20mmol) and stirred at 95 ℃ for 16 h (reaction condition f). The reaction mixture was cooled to room temperature, water was added, and the compound was extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using silica gel and the eluent 15% to 20% ethyl acetate in hexane to give methyl 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2-diazacenaphthylene-7-carboxylate as a yellow solid (0.18g, 12% yield). MS (ESI): c 23 H 21 N 3 O 3 Has a mass calculated value of 387.4; measured value of m/z is 388.1[ m ] +H] + 。
And 7: preparation of 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diaza Acenaphthene-7-carboxylic acid (9)
To a stirred solution of methyl 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2 diazacenaphthylene-7-carboxylate (8, 0.18g, 0.46mmol) in MeOH (2 mL) was added a 5N NaOH solution (0.4 mL) at 75 deg.CThe mixture was stirred for 1 hour (reaction condition g). The reaction mixture was completely evaporated. The resulting crude was dissolved in water and acidified with citric acid (pH 4 to 6) and extracted with DCM (20 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product as a yellow solid to give 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylic acid as a brown solid (0.07g, 41% yield). MS (ESI): c 22 H 19 N 3 O 3 373.4; measured value of m/z is 374.1[ 2 ], [ M ] +H] + 。
And step 8: preparation of (R) - (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydrooxa-1, 2a- Diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamic acid tert-butyl ester (10)
2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3-methyl-3H-imidazo [4,5-b ] with downward stirring]A solution of pyridine-6-carboxylic acid (9,0.089g, 0.24mmol) in DCM (2 mL) was added tert-butyl (R) -piperidin-3-ylcarbamate (0.05g, 0.26mmol), triethylamine (0.1g, 0.72mmol), followed by a solution of 50% T3P in ethyl acetate (0.2g, 0.72mmol) and stirred at room temperature for 12 hours (reaction condition h). Water was added to the reaction mixture and the compound was extracted with DCM (20 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 5% meoh in DCM to give the product as a yellow solid (0.07g, 53.8% yield). MS (ESI): c 32 H 37 N 5 The mass calculated value of O is 555.6; measured value of m/z is 556.3[ M + ] H] + 。
And step 9: preparation of (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3,4- Dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone (example-1)
To a stirred solution of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (10, 0.08g, 0.14mol) in dichloromethane (10 mL) was added trifluoroacetic acid (0.5 mL) and stirred at room temperature for 2 hours (reaction condition i). The reaction mixture was completely evaporated, dissolved in a minimum volume of water (30 mL) and passed through saturated NaHCO 3 The solution was basified (20 mL). The compound was extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the product as a pale yellow solid (0.044g, 67.5% yield).
MS(ESI)：C 32 H 37 N 5 O 4 455.0 is calculated as the mass of; measured value of m/z is 456.4[ m ] +H] + 。
The following compounds (examples 2 to 8) were synthesized using the corresponding reactants using the above procedure as exemplified in example-1 above.
Example-2:
(R) - (3-Aminopyrrolidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 26 H 27 N 5 O 2 A mass calculated value of (d) of 441.22; measured value of m/z is 442.0[ m ] +H] + 。
Example-3:
(R) - (3-aminopiperidin-1-yl) (2- (1-ethyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 25 H 27 N 5 O 2 A calculated mass of 429.52; measured value of m/z is 430.2[ m ] +H] + 。
Example-4:
(2- (aminomethyl) piperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 31 N 5 O 2 A mass calculated value of 469.59; m/z found value of 470.3[ m ] +H] + 。
Example-5:
(R) - (3-aminopiperidin-1-yl) (2- (1-ethyl-1H-pyrrolo [2,3-b ] pyridin-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 24 H 26 N 6 O 2 A calculated mass value of 430.51; m/z found value of 431.4[ m ] +H] + 。
Example-6:
(R) - (3-Aminopiperidin-1-yl) (1- (1- (cyclopropylmethyl) -1H-indol-2-yl) -8, 9-dihydro-7H-6-oxa-2, 9 a-diazabenz [ cd ] azulen-4-yl) methanone
MS(ESI)：C 28 H 31 N 5 O 2 A mass calculated value of 469.59; m/z found value of 470.2[ M ] +H] + 。
Example-7:
(R) - (3-Aminopyrrolidin-1-yl) (1- (1- (cyclopropylmethyl) -1H-indol-2-yl) -8, 9-dihydro-7H-6-oxa-2, 9 a-diazabenz [ cd ] azulen-4-yl) methanone
MS(ESI)：C 27 H 29 N 5 O 2 A calculated mass of 455.56; measured value of m/z is 456.3[ m ] +H ] + 。
Example-8:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -7-methyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 31 N 5 O 2 A mass calculated value of 469.5; m/z measured value is 470[ m ] +H] + . Example-9:
synthesis of (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone (example-9)
Scheme 3
The reaction procedure followed to obtain intermediate (6) was similar to that outlined above for the preparation of example-1 in scheme 2.
Step 6: preparation of (E) -5- (((1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) methylene) amino) -3,4- dihydro-2H-benzo [ b][1,4] Oxazine-7-carboxylic acid methyl ester (8) />
5-Nitro-3, 4-dihydro-2H-benzo [ b ] with downward stirring][1,4]Oxazine-7-carboxylic acid methyl esterA solution of the ester (6,0.25g, 1.05mmol) in ethanol (6 mL) was added 1- (cyclopropylmethyl) -5-fluoro-1H-indole-2-carbaldehyde (7,0.27g, 1.26mmol), sodium dithionite (0.91g, 5.25mmol) and water (3 mL). The reaction mixture was then heated to 90 ℃ in a closed tube for 12 hours (reaction conditions f). The reaction mixture was evaporated, diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with water, brine, dried over sodium sulfate, filtered and evaporated to give the crude product as a yellow solid (0.25 g, crude). MS (ESI): c 23 H 22 FN 3 O 3 The mass calculated value of (b) is 407.45; measured value of m/z is 408.1[ m ] +H] + 。
And 7: preparation of 2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid methyl ester (9)
(E) -5- (((1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) methylene) amino) -3, 4-dihydro-2H-benzo [ b ] at room temperature with stirring][1,4]A solution of methyl oxazine-7-carboxylate (8,0.25g, 0.61mmol) in toluene (3 mL) was added p-toluenesulfonic acid (0.012g, 0.0614 mmol). The reaction mixture was then heated to 90 ℃ for 12 hours (reaction conditions g). The reaction mixture was quenched with sodium bicarbonate and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using silica gel and the eluent 15% to 20% ethyl acetate in hexane to afford the product as a yellow solid (0.15g, 35% yield). MS (ESI): c 23 H 20 FN 3 O 3 A mass calculated value of (d) of 405.43; m/z found value of 406.1[ m ] +H] + 。
And step 8: preparation of 2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1,2a- Diazacenaphthene-7-carboxylic acid (10)
To a stirred solution of methyl 2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylate (9, 0.15g, 0.37mmol) in methanol (5 mL) was added a solution of 5N NaOH (0.37mL, 1.85mmol) and heated to 80 ℃ for 1 hour (reaction conditions H). The solvent was evaporated completely and dissolved in water (10 mL) and acidified with citric acid and extracted with DCM (20 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product as a yellow solid (0.13g, 90% yield). MS (ESI): c 22 H 18 FN 3 O 3 391.40; measured value of m/z, is 392.1[ 2 ], [ M + ] H] + 。
And step 9: preparation of (R) - (1- (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxo Hetero-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamic acid tert-butyl ester (11)
To a stirred solution of 2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (10, 0.13g, 0.33mmol) in DCM (4 mL) was added tert-butyl (R) -piperidin-3-ylcarbamate (0.079g, 0.398mmol), triethylamine (0.09mL, 0.66mmol), and propylphosphonic anhydride in 50% ethyl acetate (0.316mL, 0.498mmol). The reaction mixture was stirred at room temperature for 1 hour (reaction condition i). The reaction mixture was quenched with sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (20 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using silica gel and eluent DCM 5% to 10%Purification of methanol gave the product as a yellow solid (0.13g, 68% yield). MS (ESI): c 32 H 36 FN 5 O 4 Calculated mass value of (a), 573.67; the measured value of m/z is 574.3[ m ] +H] + 。
Step 10: preparation of (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2- Yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl methanone (example-9)
To a stirred solution of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (11, 0.13g, 0.226mmol) in DCM (4 mL) at 0 deg.C was added trifluoroacetic acid (0.5 mL). The reaction mixture was then stirred at room temperature for 1 hour (reaction condition j). The reaction mixture was evaporated under reduced pressure, washed with diethyl ether, and the reaction mixture was basified with saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using silica gel and the eluent DCM 5% to 10% methanol to give the product as an off-white solid (0.06g, 57% yield).
MS(ESI)：C 27 H 28 FN 5 O 2 The calculated mass value of (a) is 473.55; the measured value of m/z is 474.2[ M ] +H] + 。
The following compounds (examples 10 to 60) were synthesized using the above-described method as exemplified in example-9.
Example-10:
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-4-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 28 N 6 O 2 492.23; measured value of m/z is 493[ 2 ] M + H] + 。
Example-11:
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 28 N 6 O 2 492.23; the measured value of m/z is 493.2[ M ] +H] + 。
Example-12:
(R) - (3-aminopiperidin-1-yl) (2- (3-ethylbenzo [ b ] thiophen-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone:
MS(ESI)：C 25 H 26 N 4 O 2 quality of SCalculated value, 446.57; measured value of m/z is 447.2, [ M ] +H] + 。
Example-13:
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-chlorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 30 H 28 ClN 5 O 2 A mass calculated value of 525.19; the measured value of m/z is 526.2[ m ] +H] + 。
Example-14:
(R) - (3-aminopiperidin-1-yl) (2- (1- (2-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 30 H 28 FN 5 O 2 A calculated mass value of 509.22; the measured value of m/z is 510.2[ m ] +H] + 。
Example-15:
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 30 H 28 FN 5 O 2 509.59; measured value of m/z is 510.2[ m ] +H] + 。
Example-16:
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 28 N 6 O 2 492.58; the measured value of m/z is 493.4[ m ] +H] + 。
Example-17:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-dimethoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 33 FN 5 O 4 A mass calculated value of 515.61; the measured value of m/z is 516.3[ m ] +H] + 。
Example-18:
(R) - (3-aminopiperidin-1-yl) (2- (1-benzyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 30 H 29 N 5 O 2 491.6 is adopted as the mass calculation value of (A); m/z measured value is 492.2[ M ] +H] + 。
Example-19:
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 31 H 31 N 5 O 3 521.62; m/z found value of 522.2[ M ] +H] + 。
Example-20:
synthesis of (R) - (3-aminopiperidin-1-yl) (2- (1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 26 H 29 N 5 O 3 A calculated mass value of 459.23; m/z is measured as460.10[M+H] + 。
Example-21:
(R) - (3-aminopiperidin-1-yl) (2- (6-methoxy-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 31 N 5 O 4 A calculated mass value of 489.19; the measured value of m/z is 490.27[ mu ] M +1] + 。
Example-22:
(R) - (3-aminopiperidin-1-yl) (2- (1- (2-hydroxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 25 H 27 N 5 O 3 A calculated mass value of 445.21; m/z found value of 446.24[ m ] +H] +1 。
Example-23:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 31 N 5 O 3 The calculated mass value of (a) is 485.24; the measured value of m/z is 486.20[ m ] +H] +1 。
Example-24:
(R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
/>
MS(ESI)：C 29 H 27 FN 6 O 2 A calculated mass value of 511.23; measured value of m/z is 511.14[ 2 ], [ M + [ H ]] + 。
Example-25:
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyrazin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 27 N 7 O 2 Has a mass calculated value of 493.12; the measured value of m/z is 494.10[ M ] +H] + 。
Example-26:
(R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 27 FN 6 O 2 A calculated mass value of 510.22; measured value of m/z is 511.18[ m ] +H ] + 。
Example-27:
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyrimidin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
/>
MS(ESI)：C 28 H 27 N 7 O 2 A mass calculated value of 493.22; the measured value of m/z is 494.23[ m ] +H] + 。
Example-28:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 28 FN 5 O 2 473.12; m/z actual measurementThe value is 474.20[ m ] +H] + 。
Example-29:
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 27 N 7 O 2 Has a mass calculated value of 493.12; measured value of m/z is 494.27[ m ] +H] + 。
Example-30:
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridazin-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 27 N 7 O 2 Has a mass calculated value of 493.12; the measured value of m/z is 494.24[ m ] +H] + 。
Example-31:
(R) - (3-aminopiperidin-1-yl) (2- (1-isobutyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 31 N 5 O 2 A mass calculated value of 457.25; the measured value of m/z is 458.28[ M ] +H] + 。
Example-32:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-difluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 27 F 2 N 5 O 2 The calculated mass value of (a) is 491.12; m/z measured value of 492.25[ m ] +H] + 。
Example 33:
(R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-2-yl) methyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 30 H 29 FN 6 O 3 540.60; the measured value of m/z is 541.29[ M ] +H] + 。
Example-34:
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 26 ClFN 6 O 2 A calculated mass value of 544.18; measured value of m/z is 545.27[ M + H ]] + 。
Example-35:
(R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
/>
MS(ESI)：C 29 H 26 F 2 N 6 O 2 528.18 mass calculated value of (a); the measured value of m/z is 529.26[ M + ] H] + 。
Example-36:
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 26 H 28 ClN 5 O 3 A mass calculated value of 493.1; the measured value of m/z is 494.5[ m ] +H] + 。
Example-37:
(R) - (3-Aminopiperidin-1-yl) (2- (1- (4- (hydroxymethyl) benzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone trifluoroacetate salt
MS(ESI)：C 31 H 31 N 5 O 3 521.2; m/z found value of 522.25[ m ] +H] + 。
Example-38:
(R, E) -N- (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) -4- (dimethylamino) but-2-enamide trifluoroacetate
/>
MS(ESI)：C 35 H 39 N 6 F 3 O 4 A calculated mass of 566.30; found in m/z, 567.42.
Example-39:
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 31 H 30 ClN 5 O 3 The mass calculated value of (b) is 555.18; measured value of m/z is 556.36[ m + H ]] + 。
Example-40:
(R) - (3-aminopiperidin-1-yl) (2- (1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 33 N 5 O 3 A calculated mass of 499.26; m/z found value of 500.30[ m ] +H] + 。
Example-41:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclobutylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
/>
MS(ESI)：C 28 H 31 N 5 O 2 A mass calculated value of 469.25; m/z found value of 470.31[ m ] +H] + 。
Example-42:
(R) -2- (2- (7- (3-aminopiperidine-1-carbonyl) -3, 4-dihydro-5-oxa 1,2a diazacenaphthen-2-yl) -1H-indol-1-yl) acetic acid
MS(ESI)：C 25 H 25 N 5 O 4 Is 459.18; the measured value of m/z is 460.21[ deg. ] M + H] + 。
Example-43:
(R) - (3-aminopiperidin-1-yl) (2- (1- (piperidin-4-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 29 H 34 N 6 O 2 The mass calculation value of (b) is 498.1; measured value of m/z is 499.29[ m + H ]] + 。
Example-44:
(R) - (3-aminopiperidin-1-yl) (2- (1- (oxetan-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 29 N 5 O 3 471.23; measured value of m/z is 472.27[ m ] +H] + 。
Example-45:
(R) - (3-aminopiperidin-1-yl) (2- (1- ((1-methylpiperidin-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 30 H 36 N 6 O 2 A mass calculated value of (d) of 512; the measured value of m/z is 513.34[ M + ] H] + 。
Example-46:
(R) - (3-aminopiperidin-1-yl) (2- (5-fluoro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
/>
MS(ESI)：C 31 H 30 FN 5 O 3 539.23; m/z found value of 540.33[ deg. ] M + H] + 。
Example-47:
(R) - (3-aminopiperidin-1-yl) (2- (1- (2, 2-difluoroethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 25 H 25 F 2 N 5 O 2 A mass calculated value of (b) of 465.12; the measured value of m/z is 466.26[ m ] +H ] + 。
Example-48:
(R) - (3-aminopiperidin-1-yl) (2- (5-fluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 26 H 28 FN 5 O 3 477.23 is calculated by the mass; m/z found value of 478.39[ m ] +H] + 。
Example-49:
(R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- (4-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 30 H 27 F 2 N 5 O 2 527.21; m/z found value of 528.36[ m ] +H] + 。
Example-50:
(R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 31 H 30 FN 5 O 3 539.23; m/z found value of 540.27[ deg. ] M + H] + 。
Example-51:
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-fluorobenzyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
/>
MS(ESI)：C 31 H 30 FN 5 O 3 539.23; m/z found value of 540.42[ m ] +H] + 。
Example-52
3-aminopiperidin-1-yl) (2- (6-fluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 26 H 28 FN 5 O 3 477.12 is calculated as the mass; measured value of m/z is 478.26 2[ m + ] H] + 。
Example 53
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclobutylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 30 ClFN 5 O 2 A mass calculated value of 503.26; m/z found value of 504.44[ m ] +H] + 。
Example-54
(R) - (3-aminopiperidin-1-yl) (2- (5, 6-difluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 26 H 27 F 2 N 5 O 3 Has a mass calculated value of 495.21; measured value of m/z is 496.15[ m ] +H] + 。
Example 55
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1-isobutyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 30 ClN 5 O 2 A calculated mass value of 492.02; m/z measured value, 492.41[ m ] +H] + 。
Example 56
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (2, 2-difluoroethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 25 H 24 ClF 2 N 5 O 2 A calculated mass of 499.16; m/z found value of 500.35[ m ] +H] + 。
Example 57
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 28 ClN 5 O 2 A mass calculated value of 490.0; found in M/z was 490.2 (M + H).
Example 58
(R, E) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-styryl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 35 H 35 N 5 O 2 The calculated mass value of (a) is 557.0; found M/z of 558.6 (M + H) + 。
Example-59:
(R) - (3-aminopiperidin-1-yl) (2- (1- ((4-methylthiazol-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 27 H 28 N 6 The mass calculated value of OS was 484.20; found value of M/z, 485.1 (M + H) + 。
Example-60
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
MS(ESI)：C 28 H 31 N 5 O 3 The mass calculated value of (a) is 485.5; found M/z of 486.5 (M + H) + 。
Example 61
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
Scheme 4
Intermediate 1 was synthesized using the procedure described in scheme 3.
Step 1: synthesis of 5-amino-3, 4-dihydro-2H-benzo [ b ]][1,4]Oxazine-7-carboxylic acid methyl ester (2).
5-Nitro-3, 4-dihydro-2H-benzo [ b ] at room temperature with stirring][1,4]A solution of methyl oxazine-7-carboxylate (1, 11.0g, 46.18mmol) in a mixture of ethanol (110mL, 10 vol.) and water (33mL, 3 vol.) was added with ammonium chloride (37.0g, 692.0mmol) and iron powder (38.6g, 692.0mmol), and the resulting mixture was stirred at 80 ℃ for 3 hours. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was evaporated, filtered through celite, and the celite bed was washed with ethyl acetate (200 mL × 3). The combined ethyl acetate layers were washed with water and brine. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 5-amino-3, 4-dihydro-2H-benzo [ b ] as a brown solid ][1,4]Oxazine-7-carboxylic acid methyl ester (2), yield: 9.0g (93%). />
MS (ESI): 208.12; measured value of m/z is 209.20[ m ] +H] +1 。
Step-2: synthesis of methyl 2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylate (3)
5-amino-3, 4-dihydro-2H-benzo [ b ] at room temperature with stirring][1,4]A solution of methyl oxazine-7-carboxylate (2,1.0 g, 4.80mmol) and 1- (cyclopropylmethyl) -6-vinyl-1H-indole-2-carbaldehyde (6 a,1.2g, 5.70mmol) in N, N-dimethylformamide (10.0 mL) and water (3.0 mL) was added potassium peroxymonosulfate (0.88g, 5.76mmol). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and water was added. The precipitated solid was filtered and washed with water (20 mL. Times.2) and methanol (10 mL. Times.2). The resulting compound was dried under vacuum to give methyl 2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (3) as a yellow solid. Yield: 0.550g (crude). MS (ESI): 413.17; measured value of m/z, is 414.26[ m + H ]] +1 。
Step-3: synthesis of 2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (4)
To the stirred 2- (1- (cyclopropylmethyl) -6-vinyl-1)A solution of methyl H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (3, 0.55g,1.3 mmol) in tetrahydrofuran (5.0 mL) and methanol (3.0 mL) was added 5N sodium hydroxide solution (3.0 mL) and the reaction mixture was stirred at 60 ℃ for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The resulting crude was dissolved in a minimum volume of water and acidified to pH 2 to 3 with a saturated citric acid solution at 0 ℃. The precipitated solid was filtered and washed with water (10 mL. Times.2). The resulting compound was dried under vacuum to give 2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylic acid (4) as a white solid. Yield: 0.440g (crude). MS (ESI): 399.16; measured value of m/z is 400.16[ m ] +H] +1 。
Step-4: synthesis of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (5)
To a stirred solution of 2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (4, 0.44g, 1.10mmol) in dichloromethane (10.0 mL) was added tert-butyl (R) -piperidin-3-ylcarbamate (3 b,0.26g, 1.29mmol) and triethylamine (0.4mL, 3.31mmol), followed by propylphosphonic anhydride (50% solution in ethyl acetate, 0.8mL, 3.37mmol). The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (10 mL × 2). The combined organic layers were washed with water and brine solution, further dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude was purified by CombiFlash using 12.0g, redisep and 70% ethyl acetate in hexane as eluent to give tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (5) as a brown solid. Yield: 0.250g (44%). MS (ESI): 5 81.30; the measured value of m/z is 582.41[ M + ] 1] + 。
Step-5: preparation of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6-formyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (6)
To a stirred solution of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (5, 0.25g, 0.43mmol) in tetrahydrofuran (10.0 mL) and water (3.0 mL) at 0 deg.C was added osmium tetroxide (0.6 mL, 0.08mmol) and sodium periodate (0.29g, 1.37mmol). The reaction mixture was stirred at room temperature for 20 minutes. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with water and brine solution, further dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude was purified by CombiFlash using 12.0g, rediSep and 70% ethyl acetate in hexane as eluent to give tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6-formyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (6) as a white solid. Yield: 0.200g (80%). MS (ESI): 583.28; the measured value of m/z is 584.30[ M + ] 1 ] + 。
Step-6: preparation of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (7)
(R) - (1- (2- (1- (cyclopropylmethyl) -6-formyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamic acid tert-butyl ester (6, 0.2g, 0.34mmol) in methanol (10.0 mL) with stirring at 0 deg.CTo the solution was added sodium borohydride (0.014g, 0.34mmol). The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (10 mL × 2). The combined organic layers were washed with water and brine solution, further dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude was purified by CombiFlash using 12.0g, redisep and 70% ethyl acetate in hexane as eluent to give tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (7) as a yellow solid. Yield: 0.100g (51%). MS (ESI): 585.30; m/z found value is 586.30[ M + ] 1 ] + 。
Step-7: preparation of (R) - (3-Aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone (example 61)
To a stirred solution of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (6, 0.1g, 0.17mmol) in dichloromethane (10.0 mL) at 0 deg.C was added trifluoroacetic acid (1.0 mL) and stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was completely concentrated and basified with saturated sodium bicarbonate solution (10 mL). The compound was extracted with dichloromethane (10 mL. Times.2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude product was purified by reverse phase preparative HPLC to give ((R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-yl) methanone as an off-white solid in 0.0023g (0.02%).
MS(ESI)：C 28 H 31 N 5 O 3 The calculated mass value of (a) is 485.24; measured value of m/z is 486.32[ 2 ], [ M ] +1] + 。
Example-62:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
Scheme 5
Step-1: synthesis of 3, 3-dimethyl-5-nitro-3, 4-dihydro-2H-benzo [ b ]][1,4]Oxazine-7-carboxylic acid methyl ester (2)
To a stirred solution of methyl 4-chloro-3, 5-dinitrobenzoate (1,5.0g, 19.19mmol) in methanol (30.0 mL) was added 2-amino-2-methylpropan-1-ol (1a, 2.6g, 28.7mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After 3 hours, a 25% sodium methoxide solution in methanol (12.5mL, 57.6 mmol) was added to the reaction mixture at 0 ℃. The reaction mixture was allowed to react at 80 ℃ for 3 hours. After completion of the reaction, the reaction mixture was diluted with water. The precipitated solid was filtered and washed with water. The crude material was dried under reduced pressure to give 3, 3-dimethyl-5-nitro-3, 4-dihydro-2H-benzo [ b ] as a yellow solid][1,4]Oxazine-7-carboxylic acid methyl ester (2). Yield: 1.8g (35%). MS (ESI): 266.0, found in m/z, is 267.1[ m ] +H] +1 。
Step-2: synthesis of 5-amino-3, 3-dimethyl-3, 4-dihydro-2H-benzo [ b ]][1,4]Oxazine-7-carboxylic acid methyl ester (3)
3, 3-dimethyl-5-nitro-3, 4-dihydro-2H-benzo [ b ] at room temperature with stirring][1,4]A solution of methyl oxazine-7-carboxylate (2,1.8g, 6.76mmol) in ethanol (20 mL) -water (10 mL) was added ammonium chloride (5.4g, 101.4mmol) and iron powder (5.6g, 101.4mmol) and the resulting mixture was stirred at 60 ℃ for 3 hours. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was evaporated, filtered through celite, and washed with ethyl acetate (50 mL × 3). The combined ethyl acetate layers were washed with water and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 5-amino-3, 3-dimethyl-3, 4-dihydro-2H-benzo [ b ] as a yellow solid ][1,4]/>Oxazine-7-carboxylic acid methyl ester (3).
Yield: 1.0g (55%). MS (ESI): 236.11, m/z found value, is 237.20, [ M ] +H] +1 . Step-3: synthesis of methyl 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylate (4)
5-amino-3, 3-dimethyl-3, 4-dihydro-2H-benzo [ b ] at room temperature with stirring][1,4]Oxazine-7-carboxylic acid methyl ester (3,0.5g, 2.12mmol) and 1- (cyclopropylmethyl) -1H-indole-2-carbaldehyde (3a, 0.46g,2.33 mmol) in N, N-dimethylformamide (5.0 mL) and water (0.5 mL) potassium peroxymonosulfate (Oxone, 0.39g, 2.54mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and water was added. The precipitated solid was filtered and washed with water (10 mL. Times.2) and methanol (5 mL. Times.2). The compound obtained was dried under vacuum to give methyl 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (4) as a yellow solid. Yield: 0.50g, crude, MS (ESI): 415.19; m/z found value of 416.27[ m ] +H] +1 。
Step-4: synthesis of 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (5)
To a stirred solution of the obtained methyl 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (4, 0.5g,1.2 mmol) in tetrahydrofuran (10.0 mL) and methanol (5.0 mL) was added a 5N sodium hydroxide solution (5.0 mL), and the reaction mixture was stirred at 60 ℃ for 3 hours. After completion of the reaction, the reaction mixture was completely concentrated under reduced pressure. The resulting crude was dissolved in a minimum volume of water and acidified to pH 2 to 3 with a saturated citric acid solution at 0 ℃. The precipitated solid was filtered and washed with water (10 mL. Times.2). The resulting compound was dried under vacuum to give 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylic acid (5) as an orange solid. Yield: 0.50g (crude). MS (ESI): 401.17; measured value of m/z is 402.27[ m ] +H] +1 。
Step-5: synthesis of tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (6)
To a stirred solution of 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (5, 0.5g, 1.25mmol) in dichloromethane (20.0 mL) was added tert-butyl (R) -piperidin-3-ylcarbamate (5a, 0.3g, 1.49mmol) and triethylamine (0.6 mL, 3.99mmol), followed by propylphosphonic anhydride (50% solution in ethyl acetate, 2.5mL, 3.99mmol). The reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (40 mL × 2). The combined organic layers were washed with water and brine solution, further dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude was purified by CombiFlash using 12.0g, rediSep and 70% ethyl acetate in hexane as eluent to give tert-butyl (R) - (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2 a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (6) as a yellow solid. Yield: 0.25g (34%). MS (ESI): 583.32; the measured value of m/z is 584.37[ M + ] 1 ] + 。
Step-6: preparation of (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone (example 62)
MS(ESI)：C 29 H 33 N 5 O 2 The mass calculated value of (b) is 483.2; measured value of m/z is 484.37[ m + ] H] + 。
Example-63:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
Scheme 6
Intermediate (1) used to prepare example 61 was purchased commercially (from Reddy N Reddy Pharmaceuticals). The intermediate (1) mentioned in scheme 4 is identical to the intermediate (3) in scheme 2 above.
And 3, step 3: preparation of methyl 4- ((2-chloroethyl) amino) -3, 5-dinitrobenzoate (2)
To a stirred solution of (1,0.5g, 1.92mmol) in MeOH (50 mL) was added 2-chloroethylamine hydrochloride (0.46g, 4.03mmol), followed by triethylamine (0.7ml, 4.031mmol), and the resulting mixture was heated to 80 ℃ for 1 hour (reaction condition a). The reaction mixture was cooled to room temperature and diluted with ethyl acetate (100 mL × 2), and the organic phase was evaporated in vacuo and the crude was used in the next step without purification to give a yellow solid (0.9 g,100% yield). MS (ESI): c 10 H 10 ClN 3 O 6 A calculated mass value of 303.66; m/z found value of 304.0[ M ] +H] + 。
A step of; preparation of 8-nitro-1, 2,3, 4-tetrahydroquinoxaline-6-carboxylic acid methyl ester (3)
To a stirred solution of methyl 4- ((2-chloroethyl) amino) -3, 5-dinitrobenzoate (2, 0.3g, 0.99mmol) in AcOH (30 mL) at room temperature was added iron powder (0.27g, 4.95mmol) and the resulting mixture was placed in a chamberStirred at room temperature for 12 hours (reaction conditions b). The progress of the reaction was monitored by TLC. The reaction mixture was then evaporated, filtered through celite, and extracted with ethyl acetate (50 mL × 3). The combined organic extracts were washed with brine NaHCO 3 The solution was dried over sodium sulfate and concentrated under reduced pressure to give the crude compound which was purified by column chromatography (silica gel, 0% to 20% EtOAc in hexanes) to give a dark brown solid (0.23g, 99% yield). MS (ESI): c 10 H 11 N 3 O 4 A calculated mass value of 237.22; m/z found value of 238.1[ m ] +H] + 。
And 5: preparation of 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4- de]Quinoxaline-8-carboxylic acid methyl ester (5)
5-Nitro-3, 4-dihydro-2H-benzo [ b ] with downward stirring][1,4]A solution of a mixture of oxazine-7-carboxylic acid methyl ester (3,0.1g, 0.42mmol) and 1- (cyclopropylmethyl) -1H-indole-2-carbaldehyde (4,0.09g, 0.46mmol) in EtOH (10 mL) was added to water (5 mL) Na 2 S 2 O 4 (0.4 g, 2.32mmol) and the reaction mixture was stirred at 80 ℃ for 16 h (reaction condition c). The reaction mixture was cooled to room temperature, water was added, and the compound was extracted with ethyl acetate (50 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using silica gel and the eluent 15% to 20% ethyl acetate in hexane to give a yellow solid (0.08g, 62% yield). MS (ESI): c 23 H 22 N 4 O 2 A calculated mass of 386.46; m/z found value of 387.2[ M ] +H] + 。
Step 6: preparation of 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidOxazolo [1,5,4- de]Quinoxaline-8-carboxylic acid (6)
Stirred-down 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de]A solution of methyl quinoxaline-8-carboxylate (5,0.1 g, 0.25mmol) in MeOH (2 mL) was added with a 5N NaOH solution (0.4 mL) and stirred at 75 ℃ for 1h (reaction condition d). The reaction mixture was completely evaporated. The resulting crude product was dissolved in a minimum volume of water and acidified with a saturated citric acid solution. The compound was extracted with DCM (50 mL × 2), washed with brine, dried over sodium sulfate and evaporated to give the crude product as a pale yellow solid (0.07g, 72% yield). MS (ESI): c 22 H 20 N 4 O 2 A mass calculated value of 372.43; the measured value of m/z is 373[ m ] +H] + 。
And 7: preparation of (R) - (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de]Quinoxaline-8-carbonyl) piperidin-3-yl) carbamic acid tert-butyl ester (8)
Stirred-down 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de]A solution of quinoxaline-8-carboxylic acid (6,0.07g, 0.18mmol) in DCM (5 mL) was added tert-butyl (R) -piperidin-3-ylcarbamate (7,0.041g, 0.206mmol), triethylamine (0.07mL, 0.56mmol), followed by a 50% solution of T3P in ethyl acetate (0.17g, 0.565mmol) and stirred at room temperature for 12 hours (reaction condition e). Water was added to the reaction mixture, and the compound was extracted with DCM (50 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using silica gel and the eluent 5% MeOH in DCM to give as a yellow solidProduct (0.1g.71% yield). MS (ESI): c 32 H 38 N 6 O 3 A mass calculated value of 554.7; measured value of m/z is 555.3[ m ] +H] + 。
And 8: preparation of (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5,6- dihydro-4H-imidazo [1,5,4-de]Quinoxalin-8-yl methanone (example 63)
(R) - (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5, 4-de) with stirring]Quinoxaline-8-carbonyl) piperidin-3-yl) carbamic acid tert-butyl ester (8,0.05g, 0.09mmol) in dichloromethane (10 mL) trifluoroacetic acid (0.5 mL) was added and stirred at room temperature for 2 hours (reaction condition f). The reaction mixture was completely evaporated, dissolved in a minimum volume of water and passed through saturated NaHCO 3 The solution (20 mL) was basified. The compound was extracted with DCM (20 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the product as a pale yellow solid (0.025g, 62.5% yield).
MS(ESI)：C 27 H 30 N 6 A calculated mass value of O of 455.58; measured value of m/z is 456.2[ m ] +H] + 。
The following compounds (examples 64 to 80) were synthesized using the procedure as described for example-63.
Example 64
R- (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 27 H 29 FN 6 Calculated mass of O, 472.57; measured value of m/z is 473.58[ cm ] +H] + 。
Example 65
Synthesis of (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone (example-65)
Scheme-7
Intermediate (1) was synthesized from intermediate (3) of scheme-6 under reducing conditions.
And 5:2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4- de]Preparation of quinoxaline-8-carboxylic acid methyl ester (3)
To a stirred solution of methyl 8-amino-1, 2,3, 4-tetrahydroquinoxaline-6-carboxylate (1, 0.1g, 0.48mmol) and 1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (2, 0.11g, 0.53mmol) in DMF (3 mL) was added water (0.1 mL) and finallyKetone (oxone) (0.09g, 0.31mmol). The reaction mixture was then allowed to stir at room temperature for about 1 hour. The reaction mixture was quenched with potassium carbonate (0.005 g), and extracted with ethyl acetate (20 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. Subjecting the crude residue to gradient column chromatographyPurification was performed using silica gel and 20% to 30% ethyl acetate in hexane as eluent to give the product as a yellow solid (0.15g, 65.2% yield). MS (ESI): c 23 H 21 FN 4 O 2 A mass calculated value of 404.16; m/z found value of 405.2[ m ] +H] + 。
The following compounds (examples 65 to 71) were synthesized using the above intermediate (3) and the procedure as described for example-63.
Example-65:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
/>
MS(ESI)：C 27 H 29 FN 6 Calculated mass O, 472.24; m/z measured value is 473.3[ m ] +H] + 。
Example 66
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-3-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 29 H 29 N 7 The mass calculated value of O is 491.60; m/z measured value is 492.4[ M ] +H] + 。
Example 67
(R) - (3-aminopiperidin-1-yl) (2- (5-bromo-1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 27 H 29 BrN 6 Calculated mass value of O, 533.47; measured value of m/z is 497[ m ] +H]+。
Example 68
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5- (pyridin-3-yl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
/>
MS(ESI)：C 32 H 33 N 7 The mass calculated value of O is 531.6; m/z found value of 533.2[ M + ] H]+。
Example 69
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-2-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 29 H 29 N 7 The mass calculated value of O is 491.02; m/z found value of 492.09[ m ] +H ] + 。
Example-70
(R) - (3-aminopiperidin-1-yl) (2- (1- (2-fluorobenzyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 30 H 29 FN 6 The calculated mass value of O is 508.2; measured value m/z:509.16[ 2 ] M + H] + 。
Example 71
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-4-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 29 H 29 N 7 The mass calculation value of O is 491.12; measured value m/z:492.22[ 2 ] M + H] + 。
The following compounds were synthesized using the above intermediate 3, and following the procedure as shown for example 63.
Example-72
R- (3-Aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone (example-72)
2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de]Quinoline derivatives Preparation of methyl oxine-8-carboxylate (2)
The intermediate (3) obtained from scheme-6 above was methylated to obtain the intermediate (2) given below. The remaining reaction steps are the same as those exemplified for example-63.
Scheme-8
To stirred 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de at room temperature]A solution of quinoxaline-8-carboxylic acid methyl ester (1.1 g, 0.25mmol) in DMF (10 mL) was added potassium carbonate (0.07g, 0.51mmol) followed by methyl iodide (0.01mL, 0.28mmol) and the reaction mixture was allowed to stir at room temperature for 12 hours. The progress of the reaction was monitored by TLC. The reaction mixture was then evaporated and extracted with ethyl acetate (50 mL × 3), dried over sodium sulfate, and concentrated under reduced pressure to give the crude compound, which was purified by column chromatography (silica gel, 0 to 20% EtOAc in hexanes) to give a light yellow solid (0.05g, 50% yield). MS (ESI): c 24 H 24 N 4 O 2 A mass calculated value of 400.48; m/z found value of 401.2[ m ] +H] + 。
R- (3-Aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone (example-72)
MS(ESI)：C 28 H 32 N 6 A mass calculated value of O of 468.61; measured value of m/z is 469.3 2M + H] + 。
The following compounds (examples 73, 77 and 80) were synthesized using the procedure as shown for example-63.
Example-73
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 28 H 32 N 6 O 2 The calculated mass value of (a) is 484.26; measured value of m/z is 485.3 2M + H] + 。
Example 74
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 28 H 31 N 5 O 3 The mass calculated value of (a) is 485.5; found M/z of 486.5 (M + H) + 。
Example-75
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 28 H 31 FN 6 Calculated O, 486.25; measured value of M/z, 487.3 (M + H) + 。
Example 76
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (methylsulfonyl) - 5, 6-dihydro-4H-imidazo [1,5,4-de]Quinoxalin-8-yl) methanones
Scheme-9
The intermediate (1) of scheme-9 above was obtained by a similar procedure as exemplified for example-63 (scheme 6).
Step 6:2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (methylsulfonyl) -5, 6-dihydro-4H-imidazole And [1,5,4-de ]]Preparation of methyl quinoxaline-8-carboxylate (2)
2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5, 4-de) at 0 ℃ with stirring]A solution of methyl quinoxaline-8-carboxylate (1,0.15g, 0.39mmol) in DCM (10 mL) was added pyridine (0.061g, 0.77mmol) followed by methanesulfonyl chloride (0.03ml, 0.39mmol) and the resulting mixture was allowed to stir at room temperature for 1 hour. The progress of the reaction was monitored by TLC. The reaction mixture was then evaporated and made up with DCM (50 mL;)3) Extraction, drying over sodium sulfate and concentration under reduced pressure gave a brown solid (0.18 g, crude product). LC-MS: c 24 H 24 N 4 O 4 Calculated m/z for S: 464.5; measured value of m/z, is 465.1[ m ] +H] + 。
And 7:2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (methylsulfonyl) -5, 6-dihydro-4H-imidazole And [1,5,4-de ]]Preparation of quinoxaline-8-carboxylic acid- (3)
To stirred 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (methylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ]A solution of quinoxaline-8-carboxylic acid methyl ester (2,0.18g, 0.39mmol) in MeOH (5 mL) and water (0.5 mL) was added LiOH. H 2 O (0.027g, 0.12mmol), and stirred at 60 ℃ for 2 hours. The reaction mixture was completely evaporated. The resulting crude product was dissolved in a minimum volume of water and acidified with a saturated citric acid solution. The compound was extracted with DCM (30 mL × 2), washed with brine, dried over sodium sulfate and evaporated to give the crude product as a pale yellow solid (0.15 g, crude product). MS (ESI): c 23 H 22 N 4 O 4 The calculated mass value of S is 450.51; measured value of m/z is 451.1[ 2 ], [ M ] +H] + . Further steps of example-76 were performed using a similar procedure as exemplified for example-63.
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (methylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
(example-76)
MS(ESI)：C 28 H 32 N 6 O 3 The calculated mass value of S is 532.6; m/z measured value of 533[ m ] +H] + 。
Example 77
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-difluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 27 H 28 F 2 N 6 A calculated mass value of O of 490.23; m/z found value of 491.2[ M ] +H] + 。
Example 78
(R) - (3-Aminopiperidin-1-yl) (6-cyclopropyl-2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-di hydro-4H-imidazo [1,5,4-de]Quinoxalin-8-yl) methanones(example 78)
Scheme-10
Step 6: preparation of methyl 6-cyclopropyl-2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxaline-8-carboxylate (2)
2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5, 4-de) at room temperature with stirring]A solution of methyl quinoxaline-8-carboxylate (1, 0.2g, 0.52mmol) and cyclopropylboronic acid (0.088g, 1.04mmol) in DCM (10 mL) was added copper (II) acetate (0.164g, 1.036 mmol), followed by pyridine (0.1mL, 1.04mmol), and the resulting mixture was allowed to stir at room temperature in the presence of air for 24 hours. The reaction progresses throughMonitored by TLC. The reaction mixture was then quenched with dilute HCl, extracted with DCM (50 mL × 3), dried over sodium sulfate and concentrated under reduced pressure to give the crude compound. It was purified by column chromatography (silica gel, 0 to 20% EtOAc in hexanes) to give a pale yellow solid (0.11g, 50% yield). MS (ESI): c 26 H 26 N 4 O 2 A mass calculated value of 426.2; the measured value of m/z is 427[ M ] +H] + 。
Further steps of example-78 were performed using similar procedures as exemplified for example-63.
(R) - (3-Aminopiperidin-1-yl) (6-cyclopropyl-2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone (example-78)
MS(ESI)：C 30 H 34 N 60 Is 494.64; the measured value of m/z is 495.5[ m ] +H] + 。
Example 79 was synthesized using the procedure described above as exemplified for example-76.
Example 79
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (phenethylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 35 H 38 N 6 O 3 The calculated mass value of S is 622.27; found value of M/z, 623.2 (M + H) + 。
Example 80
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -4-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 27 H 29 Calculated mass of FN6O, 472.57; m/z found value is 473.2[ m ] +H] + 。
Examples 81 to 83 were synthesized using the procedure described above as exemplified for example-76. Example 84 was synthesized using the procedure described above as exemplified for example-63.
Example 81
(R) - (3-Aminopiperidin-1-yl) (6- ((4-chlorophenyl) sulfonyl) -2- (1- (cyclopropylmethyl) -1H-indole-) 2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de]Quinoxalin-8-yl) methanones
/>
MS(ESI)：C 30 H 34 N 6 O 3 The calculated mass value of S is 629.18; measured value of m/z is 629.2[ m + H ] ] + 。
Example-82
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (cyclopropylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 30 H 34 N 6 O 3 The calculated mass value of S was 558.7; measured value of m/z is 559.2[ m ] +H] + 。
Example 83
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- ((2-ethoxyethyl) sulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 31 H 38 N 6 O 4 The calculated mass value of S is 590.27; found M/z 591.3 (M + H) + 。
Example 84
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -7-methyl-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone
MS(ESI)：C 28 H 32 N 6 A mass calculated value of O of 468.61; measured value of m/z is 469.1[ 2 ], [ M + H ]] + 。
Example 85
(R) -1- (8- (3-aminopiperidine-1-carbonyl) -2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -4, 5-dihydro-6H-imidazo [1,5,4-de ] quinoxalin-6-yl) ethan-1-one
Scheme-11
The intermediate (1) of scheme-11 above was obtained by similar procedures as exemplified for example-63 (scheme 6).
And 6: preparation of 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxaline-8-carboxylic acid- (2)
Stirred-down 2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de]Quinoxaline-8-carboxylic acid methyl ester (1,0.09g, 0.21mmol) in MeOH (5 mL) and water (0.5 mL) LiOH. H. 2 O (0.044g, 1.05mmol), and stirred at room temperature for 12 hours. The reaction mixture was evaporated completely. The resulting crude product was dissolved in a minimum volume of water and acidified with a saturated citric acid solution. The compound was extracted with DCM (30 mL × 2), washed with brine, dried over sodium sulfate and evaporated to give the crude product as a pale yellow solid (0.07 g, crude product). MS (ESI): c 22 H 20 N 4 O 2 A mass calculated value of 372.43; the measured value of m/z is 373.0[ M ] +H] + 。
And 7: 6-acetyl-2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1, 5,4-de]preparation of quinoxaline-8-carboxylic acid (3)
2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5, 4-de) at 0 ℃ with stirring]A solution of quinoxaline-8-carboxylic acid (0.07g, 0.19mmol) in DCM (10 mL) was added pyridine (0.03mL, 0.37mmol) followed by acetyl chloride (0.02mL, 0.28mmol) and the resulting mixture was stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC. The reaction mixture was evaporated, extracted with DCM (50 mL × 3), dried over sodium sulfate and concentrated under reduced pressure to give a brown solid (0.059g, 76%). LC-MS: c 24 H 22 N 4 O 3 Calculated m/z of (c): 414.4; measured value is 415.1[ deg. ] M +H] + 。
The remaining steps of preparation example-85 were carried out using similar procedures as exemplified for example-63.
Example 85
(R) -1- (8- (3-aminopiperidine-1-carbonyl) -2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -4, 5-dihydro-6H-imidazo [1,5,4-de ] quinoxalin-6-yl) ethan-1-one
MS(ESI)：C 29 H 32 N 6 O 2 The calculated mass value of (a) is 496.6; measured value of m/z is 497.3[ m + H ]] + 。
Example-86
(R) - (3-Aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazole Azolo [1,5,4-de]Quinoxalin-8-yl) methanethione
Scheme-12
(R) - (3-Aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5, 4-de) to stirring at room temperature]A solution of quinoxalin-8-yl) methanone (example-63, 0.07g, 0.15mmol) in toluene (50 mL) was added Lawson's reagent (Lawessons reagent) (0.12g, 0.39mmol). The reaction mixture was refluxed at a bath temperature of 100 ℃ for 12 hours. The reaction mixture was washed with NaHCO 3 Diluted (50 mL. Times.2) and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 15% to 100% ethyl acetate in hexane to give (R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5, 4-de) as a yellow solid ]Quinoxalin-8-yl) methanethiol (0.007g, 10% yield).
MS(ESI)：C 27 H 30 N 6 The calculated mass value of S is 470.64; m/z found value of 471.2[ M ] +H] + 。
Example-87
Synthesis of (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
Scheme-13
Step-1: synthesis of methyl 2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (2)
5-amino-3, 4-dihydro-2H-benzo [ b ] at room temperature with stirring][1,4]A solution of methyl oxazine-7-carboxylate (1,0.33g, 1.31mmol) and 7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (7a, 0.27g, 1.31mmol) in N, N-dimethylformamide (10.0 mL) and water (3.0 mL) was added potassium peroxymonosulfonate (` ion `)>Ketone, 0.484g, 1.57mmol). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and water was added. The precipitated solid was filtered and washed with water (20 mL. Times.2) and methanol (10 mL. Times.2). The obtained compound was dried under vacuum to give methyl 2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylate (2) as a yellow solid. Yield: 0.12g (22%). MS (ESI): 439.11; m/z found value of 440.28[ m ] +H ] +1 。
Step-2: synthesis of 2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (3)
To a stirred solution of methyl 2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2 a-diazacenaphthylene-7-carboxylate (2, 0.12g, 0.29mmol) in tetrahydrofuran (5.0 mL) and methanol (3.0 mL) was added 5N sodium hydroxide solution (3.0 mL) and the reaction mixture was stirred at 60 ℃ for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The resulting crude product was dissolved in a minimum volume of water and acidified to pH 2-3 with a saturated citric acid solution at 0 ℃. The precipitated solid was filtered and washed with water (10 mL. Times.2). The obtained compound was dried under vacuum to obtain 2- (7-chloro-1) as a white solid- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylic acid (3). Yield: 0.11g (89%). MS (ESI): 425.09; the found value of m/z is 424.13[ M-H ]] -1 。
Step-3: synthesis of (R) - (1- (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamic acid tert-butyl ester (4)
To a stirred solution of 2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (3, 0.11g, 0.25mmol) in dichloromethane (10.0 mL) was added tert-butyl (R) -piperidin-3-ylcarbamate (3b, 0.06g, 0.31mmol) and triethylamine (0.11mL, 0.83mmol), followed by propylphosphonic anhydride (50% solution in ethyl acetate, 0.25mL, 0.86mmol). The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (10 mL × 2). The combined organic layers were washed with water and brine solution, further dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude product was purified by CombiFlash using 4.0g RediSep column and 70% ethyl acetate in hexane as eluent to give tert-butyl (R) - (1- (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (4) as a yellow solid. Yield: 0.07g (45%). MS (ESI): 607.24; measured value of m/z is 608.32[ m ] +1] +1 。
Step-4: synthesis of (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone (example-87)
To a stirred solution of tert-butyl (R) - (1- (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (4, 0.07g, 0.11mmol) in dichloromethane (5.0 mL) at 0 deg.C was added trifluoroacetic acid (1.0 mL) and stirred at room temperature for 2 hours. After the reaction was complete, the reaction mixture was completely concentrated and basified by saturated sodium bicarbonate solution (10 mL). The compound was extracted with dichloromethane (10 mL. Times.2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to give (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-yl) methanone as a white solid. Yield: 0.042g (72%).
MS (ESI): 507.18; measured value m/z:508.36[ M ] +H] + 。
Example-88
Synthesis of (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone
Scheme-14
Step-1: synthesis of methyl 2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-inden-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (2)
5-amino-3, 4-dihydro-2H-benzo [ b ] at room temperature with stirring][1,4]Oxazine-7-carboxylic acid methyl ester (1,0.200g, 0.96mmol) and 7-chloro(vii) -1- (pyrimidin-5-ylmethyl) -1H-indole-2-carbaldehyde (2a, 0.260g, 1.05mmol) in N, N-dimethylformamide (5.0 mL) and water (1.5 mL) was added potassium peroxymonosulfonate (` Liang `)>Ketone, 0.175g, 1.15mmol). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and water was added. The precipitated solid was filtered and washed with water (10 mL. Times.2) and methanol (5 mL. Times.2). The obtained compound was dried under vacuum to give methyl 2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-inden-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (2) as a yellow solid. Yield: 0.30g (crude). MS (ESI): 458.90; measured value of m/z is 459.80[ m + H ]] +1 。
Step-2: synthesis of 2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (3)
To a stirred solution of methyl 2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-inden-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carboxylate (2, 0.30g, 0.65mmol) in tetrahydrofuran (5.0 mL) and methanol (3.0 mL) was added a 5N sodium hydroxide solution (3.0 mL), and the reaction mixture was stirred at 60 ℃ for 2 hours. After completion of the reaction, the reaction mixture was completely concentrated under reduced pressure. The resulting crude product was dissolved in a minimum volume of water and acidified to pH 2-3 with a saturated citric acid solution at 0 ℃. The precipitated solid was filtered and washed with water (10 mL. Times.2). The obtained compound was dried under vacuum to give 2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (3) as a white solid. Yield: 0.250g (crude). MS (ESI): 445.86; the measured value of m/z is 446.89[ deg. ] M + H ] +1 。
Step-3: synthesis of (R) - (1- (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5 ] -oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamic acid tert-butyl ester (4)
To a stirred solution of 2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carboxylic acid (3, 0.25g, 0.56mmol) in dichloromethane (10.0 mL) was added tert-butyl (R) -piperidin-3-ylcarbamate (3 b,0.134g, 0.67mmol) and triethylamine (0.2mL, 1.74mmol), followed by propyl phosphonic anhydride (50% solution in ethyl acetate, 0.5mL, 1.96mmol). The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (10 mL × 2). The combined organic layers were washed with water, brine solution and dried over anhydrous sodium sulfate. The organic layer was filtered and concentrated to give the crude product. The crude product was purified by CombiFlash using 12.0g reisep column and 70% ethyl acetate in hexane as eluent to give tert-butyl (R) - (1- (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-carbonyl) piperidin-3-yl) carbamate (4) as a white solid. Yield: 0.10g (30%). MS (ESI): 628.13; measured value of m/z is 629.35[ m ] +1 ] + 。
Step-4: synthesis of (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone (example-88)
To a stirred solution of tert-butyl (R) - (1- (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) carbamate (4, 0.1g,0.1 mmol) in dichloromethane (5.0 mL) at 0 deg.C was added trifluoroacetic acid (1.0 mL) and stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was concentrated. The reaction mixture was basified by saturated sodium bicarbonate solution (5.0 mL). The compound was extracted with dichloromethane (10 mL. Times.2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give (R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthylene-7-yl) methanone as an off-white solid. Yield: 0.025g (30%).
MS (ESI): 528.01; measured value m/z:528.42[ M ] +H] + 。
Synthesis of intermediates
Synthesis of 1-ethyl-1H-pyrrolo [2,3-b ] pyridine-2-carbaldehyde (intermediate of example-5):
Step-1: 1H-pyrrolo [2,3-b ]]Pyridine-2-carboxylic acid ethyl ester (3)
To a stirred solution of 2-bromonicotinamidal (1, 10.0g,53.7 mmol) in DMSO (100 mL) was added Cs 2 CO 3 (35.0 g, 107mmol), cuI (1.05g, 5.37mmol), followed by the addition of ethyl-2-isocyanoacetate (2, 7.9mL, 69.8mmol), and stirring at 80 ℃ for 16 hours (reaction condition a). The reaction mixture was cooled to room temperature and filtered through celite. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (200 mL). Subjecting the organic layer to anhydrous Na 2 SO 4 Dried and evaporated under vacuum. The crude product was purified by column chromatography using 30% to 50% EtOAc in hexanes to give the product as a brown gum. (yield: 45%,4.5 g). MS (ESI): c 10 H 10 N 2 O 2 The mass calculated value of (a) is 190.20; found M/z of 191.0 (M + H) + 。
Step-2: 1- (tert-butyl) 2-ethyl-1H-pyrrolo [2,3-b ]]Pyridine-1, 2-dicarboxylic acid ester (4)
1H-pyrrolo [2,3-b ] with downward stirring]A solution of pyridine-2-carboxylic acid ethyl ester (3, 34.5g,23.6 mmol) in THF (50 mL) was added triethylamine (6.5mL, 47.3 mmol) followed by Boc anhydride (3.6 g,35.5 mmol) and stirred at room temperature for 16 hours (reaction condition b). Water (100 mL) was added to the reaction mixture and extracted with EtOAc (200 mL). Subjecting the organic layer to anhydrous Na 2 SO 4 Dried and evaporated under vacuum. The crude product was purified by column chromatography using silica gel and the eluent 20% to 30% EtOAc in hexanes to give the product as a brown gum. (yield: 81%,5.5 g). MS (ESI): c 15 H 18 N 2 O 4 A calculated mass value of 290.32; found M/z of 291.1 (M + H) + 。
Step-3: 1H-pyrrolo [2,3-b]Pyridine-2-carboxylic acid (5)
1- (tert-butyl) 2-ethyl-1H-pyrrolo [2,3-b ] with downward stirring]A solution of pyridine-1, 2-dicarboxylate (4,5.5g, 18.9mmol) in THF (40 mL) was added water (10 mL) LiOH (3.9g, 94.8mmol) and stirred at room temperature for 4 h. The reaction mixture was evaporated and dissolved in a minimal amount of water. A saturated citric acid solution was added thereto until it was acidic, and the formed precipitate was collected by filtration and dried to obtain the product as a white solid. (yield: 81%,2.5 g). MS (ESI): c 8 H 6 N 2 O 2 The calculated mass value of (a) is 162.04; found M/z of 163.1 (M + H) + 。
Step-4: N-methoxy-N-methyl-1H-pyrrolo [2,3-b]Pyridine-2-carboxamide (7)
1H-pyrrolo [2,3-b ] at 0 ℃ with downward stirring]Pyridine-2-carboxylic acid (5,2.5g, 15.4 mmol) and N, O-dimethylhydroxylamine hydrochloride (6,1.8g, 18.5 mmol) in DCM (50 mL) were added triethylamine (10.6mL, 77.1mmol), HOBt (3.54g, 23.14mmol), followed by EDC.HCl (4.42g, 23.18mmol), and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was cooled to room temperature, filtered through celite and the filtrate was evaporated. To the crude product was added water (10 mL) and the compound was extracted with DCM (30 mL). The organic layer was dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using silica gel and the eluent 2% to 4% MeOH in DCM to give the product as an off white solid. (yield: 82%,2.6 g). MS (ESI): c 10 H 11 N 3 O 2 A mass calculated value of 205.09; found M/z of 206.1 (M + H) + 。
Step-5: 1H-pyrrolo [2,3-b ]]Pyridine-2-carbaldehyde (8)
N-methoxy-N-methyl-1H-pyrrolo [2,3-b ] at-78 ℃ with downward stirring]Solution of pyridine-2-carboxamide (7,0.5g, 2.43mmol) in THF (10 mL) 1M LAH in THF (3.6 mL, 3.65mmol) was added and the reaction mixture was stirred at the same temperature for 3 hours. The reaction mixture was taken up with saturated Na 2 CO 3 The solution was basified and extracted with DCM (2 × 25 mL). Reacting with saturated NH 4 The Cl (10 mL) solution was quenched and the compound was extracted with EtOAc (50 mL). Subjecting the organic layer to anhydrous Na 2 SO 4 And (5) drying. Subjecting the crude product to flash column chromatography using 25 in hexane% to 30% EtOAc was purified to give the compound as a white solid. (yield: 85%,0.3 g). MS (ESI): c 8 H 6 N 2 A mass calculated value of O of 146.15; found M/z of 147.1 (M + H) + 。
Step-6: 1-Ethyl-1H-pyrrolo [2,3-b ]]Pyridine-2-carbaldehyde (9)
1H-pyrrolo [2,3-b ] with downward stirring]Solution of pyridine-2-carbaldehyde (8,0.3g, 2.19mmol) in DMF (10 mL) was added K 2 CO 3 (0.91g, 6.57mmol), followed by addition of iodoethane (0.5g, 3.28mmol) and stirring of the reaction mixture at the same temperature for 16 h. Water (15 mL) was added to the reaction mixture and extracted with EtOAc (50 mL). Subjecting the organic layer to anhydrous Na 2 SO 4 And (5) drying. The crude product was purified by flash column chromatography using 15% to 20% EtOAc in hexanes to give the compound as a colorless oil. (yield: 95%,0.34 g).
MS(ESI)：C 10 H 10 N 2 Calculated mass of O, 174.08; found M/z of 175.2 (M + H) + 。
Synthesis of 1- (cyclopropylmethyl) -6-methoxy-1H-indole-2-carbaldehyde (intermediate of example-74):
the scheme is as follows:
step-1: preparation of N, 6-dimethoxy-N-methyl-1H-indole-2-carboxamide (3)
To a stirred solution of 6-methoxy-1H-indole-2-carboxylic acid (1,3g, 15.69mmol) in DCM (20 mL) was added N, O-dimethylhydroxylamine hydrochloride (2,3g, 31.38mmol), followed by hydroxybenzotriazole (3.6 g, 23.5mmol), N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride (4.5g, 23.5mmol), and TEA (11.3mL, 120.7 mmol), and the reaction mixture was stirred at the same temperature for 5 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 25% to 30% ethyl acetate in hexane to give the product as a beige solid. (yield: 75%,0.86 g). MS (ESI): c 12 H 14 N 2 O 3 A calculated mass of 234.10; found value of M/z, 235 (M + H) + 。
Step-2: preparation of 6-methoxy-1H-indole-2-carbaldehyde (4)
To a stirred solution of N, 6-dimethoxy-N-methyl-1H-indole-2-carboxamide (3,2g, 8.54mmol) in THF (20 mL) was slowly added a solution of LAH 1M in THF (12.8ml, 12.75mmol) with cooling and the reaction mixture was then allowed to stir at room temperature for 1 hour. The reaction mixture was quenched with ammonium chloride and extracted with ethyl acetate (50 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 5% to 10% ethyl acetate in hexane to give the product as a white solid. (yield: 60%,0.9 g). MS (ESI): c 10 H 9 NO 2 A mass calculated value of 175.06; found M/z of 176.1 (M + H) + 。
Step-3: preparation of 1- (cyclopropylmethyl) -6-methoxy-1H-indole-2-carbaldehyde (6)
To a stirred solution of 6-methoxy-1H-indole-2-carbaldehyde (4,0.28g, 1.6 mmol) in DMF (5 mL) was added potassium carbonate (1.1g, 8mmol), followed by (bromomethyl) cyclopropane (5,0.23mL, 1.72mmol), and the reaction mixture was stirred at the same temperature for 4 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (20 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 5% to 10% ethyl acetate in hexane to give the product as a brown liquid. (yield: 63%,0.23 g).
MS(ESI)：C 14 H 15 NO 2 A calculated mass value of 229.1; found M/z of 230.2 (M + H) + 。
Synthesis of 1- (4-chlorobenzyl) -1H-indole-2-carbaldehyde (intermediate of example-13)
To a stirred solution of 1H-indole-2-carbaldehyde (1,0.5g, 3.44mmol) in DMF (10 mL) was added potassium carbonate (1.42g, 10.3mmol), followed by 1- (bromomethyl) -4-chlorobenzene (0.84g, 4.13mmol), and the reaction mixture was stirred at the same temperature for 4 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (30 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 10% to 15% ethyl acetate in hexane to give the product as a semi-white solid. (yield: 93.4%,0.86 g).
MS(ESI)：C 16 H 12 Mass calculation of ClNO, 269.73; found value of M/z of 270.1 (M + H) + 。
Synthesis of 1- (cyclopropylmethyl) -1H-indole-2-carbaldehyde (an intermediate of examples-1, 2, 4, 6, 7, 38, 62, 72, 76, 78, 79, 85, and 86)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1g, 6.89mmol) in DMF (20 mL) at room temperature were added potassium carbonate (2.8g, 20.67mmol) and (bromomethyl) cyclopropane (0.68mL, 7.58mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (cyclopropylmethyl) -1H-indole-2-carbaldehyde as a yellow solid (1g, 76% yield).
MS(ESI)：C 13 H 13 Mass calculated value of NO, 199.1; found value of M/z, 200.1 (M + H) + 。
Synthesis of 1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (intermediate of example-65)
Step 1: preparation of 6-fluoro-1- (phenylsulfonyl) -1H-indole (2)
To a solution of sodium hydride (0.88g, 22.2 mmol) in DMF (50 mL) at 0 deg.C over 15 minutes was added dropwise a solution of 6-fluoro-1H-indole (1, 3.0g,22.2 mmol) in DMF. Benzenesulfonyl chloride in DMF (2.86mL, 22.2mmol) was added at 0 deg.C and at room temperature under N 2 Stirred under atmosphere for 2 hours. Ice-cold water (50 mL) was added to the reaction mixture, and then the precipitate was filtered off and washed with ice-cold water to obtain a white solid. (6.0 g, 98.19% yield).
Step 2: preparation of 6-fluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3)
To a solution of 6-fluoro-1- (phenylsulfonyl) -1H-indole (2, 6.0g, 22.0mmol) in anhydrous THF (60 mL) at-78 deg.C was added lithium diisopropylamide 2M in THF (10.9mL g, 22.0mmol), and stirred for 5 to 8 minutes, followed by addition of anhydrous DMF (2.5mL, 33.0mmol) at-78 deg.C, and N at-78 deg.C 2 Stirred under atmosphere for 10 minutes. Aqueous ammonium chloride (20 mL) was added to the reaction mixture, which was then extracted into EtOAc. The organic layer was treated with saturated NH 4 The Cl solution and brine were washed, dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a yellow solid (6.0 g, yield 90.90%). MS (ESI): m/z 304.2 (M + H) + 。
And step 3: preparation of 6-fluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (4)
Stirred downward at room temperature 6-difluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3.1g, 3.3mmol) in THF (50 mL) was added TBAF (1M in THF) (9.15mL, 16.5mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 15% to 25% ethyl acetate in hexane to give 6-fluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde as a viscous solid, (0.45g, 90% yield). MS (ESI): c 9 H 6 Mass calculated for FNO of 163; m/z found 164 (M + H) + 。
And 4, step 4: preparation of 1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (5)
To a stirred solution of 6-fluoro-1H-indole-2-carbaldehyde (4,0.5g, 3.44mmol) in DMF (10 mL) was added potassium carbonate (1.42g, 10.3mmol), followed by (bromomethyl) cyclopropane (0.84g, 4.13mmol), and the reaction mixture was stirred at the same temperature for 4 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 10% to 15% ethyl acetate in hexane to give the product as a semi-white solid. (yield: 93.4%,0.86 g).
MS(ESI)：C 13 H 12 The mass calculated value of FNO was 217.09; found M/z of 218.0 (M + H) + 。
Synthesis of 1- (pyridin-4-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-10)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1g, 6.89mmol) in DMF (20 mL) at room temperature was added cesium carbonate (6.7 g, 20.68mmol) and (4- (bromomethyl) pyridine (1.1g, 6.89mmol.) the reaction mixture was refluxed at 80 ℃ for 12 hours, the reaction mixture was diluted with water and extracted with ethyl acetate (50 mL × 2), the combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product, the crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (pyridin-4-ylmethyl) -1H-indole-2-carbaldehyde as a yellow solid (0.5g, 31% yield).
MS(ESI)：C 15 H 12 N 2 Calculated mass O of 236.09; found M/z of 237.0 (M + H) + 。
Synthesis of 1- (pyridin-3-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of examples-16 and 66)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1g, 6.89mmol) in DMF (20 mL) was added cesium carbonate (6.7g, 20.68mmol) and 3- (chloromethyl) pyridine hydrochloride (1.1g, 6.89mmol) at room temperature. The reaction mixture was refluxed at 80 ℃ for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (pyridin-3-ylmethyl) -1H-indole-2-carbaldehyde as a yellow solid (0.4 g,25% yield).
MS(ESI)：C 15 H 12 N 2 Calculated mass of O, 236.27; found value of M/z of 237.1 (M + H) + 。
Synthesis of 1- (pyridin-2-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-11 &69)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1g, 6.89mmol) in DMF (20 mL) at room temperature were added cesium carbonate (6.7g, 20.68mmol) and 2- (bromomethyl) pyridine (1.1g, 6.89mmol). The reaction mixture was refluxed at 80 ℃ for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (pyridin-2-ylmethyl) -1H-indole-2-carbaldehyde as a yellow solid (0.8g, 50% yield).
MS(ESI)：C 16 H 12 Mass calculation of ClNO, 269.73; found value of M/z of 270.1 (M + H) + 。
Synthesis of 1-ethyl-1H-indole-2-carbaldehyde (intermediate of example-3)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1g, 6.89mmol) in DMF (15 mL) was added potassium carbonate (2.85g, 20.6 mmol), followed by iodoethane (0.6 mL, 7.58mmol), and the reaction mixture was stirred at the same temperature for 4 hours. The reaction mixture was poured into crushed ice, diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and evaporated under vacuum to give the crude product. The crude product was purified by flash column chromatography using ethyl acetate and hexane to obtain 1-ethyl-1H-indole-2-carbaldehyde as a viscous liquid. (yield: 1g, 90%).
MS(ESI)：C 11 H 11 Calculated mass NO value of 173.08; found M/z of 174.0 (M + H) + 。
Synthesis of 1-benzyl-1H-indole-2-carbaldehyde (intermediate of example-18)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1g, 6.89mmol) in DMF (20 mL) at room temperature were added potassium carbonate (2.8g, 20.68mmol) and (bromomethyl) benzene (1.2g, 7.58mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1-benzyl-1H-indole-2-carbaldehyde as a viscous liquid (0.5g, 33% yield).
MS(ESI)：C 16 H 13 Mass calculated value of NO, 235.10; found M/z of 236.1 (M + H) + 。
Synthesis of 1- (2-fluorobenzyl) -1H-indole-2-carbaldehyde (intermediate of example-14)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1g, 6.89mmol) in DMF (15 mL) was added potassium carbonate (2.85g, 20.6 mmol), followed by 1- (chloromethyl) -2-fluorobenzene (1.19g, 8.26mmol), and the reaction mixture was stirred at the same temperature for 4 hours. The reaction mixture was poured into crushed ice, diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and evaporated under vacuum to give the crude product. The crude product was purified by flash column chromatography using ethyl acetate and hexane to give 1- (2-fluorobenzyl) -1H-indole-2-carbaldehyde as a gray solid (yield: 1.8g, 96.5%).
/>
MS(ESI)：C 16 H 12 The calculated mass value of FNO was 253.09; found M/z 254.0 (M + H) + 。
Synthesis of 1- (cyclopropylmethyl) -5-fluoro-1H-indole-2-carbaldehyde (intermediate of example-9, 64 &75)
Step 1: preparation of 5-fluoro-1- (phenylsulfonyl) -1H-indole (3)
To a solution of sodium hydride (0.06g, 15mmol) in DMF (10 mL) at 0 ℃ over 15 minutes was added dropwise a solution of 5-fluoro-1H-indole (1, 0.2g, 15mmol) in DMF. Subsequently a solution of benzenesulfonyl chloride (2,0.26g, 15mmol) in DMF was added at 0 ℃ and the reaction mixture was cooled at room temperatureUnder N 2 Stirred under atmosphere for 2 hours. Ice-cold water (50 mL) was added to the reaction mixture, and then the precipitate was filtered off and washed with ice-cold water to obtain a brown solid. (0.25g, 62.50% yield). MS (ESI): m/z 275.0 (M + H) + 。
Step 2: preparation of 5-fluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (4)
To a solution of 5-fluoro-1- (phenylsulfonyl) -1H-indole (3, 0.250g, 1.0mmol) in anhydrous THF (50 mL) at-78 deg.C was added lithium diisopropylamide 1M in THF (0.5mL g, 1.0mmol), followed by anhydrous DMF (0.11mL, 1.5mmol) at-78 deg.C, and N at-78 deg.C 2 Stirred under atmosphere for 10 minutes. Aqueous ammonium chloride (20 mL) was added to the reaction mixture and extracted with EtOAc. The organic layer was treated with saturated NH 4 The Cl solution and brine were washed, dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a brown solid. (0.150g, 54.54% yield). MS (ESI): m/z 304.1 (M + H) + 。
And 3, step 3: preparation of 5-fluoro-1H-indole-2-carbaldehyde (5)
To a stirred solution of 5-fluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (4,1.85g, 6.105mmol) in THF (50 mL) was added TBAF (1M in THF) (9.15mL, 9.158mmol) at room temperature. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 15% to 25% ethyl acetate in hexane to give 5-fluoro-1H-indole-2-carbaldehyde as a viscous solid (0.65g, 65% yield), MS (ESI): c 9 H 6 The calculated mass value of FNO was 163.15; the value of m/z is 162.0[ M-H ]] - 。
And 4, step 4: preparation of 1- (cyclopropylmethyl) -5-fluoro-1H-indole-2-carbaldehyde (7)
To a stirred solution of 5-fluoro-1H-indole-2-carbaldehyde (5,0.65g, 3.98mmol) in DMF (50 mL) at room temperature was added potassium carbonate (1.64g, 11.94mmol) and (bromomethyl) cyclopropane (6,0.58mL, 5.98mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (cyclopropylmethyl) -5-fluoro-1H-indole-2-carbaldehyde as a viscous solid (0.76g, 88% yield).
MS(ESI)：C 13 H 12 The calculated mass value of FNO is 217.24; measured value of m/z, is 218.1[ m ] +H] + 。
Synthesis of 1- (cyclopropylmethyl) -7-methyl-1H-indole-2-carbaldehyde (intermediate of example-8 &84)
Step 1: preparation of 7-methyl-1- (phenylsulfonyl) -1H-indole (2)
To a solution of sodium hydride (0.92g, 23mmol) in DMF (10 mL) was added dropwise a solution of 7-methyl-1H-indole (1, 3.0g, 23mmol) in DMF over 15 minutes at 0 ℃. Benzenesulfonyl chloride in DMF (2.96mL, 23mmol) was added at 0 deg.C and at room temperature under N 2 Stirred under atmosphere for 2 hours. Ice-cold water (50 mL) was added to the reaction mixture, and then the precipitate was filtered off and washed with ice-cold water to obtain a brown solid (5.30g, 85.50%). MS (ESI): m/z 272.1 (M + H) + 。
And 2, step: preparation of 7-methyl-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3)
To a solution of 7-methyl-1- (phenylsulfonyl) -1H-indole (2, 5.3g, 20.0mmol) in anhydrous THF (50 mL) at-78 deg.C was added 1.5M lithium diisopropylamide in THF (13.0mL, 20.0mmol) and stirred for 5 to 8 minutes, followed by addition of anhydrous DMF (2.33mL, 30.0mmol) at-78 deg.C and N at-78 deg.C 2 Stirred under atmosphere for 10 minutes. Aqueous ammonium chloride (20 mL) was added to the reaction mixture, which was then extracted into EtOAc. The organic layer was treated with saturated NH 4 The Cl solution and brine were washed, dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a red viscous liquid (5.0 g, 85.47%). MS (ESI): m/z 300.2 (M + H) + 。
And step 3: preparation of 7-methyl-1H-indole-2-carbaldehyde (4)
To a stirred solution of 7-methyl-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3,2g, 6.68mmol) in THF (20 mL) was added a 1M solution of tetrabutylammonium fluoride in THF (10 mL,10.2 mmol), and the mixture was stirred at 80 ℃ for 1 hour. The reaction mixture was cooled to room temperature, water (20 mL) was added, and extracted with EtOAc (100 mL). Subjecting the organic layer to anhydrous Na 2 SO 4 Dried and evaporated under vacuum. The crude product was purified by column chromatography using 15% to 20% etoac in hexanes to give the product as a brown solid. (0.8 g,58% yield). MS (ESI): c 10 H 9 Calculated mass NO of 159.07; found M/z of 160.1 (M + H) + 。
And 4, step 4:1- (cyclopropylmethyl) -7-methyl-1H-indole-2-carbaldehyde (5)
To a stirred solution of 7-methyl-1H-indole-2-carbaldehyde (4,0.85g, 5.345mmol) in DMF (20 mL) at room temperature were added potassium carbonate (2.21g, 16.035 mmol) and (bromomethyl) cyclopropane (4 a,0.78mL, 8.018mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (cyclopropylmethyl) -7-methyl-1H-indole-2-carbaldehyde as a viscous solid (0.52g, 45% yield).
MS(ESI)：C 14 H 15 Mass calculated value of NO, 213.28; the measured value of m/z is 214.1[ m ] +H] + 。
Synthesis of 1- (cyclopropylmethyl) -5, 6-dimethoxy-1H-indole-2-carbaldehyde (intermediate from example-17)
Step 1: preparation of 5, 6-dimethoxy-1- (phenylsulfonyl) -1H-indole (2)
To a solution of sodium hydride (0.56g, 14mmol) in DMF (50 mL) at 0 ℃ over 15 minutes was added dropwise a solution of 5, 6-dimethoxy-1H-indole (1, 2.5g, 14mmol) in DMF. Benzenesulfonyl chloride (1.8mL, 14mmol) in DMF was added at 0 ℃ and the mixture was cooled at room temperature under N 2 Stirred under atmosphere for 2 hours. Ice-cold water (50 mL) was added to the reaction mixture, and then the precipitate was filtered off and washed with ice-cold water to obtain a white solid. (4.20g, 93.95% yield). MS (ESI): c 16 H 15 NO 4 The calculated mass value of S was 317.07; measured value of m/z is 318.1[ 2 ], [ M + H ]] + 。
And 2, step: preparation of 5, 6-dimethoxy-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3)
To a solution of 5, 6-dimethoxy-1- (phenylsulfonyl) -1H-indole (2, 4.2g,13.2 mmol) in anhydrous THF (60 mL) at-78 deg.C was added lithium diisopropylamide 2M in THF (8.8mL g,13.2 mmol) and stirred for 5 to 8 minutes, followed by addition of anhydrous DMF (1.54mL, 20.0 mmol) at-78 deg.C and N at-78 deg.C 2 Stirred under atmosphere for 10 minutes. Aqueous ammonium chloride (20 mL) was added to the reaction mixture, which was then extracted into EtOAc. The organic layer was saturated with NH 4 The Cl solution and brine were washed, dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a yellow solid (3.5g, 78.26% yield). MS (ESI): c 17 H 15 NO 5 The calculated mass value of S is 345.07; measured value of m/z is 346.1[ m + H ]] + 。
And step 3: preparation of 5, 6-dimethoxy-1H-indole-2-carbaldehyde (4)
To a stirred solution of 5,6-dimethoxy-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3,2g, 5.5 mmol) in THF (50 mL) at room temperature was added TBAF (1M in THF) (8.8mL, 8.2mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 5% to 10% ethyl acetate in hexanes to give the desired compound as a gummy solid (1g, 88.6% yield). MS (ESI): c 11 H 11 Mass calculated value of NO3, 205.07; the measured value of m/z is 206.1[ m ] +H] + 。
And 4, step 4: preparation of 1- (cyclopropylmethyl) -5, 6-dimethoxy-1H-indole-2-carbaldehyde (5)
To a stirred solution of 5,6-dimethoxy-1H-indole-2-carbaldehyde (4,1g, 4.8mmol) in DMF (20 mL) at room temperature was added potassium carbonate (1.9g, 14mmol) and (bromomethyl) cyclopropane (0.7g, 5.7mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 10% ethyl acetate in hexane to give the title compound as a yellow solid (0.7 g,56.3% yield).
MS(ESI)：C 15 H 17 NO 3 A mass calculated value of 259.31; m/z found value of 260.2[ m ] +H] + 。
Synthesis of ethylbenzo [ b ] thiophene-2-carbaldehyde (intermediate of example-12)
Step 1: 3-ethylbenzo [ b ]]Thiophene-2-carboxylic acid methyl ester (3)
/>
To a suspension of NaH (60% in oil, 0.17g, 4.27mmol) in THF (10 mL) was added methyl 2-mercaptoacetate (2, 0.41g, 3.94mmol) at room temperature and stirred at the same temperature for 30 min. A solution of 1- (2-fluorophenyl) propan-1-one (1,0.5g, 3.28mmol) in THF was added to the reaction and allowed to reflux for 16 hours (reaction condition a). Completion of the reaction was monitored by LCMS. The reaction mixture was cooled to room temperature, diluted with EtOAc, and washed with 1N NaOH and water. The organic layer was washed, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude mixture was purified by column chromatography to obtain the product as a brown oil (yield: 0.4g, 57.14%). MS (ESI): c 12 H 12 O 2 The calculated mass value of S is 220.06; found M/z, 221.1 (M + H) + 。
And 2, step: (3-ethylbenzo [ b ]]Thiophen-2-yl) methanol (4)
At 0 ℃ to 3-ethylbenzo [ b ]]A solution of thiophene-2-carboxylic acid methyl ester (3,0.5g, 1.81mmol) in THF (10 mL) was added dropwise to a 1M solution of LAH in THF (2.7mL, 2.72mmol). The reaction mixture was stirred at 25 ℃ for 2 hours (reaction condition b). The reaction was monitored by TLC (1, etoac: hexane). The reaction mixture was washed with saturated NH 4 Quenched with Cl (10 mL), filtered through celite, and extracted with EtOAc. Will be provided withThe organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude mixture was purified by column chromatography to obtain the product as a yellow oil (yield: 0.24g, 70.58%). MS (ESI): c 11 H 12 A mass calculated value of OS of 192.06; found M/z of 192.9 (M + H) + 。
And step 3: ethylbenzo [ b ]]Thiophene-2-carbaldehyde (5)
At 0 deg.C, to (3-ethylbenzo [ b ]]Thien-2-yl) methanol (4,0.24g, 1.25mmol) in DCM (10 mL) was added with Dess martin periodinane (0.79g, 1.87mmol) (reaction condition c). The reaction mixture was stirred at 25 ℃ for 2 hours. The reaction was monitored by TLC (1, etoac: hexane). The reaction mixture was washed with saturated NaHCO 3 Quench (10 mL), filter through celite, and extract with DCM. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude mixture was purified by column chromatography to obtain the product as a yellow solid. (yield: 0.18g, 81.8%).
MS(ESI)：C 11 H 10 Mass calculated value of OS, 190.05; found M/z of 191.0 (M + H) + 。
Synthesis of 1- (4-fluorobenzyl) -1H-indole-2-carbaldehyde (intermediate of example-15)
To a stirred solution of 1H-indole-2-carbaldehyde (1,0.5g, 3.44mmol) in DMF (20 mL) at room temperature were added potassium carbonate (1.42g, 10.34mmol) and 1- (bromomethyl) -4-fluorobenzene (0.716g, 3.79mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (4-fluorobenzyl) -1H-indole-2-carbaldehyde (0.8g, 97% yield) as a solid.
MS(ESI)：C 16 H 12 Calculated mass for FNO, 253.28; measured value of m/z is 254.0[ m ] +H] + 。
Synthesis of 1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde (intermediate of example-19)
To a stirred solution of 1H-indole-2-carbaldehyde (1,0.5g, 3.44mmol) in DMF (20 mL) at room temperature were added potassium carbonate (1.42g, 10.34mmol) and 1- (bromomethyl) -4-methoxybenzene (0.76g, 3.79mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde as a solid (0.4 g,43% yield).
MS (ESI): the calculated mass value of C17H15NO2 is 265.31; m/z found at 266.1, M + H] + 。
Synthesis of 1- (2-methoxyethyl) -1H-indole-2-carbaldehyde (intermediate of example-20)
To a stirred solution of 1H-indole-2-carbaldehyde (1,0.80g, 5.5 mmol) in N, N-dimethylformamide (20 mL) was added cesium carbonate (5.36g, 90.5 mmol) and 1-bromo-2-methoxyethane (0.62ml, 6.7 mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 1 hour. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 20% ethyl acetate in hexane as eluent to give 1- (2-methoxyethyl) -1H-indole-2-carbaldehyde as a light yellow oil. Yield: 3.0g (42%).
Synthesis of 1- (cyclopropylmethyl) -6-methoxy-1H-indole-2-carbaldehyde (intermediate of example-23)
To a stirred solution of 6-methoxy-1H-indole-2-carbaldehyde (1,2.0g, 11.4mmol) in N, N-dimethylformamide (20 mL) were added cesium carbonate (11.14g, 34.3mmol) and (bromomethyl) cyclopropane (1.41mL, 13.7mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by Combiflash using 12g of RediSep and 20% ethyl acetate in hexane as eluent to give 1- (cyclopropylmethyl) -6-one as a light yellow oilmethoxy-1H-indole-2-carbaldehyde. Yield: 0.80g (31%), MS (ESI): 229.13 of a basic material; measured value of m/z is 230.1[ m ] +H] +1 。
Synthesis of 1- (cyclopropylmethyl) -5-methoxy-1H-indole-2-carbaldehyde (intermediate of example-60)
To a stirred solution of 6-methoxy-1H-indole-2-carbaldehyde (1,2.0g, 11.4mmol) in N, N-dimethylformamide (20 mL) were added cesium carbonate (11.14g, 34.3mmol) and (bromomethyl) cyclopropane (1.41mL, 13.7mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 20% ethyl acetate in hexane as eluent to give 1- (cyclopropylmethyl) -5-methoxy-1H-indole-2-carbaldehyde as a pale yellow oil. Yield: 0.79g (30%), MS (ESI): 229.13; m/z found value of 230.1[ m ] +H ] +1 。
Synthesis of 6-methoxy-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde (intermediate of example-21)
To a stirred solution of 6-methoxy-1H-indole-2-carbaldehyde (1,0.80g, 4.57mmol) in N, N-dimethylformamide (3 mL) was added cesium carbonate (4.4g, 13.7 mmol) and 1-bromo-2-methoxyethane (0.51mL, 5.48mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 16 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was passed through Combiflash using 12g of RediSep and 20% acetic acid in hexaneThe ethyl ester was purified as eluent to give 6-methoxy-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde as an off-white semisolid. Yield: 0.60g,60%, MS (ESI): 235; the value of m/z is found to be 234.10[ M-1 ]] -1 。
Synthesis of 1- (2-fluorobenzyl) -1H-indole-2-carbaldehyde (intermediate of example-70)
To a solution of 1H-indole-2-carbaldehyde (1,2.0g, 13.7mmol) in N, N-dimethylformamide (15 mL) were added potassium carbonate (5.6 g, 41.1mmol) and 1- (bromomethyl) -2-fluorobenzene (3.1g, 16.5mmol) at room temperature. The reaction mixture was stirred at room temperature for 4 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 20% ethyl acetate in hexane as eluent to give 1- (2-fluorobenzyl) -1H-indole-2-carbaldehyde as a yellow solid.
Synthesis of 1- (pyridin-4-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of examples-11 and 71)
To a solution of 1H-indole-2-carbaldehyde (1,1.50g, 10.3mmol) in N, N-dimethylformamide (40 mL) were added potassium carbonate (4.2g, 31.0 mmol) and 4- (bromomethyl) pyridine hydrobromide (3.1g, 12.4 mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 4 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 10% ethyl acetate in hexane as eluent to give 1- (pyridine-4) as a yellow oil-ylmethyl) -1H-indole-2-carbaldehyde. Yield: 1.0g (40%). MS (ESI): 236.01; m/z found to be 2.37.12.1[ m + H ]] +1 。
Synthesis of 1- (pyrazin-2-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-25)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0g, 6.81mmol) in N, N-dimethylformamide (20.0 mL) were added cesium carbonate (11.2g, 34.4mmol) and 2- (chloromethyl) pyrazine (1.0g, 8.27mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 10% ethyl acetate in hexane as eluent to give 1- (pyrazin-2-ylmethyl) -1H-indole-2-carbaldehyde (3 a) as a yellow solid. Yield: 0.80g (48%). MS (ESI): 237.26; m/z found value of 238.12[ m ] +H ] +1 。
Synthesis of 1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (intermediate of example-28)
To a stirred solution of 6-fluoro-1H-indole-2-carbaldehyde (1,1.5g, 9.2mmol) in N, N-dimethylformamide (30.0 mL) were added cesium carbonate (8.9g, 27.6 mmol) and (bromomethyl) cyclopropane (1.47g, 11.2mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 10% ethyl acetate in hexane as eluent to give1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde as a yellow solid. Yield: 1.5g (75%). MS (ESI): 217.24; measured value of m/z, is 218.34[ m ] +H] +1 。
Synthesis of 1- (pyrimidin-5-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-29)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.20g, 8.27mmol) in N, N-dimethylformamide (20.0 mL) were added cesium carbonate (8.08g, 24.01mmol) and 5- (chloromethyl) pyrimidine (1.0g, 8.27mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 10% ethyl acetate in hexane as eluent to give 1- (pyrimidin-5-ylmethyl) -1H-indole-2-carbaldehyde as a brown solid. Yield: 1.60g (81%). MS (ESI): 237.26; m/z found value of 238.32[ m ] +H ] +1 。
Synthesis of 1- (pyridazin-3-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-30)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0g, 6.81mmol) in N, N-dimethylformamide (10.0 mL) were added cesium carbonate (6.7g, 20.01mmol) and 3- (chloromethyl) pyridazine (1.0g, 7.10mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was passed through Combiflash using 12g RediSep and 10% ethyl acetate in hexane as eluentPurification to give 1- (pyridazin-3-ylmethyl) -1H-indole-2-carbaldehyde (3 a) as a brown solid. Yield: 1.40g (crude). MS (ESI): 237.26; measured value of m/z is 238.42[ m + H ]] +1 。
Synthesis of 1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indole-2-carbaldehyde (intermediate of example-40)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0 g, 6.89mmol) in N, N-dimethylformamide (10 mL) were added cesium carbonate (6.70g, 20.68mmol) and 4- (bromomethyl) tetrahydro-2H-pyran (1.48g, 8.27mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 5% ethyl acetate in hexane as eluent to give 1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indole-2-carbaldehyde as a white solid. Yield: 0.80g (48%). MS (ESI): 243.13; measured value of m/z is 244.17[ m ] +H ] +1 。
Synthesis of 1- (cyclobutylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-41)
To a stirred solution of 1H-indole-2-carbaldehyde (1,0.50g, 3.44mmol) in N, N-dimethylformamide (10 mL) was added cesium carbonate (3.3g, 10.34mmol) and cyclobutyl methyl methanesulfonate (2b, 0.84g, 5.17mmol) at room temperature. The reaction mixture was stirred at 100 ℃ for 1 hour. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 5% ethyl acetate in hexane as eluent to give 1- (cyclobutylmethyl) -1H-indole-2-carbaldehyde (3 a) as an oily liquid. Yield: 0.650g (88%). MS (ESI): 213.12; m/z is found to be unionized.
Synthesis of methyl 2- (2-formyl-1H-indol-1-yl) acetate intermediate (example-42)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.5g, 10.3mmol) in N, N-dimethylformamide (40.0 mL) were added cesium carbonate (10.0 g, 30.9mmol) and methyl 2-chloroacetate (2a, 1.35g,12.4 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 40g of RediSep and 5% ethyl acetate in hexane as eluent to give methyl 2- (2-formyl-1H-indol-1-yl) acetate (3 a) as a yellow oil. Yield: 1.2g (53%). MS (ESI): 217.04; m/z found value of 218.18[ m ] +H ] +1 。
Synthesis of tert-butyl 4- ((2-formyl-1H-indol-1-yl) methyl) piperidine-1-carboxylate (intermediate of example-43)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0 g, 6.81mmol) in N, N-dimethylformamide (10 mL) were added cesium carbonate (6.72g, 20.0 mmol) and tert-butyl 4- (bromomethyl) piperidine-1-carboxylate (2.29g, 8.1mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (50 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 20% ethyl acetate in hexane as eluent to give tert-butyl 4- ((2-formyl-1H-indol-1-yl) methyl) piperidine-1-carboxylate as a yellow solid. Yield: 2.0g (86%). MS (ESI): found to be unionized.
Synthesis of 1- ((1-methylpiperidin-4-yl) methyl) -1H-indole-2-carbaldehyde (intermediate of example-45)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0g, 6.81mmol) in N, N-dimethylformamide (10 mL) were added cesium carbonate (6.72g, 20.0mmol) and tert-butyl 4- (bromomethyl) -1-methylpiperidine (2.2g, 8mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (50 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 20% ethyl acetate in hexane as eluent to give 1- ((1-methylpiperidin-4-yl) methyl) -1H-indole-2-carbaldehyde as a solid. Yield: 2.2g (85%).
Synthesis of 1- (oxetan-3-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-44)
1H-indole-substituted benzene under stirring at room temperature2-Formaldehyde (1,0.700g, 4.82mmol) in N, N-dimethylformamide (10.0 mL) was added cesium carbonate (4.7 g, 14.48mmol) and (3- (chloromethyl) oxetane (0.562g, 5.31mmol). The reaction mixture was stirred at room temperature for 16 hours after the reaction was complete, the reaction mixture was diluted with water and extracted with ethyl acetate (10 mL. Times.2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.the crude product was purified by Combiflash using 12g RediseP and 30% ethyl acetate in hexane as eluent to give 1- (oxetan-3-ylmethyl) -1H-indole-2-carbaldehyde as a yellow solid yield: 0.380g (63%). MS (ESI): 215.09 m/z found, 216.18M H.,] +1 。
synthesis of 6-fluoro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde (intermediate of example-52)
To a stirred solution of 6-fluoro-1H-indole-2-carbaldehyde (1,0.90g, 5.5 mmol) in N, N-dimethylformamide (20 mL) at room temperature were added potassium carbonate (5.38g, 16.5 mmol) and 1-bromo-2-methoxyethane (0.61mL, 6.62mmol). The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 20% ethyl acetate in hexane as eluent to give 6-fluoro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde as a viscous solid. Yield: 0.60g (60%); MS (ESI): 221.09; the measured value of m/z is 222.10[ m ] +H ] +1 。
Synthesis of 1- ((3-Fluoropyridin-2-yl) methyl) -6-methoxy-1H-indole-2-carbaldehyde (intermediate of example-26)
To a stirred solution of 6-methoxy-1H-indole-2-carbaldehyde (1,0.50g, 2.85mmol) in N, N-dimethylformamide (10.0 mL) was added cesium carbonate (2.7 g, 8.57mmol) and 2- (chloromethyl) -3-fluoropyridine hydrochloride (0.452g, 3.14mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for about 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (10 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g rediesep and 30% ethyl acetate in hexane as eluent to give 1- ((3-fluoropyridin-2-yl) methyl) -6-methoxy-1H-indole-2-carbaldehyde as a solid, yield: 0.63g (79%). MS (ESI): 284.10 of the total weight of the steel; the measured value of m/z is 285.19[ m ] +H] +1 。
Synthesis of 1- ((3-Fluoropyridin-2-yl) methyl) -6-methoxy-1H-indole-2-carbaldehyde (intermediate of example-33)
To a stirred solution of 6-methoxy-1H-indole-2-carbaldehyde (1,0.50g, 2.85mmol) in N, N-dimethylformamide (10.0 mL) was added cesium carbonate (2.7 g, 8.57mmol) and 2- (chloromethyl) -3-fluoropyridine hydrochloride (0.45g, 3.14mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for about 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (10 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g rediesep and 30% ethyl acetate in hexane as eluent to give 1- ((3-fluoropyridin-2-yl) methyl) -6-methoxy-1H-indole-2-carbaldehyde as a yellow solid, yield: 0.66g (81%). MS (ESI): 284.10 of the total weight of the steel; measured value of m/z is 285.19[ m ] +H ] +1 。
Synthesis of 7-chloro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indole-2-carbaldehyde (intermediate of example-34)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (1,0.4g, 2.23mmol) in N, N-dimethylformamide (14.0 mL) was added cesium carbonate (2.1g, 6.68mmol) and 2- (chloromethyl) -3-fluoropyridine (0.39g, 2.67mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 20% ethyl acetate in hexane as eluent to give 7-chloro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indole-2-carbaldehyde as a yellow oil. Yield: 0.30g (46%). MS (ESI): 288.0; m/z found to be 289.01[ M ] +H] +1 。
Synthesis of 6-fluoro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indole-2-carbaldehyde (intermediate of example-35)
To a stirred solution of 6-fluoro-1H-indole-2-carbaldehyde (1,0.5g, 3.06mmol) in N, N-dimethylformamide (6.0 mL) were added cesium carbonate (2.99g, 9.2mmol) and 2- (chloromethyl) -3-fluoropyridine hydrochloride (0.53g, 3.6 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 5% ethyl acetate in hexane as eluent to give 6-fluoro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indole-2-carbaldehyde as a yellow solid. Yield: 0.72g (86%). MS (ESI): 272.12 of the total weight of the steel; m/z found, unionized.
Synthesis of 1- (2, 2-difluoroethyl) -1H-indole-2-carbaldehyde (intermediate of example-47)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0g, 6.81mmol) in N, N-dimethylformamide (10.0 mL) were added cesium carbonate (6.7g, 20.01mmol) and 2-bromo-1, 1-difluoroethane (1.78mL, 20.6 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 10% ethyl acetate in hexane as eluent to give 1- (2, 2-difluoroethyl) -1H-indole-2-carbaldehyde as a brown solid. Yield: 0.91g (63%). MS (ESI): 209.26; m/z found, unionized.
Synthesis of 5-fluoro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde (intermediate of example-48)
To a stirred solution of 5-fluoro-1H-indole-2-carbaldehyde (1,0.5g, 3.06mmol) in N, N-dimethylformamide (20.0 mL) were added cesium carbonate (3.0 g, 9.18mmol) and 1-bromo-2-methoxyethane (2a, 0.34mL, 3.68mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, Dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 20% ethyl acetate in hexane as eluent to give 5-fluoro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde as a brown oil. Yield: 0.58g (85%), MS (ESI): 221.0; the measured value of m/z is 221.95[ deg. ] M + H] +1 。
Synthesis of 6-fluoro-1- (4-fluorobenzyl) -1H-indole-2-carbaldehyde (intermediate of example-49)
To a stirred solution of 6-fluoro-1H-indole-2-carbaldehyde (1,1.00g, 6.13mmol) in N, N-dimethylformamide (10 mL) was added cesium carbonate (5.98g, 18.4mmol) and 1- (bromomethyl) -4-fluorobenzene (1.38g, 7.36mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 5% ethyl acetate in hexane as eluent to give 6-fluoro-1- (4-fluorobenzyl) -1H-indole-2-carbaldehyde as an off-white solid. Yield: 1.20g (75%). MS (ESI): 271.08; found in m/z, 272.19.
Synthesis of 5-bromo-1- (cyclopropylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-67)
To a stirred solution of 5-bromo-1H-indole-2-carbaldehyde (1,5g, 32.9mmol) in N, N-dimethylformamide (60 mL) was added cesium carbonate (29.5g, 90.5mmol) and (bromomethyl) cyclopropane (4.8ml, 36.2mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by combi flash using 12g of RediSep and 20% ethyl acetate in hexane as eluent to give 5-bromo-1- (cyclopropylmethyl) -1H-indole-2-carbaldehyde as a solid. Yield: 3.5g (55%). MS (ESI): 278.06; found in m/z, was 279.19.
Synthesis of 1- (cyclopropylmethyl) -7-chloro-1H-indole-2-carbaldehyde (intermediate of example-57)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (1,5.4g, 30.9mmol) in N, N-dimethylformamide (60 mL) were added cesium carbonate (29.5g, 90.5mmol) and (bromomethyl) cyclopropane (4.8mL, 36.2mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by combi flash using 12g of RediSep and 20% ethyl acetate in hexane to give 1- (cyclopropylmethyl) -7-chloro-1H-indole-2-carbaldehyde as a sticky solid. Yield: 3.0g (42%).
MS (ESI): 233.06; found m/z was 234.19.
Synthesis of 7-chloro-1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde (intermediate of example-39)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (0.5g, 2.78mmol) in N, N-dimethylformamide (10.0 mL) was added cesium carbonate (2) at room temperature.7g, 8.35mmol) and 1- (chloromethyl) -4-methoxybenzene (0.52g, 3.34mmol). The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 10% ethyl acetate in hexane as eluent to give 7-chloro-1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde as a yellow oil. Yield: 0.40g (47%). MS (ESI): 299.0; m/z found value of 300.19[ m ] +H] +1 。
Synthesis of 5-fluoro-1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde (intermediate of example-46)
To a stirred solution of 5-fluoro-1H-indole-2-carbaldehyde (1,0.5g, 3.06mmol) in N, N-dimethylformamide (20.0 mL) were added cesium carbonate (3.0g, 9.18mmol) and 1- (chloromethyl) -4- (methoxymethyl) benzene (0.72mL, 3.68mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (25 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 20% ethyl acetate in hexane as eluent to give 5-fluoro-1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde as a yellow oil. Yield: 0.52g (60%). MS (ESI): 283.06; m/z found, unionized.
Synthesis of 6-fluoro-1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde (intermediate of example-50)
To a stirred solution of 6-fluoro-1H-indole-2-carbaldehyde (0.5g, 3.06mmol) in N, N-dimethylformamide (20.0 mL) were added cesium carbonate (3.0g, 9.18mmol) and 1-bromo-2-methoxyethane (0.34mL, 3.68mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g RediSep and 20% ethyl acetate in hexane as eluent to give 6-fluoro-1- (4-methoxybenzyl) -1H-indole-2-carbaldehyde as a brown oil. Yield: 0.51g (58%), MS (ESI): 283.1; the measured value of m/z is 284.22[ deg. ] M + H] +1 。
Synthesis of 1- (4-fluorobenzyl) -6-methoxy-1H-indole-2-carbaldehyde (intermediate of example-51)
To a stirred solution of 6-methoxy-1H-indole-2-carbaldehyde (0.70g, 5.5mmol) in N, N-dimethylformamide (10 mL) was added cesium carbonate (5.31g, 16.3mmol) and 1- (bromomethyl) -4-fluorobenzene (1.22g, 5.6 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 5% ethyl acetate in hexane as eluent to give 1- (4-fluorobenzyl) -6-methoxy-1H-indole-2-carbaldehyde as a yellow solid. Yield: 1.0g (90%). MS (ESI): 283.1; the m/z found is 284.18.
Synthesis of 7-chloro-1- (2, 2-difluoroethyl) -1H-indole-2-carbaldehyde (intermediate of example-56)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (0.9g, 5.0 mmol) in N, N-dimethylformamide (20.0 mL) were added cesium carbonate (4.9g, 15mmol) and 2-bromo-1, 1-difluoroethane (0.868g, 6.0 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to give 7-chloro-1- (2, 2-difluoroethyl) -1H-indole-2-carbaldehyde. Yield: 1.46g (crude). MS (ESI): 243.03; measured value of m/z is 244.00[ 2 ], [ M ] +H] +1 。
Synthesis of 7-chloro-1-isobutyl-1H-indole-2-carbaldehyde (intermediate of example-55)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (0.7g, 3.90mmol) in N, N-dimethylformamide (20.0 mL) was added cesium carbonate (3.8g, 11.69mmol) and 1-bromo-2-methylpropane (0.53g, 3.90mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g of RediSep and 5% ethyl acetate in hexane as eluent to give 7-chloro-1-isobutyl-1H-indole-2-carbaldehyde as a yellow oil. Yield: 0.50g (54%). MS (ESI): 235.71; the measured value of m/z is 236.62[ m ] +H ] +1 。
Synthesis of 2- (chloromethyl) -4-methylthiazole (intermediate of example-59)
Step A: (4-Methylthiazol-2-yl) methanol
To a stirred solution of 4-methylthiazole-2-carbaldehyde (1,1.0g, 7 mmol) in MeOH (30 mL) was added sodium borohydride (0.52g, 14mmol) in portions at 0 ℃. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (2X 25 mL). The organic layer was washed with brine (15 mL) solution and dried over anhydrous Na 2 SO 4 Dried and evaporated. The crude residue was purified by gradient column chromatography using 40% to 60% etoac in hexanes to give the product as a light yellow gum. (0.9g, 90%, yield). MS (ESI): c 5 H 7 Mass calculated value of NOS, 129.02; found M/z of 130.1 (M + H) + 。
And B, step B:2- (chloromethyl) -4-methylthiazole
To a stirred solution of (4-methylthiazol-2-yl) methanol (2,0.9g, 6.97mmol) in DCM (5 mL) at 0 deg.C was added SOCl dropwise 2 (0.83mL, 11mmol), and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with cold NaHCO 3 The solution was neutralized (5 mL) and extracted with DCM (2X 25 mL). The organic layer was washed with brine (5 mL) solution over anhydrous Na 2 SO 4 Dried and evaporated to give the product as a yellow oil (1 g). MS (ESI): c 5 H 6 The mass calculation value of ClNS is 146.99; found M/z of 148.1 (M + H) + 。
Synthesis of 7-chloro-1- (cyclobutylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-53)
Step-1 a: preparation of Cyclobutylmethyl methanesulfonate (2 a)
To a stirred solution of cyclobutylmethanol (1a, 2.00g,23.2 mmol) in dichloromethane (20 mL) was added triethylamine (6.50mL, 46.5 mmol) and N, N-dimethylaminopyridine (0.28g, 2.3 mmol) at room temperature, and methanesulfonyl chloride (2.27mL, 27.9 mmol) was added at 0 ℃. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 10% ethyl acetate in hexane as eluent to give cyclobutyl methyl mesylate (2 a) as a colorless oil. Yield: 2.50g (66%); MS (ESI): 164.05; m/z is found to be unionized.
Step 2a: synthesis of 7-chloro-1- (cyclobutylmethyl) -1H-indole-2-carbaldehyde (3 a)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (2b, 0.90g,5.0 mmol) in N, N-dimethylformamide (10 mL) were added cesium carbonate (4.90g, 15.10 mmol) and cyclobutyl methyl methanesulfonate (2a, 0.98g,6.0 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL × 2). Will merge The organic extracts of (a) were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 20% ethyl acetate in hexane as eluent to give 7-chloro-1- (cyclobutylmethyl) -1H-indole-2-carbaldehyde (3 a) as a pale yellow viscous solid. Yield: 0.32g (26%); MS (ESI): 247.08; the measured value of m/z is 248.10[ m ] +H] +1 。
Synthesis of 1- (cyclopropylmethyl) -6-vinyl-1H-indole-2-carbaldehyde (intermediate of example-61)
Step-1a preparation of 6-bromo-1H-indole-2-carboxylic acid methyl ester (2 a)
To a stirred solution of 6-bromo-1H-indole-2-carboxylic acid (1a, 5.0g, 20.83mmol) in methanol (50 mL) was added sulfuric acid (9mL, 1.8vol) at 0 ℃. The reaction mixture was stirred at 80 ℃ for 12 hours. After completion of the reaction, the reaction mixture was quenched with ice, and the precipitated solid was filtered and washed with water (100 mL × 2). The compound obtained was dried under vacuum. The crude product was purified by CombiFlash using 40g Redisep and 10% ethyl acetate in hexane as eluent to give methyl 6-bromo-1H-indole-2-carboxylate (2 a) as a white solid. Yield: 4.5g (86%). MS (ESI): 252.99; measured value of m/z is 253.99[ m ] +H ] +1 。
Step-2 a: preparation of methyl 6-bromo-1- (cyclopropylmethyl) -1H-indole-2-carboxylate (3 a)
1H-indole-2-carbaldehyde (2a, 4.5g, 1) was stirred at room temperature7.85 mmol) in N, N-dimethylformamide (40 mL) was added cesium carbonate (17.4g, 53.27mmol) and (bromomethyl) cyclopropane (2b, 2.8g, 21.42mmol). The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 10% ethyl acetate in hexane as eluent to give methyl 6-bromo-1- (cyclopropylmethyl) -1H-indole-2-carboxylate (3 a) as a white solid. Yield: 4.0g (74%). MS (ESI): 307.18; the measured value of m/z is 308.04[ mu ] M + H] +1 。
Step-3 a: preparation of methyl 1- (cyclopropylmethyl) -6-vinyl-1H-indole-2-carboxylate (4 a)
To a stirred solution of methyl 6-bromo-1- (cyclopropylmethyl) -1H-indole-2-carboxylate (3a, 4.0g, 13.02mmol) in N, N-dimethylformamide (40.0 mL) was added lithium chloride (0.656g, 15.63mmol) and tributylvinyltin (4.9g, 15.63mmol) at room temperature. Argon was purged for 15 minutes and tetrakis (triphenylphosphine) palladium (0) (0.75g, 0.65mmol) was added at room temperature. The reaction mixture was stirred at 90 ℃ for 4 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (40 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 40g Redisep and 5% to 10% ethyl acetate in hexane as eluent to give methyl 1- (cyclopropylmethyl) -6-vinyl-1H-indole-2-carboxylate (4 a) as a brown solid. Yield: 3.1g (92%). MS (ESI): 255.13; the measured value of m/z is 256.11[ deg. ] M + H ] +1 。
Step-4 a: preparation of (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) methanol (5 a)
To a stirred solution of methyl 1- (cyclopropylmethyl) -6-vinyl-1H-indole-2-carboxylate (4a, 2.7g, 10.5mmol) in tetrahydrofuran (30.0 mL) at 0 deg.C was added 1.0M lithium aluminate hydrate in tetrahydrofuran (20mL, 21.0mmol). The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with ammonium chloride and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12.0g Redisep and 20% ethyl acetate in hexane as eluent to give (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) methanol (5 a) as a white solid. Yield: 2.0g (83%). MS (ESI): 227.13; measured value of m/z is 228.13[ m ] +H] +1 。
Step-5 a: preparation of 1- (cyclopropylmethyl) -6-vinyl-1H-indole-2-carbaldehyde
To a stirred solution of (1- (cyclopropylmethyl) -6-vinyl-1H-indol-2-yl) methanol (2.0 g, 8.73mmol) in dichloromethane (20.0 mL) was added tasmadin periodinane (4.4 g, 10.48mmol) at room temperature. The reaction mixture was stirred at room temperature for 4 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 30% ethyl acetate in hexane as eluent to give 1- (cyclopropylmethyl) -6-vinyl-1H-indole-2-carbaldehyde (6 a) as a white solid. Yield: 1.1g (55%). MS (ESI): 225.12 of the total weight of the mixture; m/z found value of 226.12[ m ] +H ] +1 。
Synthesis of 5,6-difluoro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde (intermediate of example-54)
To a stirred solution of 5,6-difluoro-1H-indole-2-carbaldehyde (1,0.50g, 2.76mmol) in N, N-dimethylformamide (10 mL) was added cesium carbonate (2.69g, 8.28mmol) and 1-bromo-2-methoxyethane (0.32mL, 3.31mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 10% ethyl acetate in hexane as eluent to give 5, 6-difluoro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde as a yellow solid. Yield: 0.66g (45%). MS (ESI): 239.08 of the root of Chinese yam; the measured value of m/z is 240.04[ m ] +H] +1 。
Synthesis of 4- (chloromethyl) -3-fluoropyridine hydrochloride (intermediate of example-24)
Step-1 a: preparation of (3-fluoropyridin-4-yl) methanol (2 a)
To a solution of 3-fluoroisonicotinic acid (1M in tetrahydrofuran) (12.0 mL,21.3 mmol) in tetrahydrofuran (20 mL) was added dropwise lithium aluminum hydride (1M in tetrahydrofuran) (12.0 mL,21.3 mmol) at 0 ℃ over 10 minutes, and the reaction mixture was stirred at 0 ℃ for 2 hours. After completion of the reaction, 40% potassium hydroxide solution (60 mL) was added to the reaction mixture. The precipitated solid was filtered off and washed with diethyl ether. The crude product was passed through Combiflash using 12g Redispe and 20% acetic acid in hexane Ethyl ester was purified as eluent to give (3-fluoropyridin-4-yl) methanol (2 a) as an off-white solid. Yield: 0.50g (28%). MS (ESI): 127.04; m/z found value of 128.01[ mu ] M + H] +1 。
Step 2a: preparation of 4- (chloromethyl) -3-fluoropyridine hydrochloride (3 a)
To a stirred solution of (3-fluoropyridin-4-yl) methanol (2a, 0.70g, 5.51mmol) in N, N-dichloromethane (5.0 mL) at 0 deg.C was added thionyl chloride (1.00g, 13.78mmol) and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, dichloromethane was removed under reduced pressure, and the obtained crude product was washed with diethyl ether and dried to give 4- (chloromethyl) -3-fluoropyridine hydrochloride 3a as a light brown solid. Yield: 1.0g (90%). MS (ESI): 180.99 of the total weight of the mixture; the measured value of m/z is 182.02[ m ] +H] + 。
Synthesis of 1- (pyrimidin-2-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-27)
To a stirred solution of 1H-indole-2-carbaldehyde (1,0.70g, 4.82mmol) in N, N-dimethylformamide (10 mL) were added cesium carbonate (7.8g, 24.1mmol) and 2- (chloromethyl) pyrimidine (0.98g, 7.24mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 3 hours. After completion of the reaction, the reaction mixture was cooled to room temperature, diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 10% ethyl acetate in hexane as eluent to give 1- (pyrimidin-2-ylmethyl) -1H-indole-2-carbaldehyde as a brown crystalline solid. Yield: 1.30g (81%). MS (ESI): 237.09; measured value of m/z is 238.14[ 2 ], [ M + [ H ] ] +1 。
Synthesis of 1-isobutyl-1H-indole-2-carbaldehyde (intermediate of example-31)
To a stirred solution of 1H-indole-2-carbaldehyde (1,0.70g, 4.82mmol) in N, N-dimethylformamide (10 mL) were added cesium carbonate (7.8g, 24.1mmol) and 1-bromo-2-methylpropane (0.98g, 7.24mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 10% ethyl acetate in hexane as eluent to give 1-isobutyl-1H-indole-2-carbaldehyde as an oily liquid. Yield: 0.80g (82%). MS (ESI): 201.12; found M/z of 202.30 (M + H) + 。
Synthesis of 1- (2-methoxyethyl) -1H-indole-2-carbaldehyde (intermediate of example-22)
/>
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0 g,6.0 mmol) in N, N-dimethylformamide (6.0 mL) were added cesium carbonate (6.6 g,20.6 mmol) and 1-bromo-2-methoxyethane (0.76mL, 8.0 mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 1.5 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 20% ethyl acetate in hexane as eluent to give 1- (2-methoxyethyl) -1H-indole-2-carbaldehyde as a light yellow solid. Yield: 0.9g (64%). MS (ESI): 203; m/z is found to be unionized.
Synthesis of 7-chloro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde (intermediate of example-36)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (1,0.5g, 2.79mmol) in N, N-dimethylformamide (15 mL) was added cesium carbonate (2.7 g, 8.37mmol) and 1-bromo-2-methoxyethane (0.31ml, 3.35mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (50 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12g Redisep and 20% ethyl acetate in hexane as eluent to give 7-chloro-1- (2-methoxyethyl) -1H-indole-2-carbaldehyde as a yellow oil. Yield: 0.34g (52%). MS (ESI): 237.06; m/z found, unionized.
Synthesis of 1- (4- (methoxymethyl) benzyl) -1H-indole-2-carbaldehyde (intermediate of example-37)
To a stirred solution of 1H-indole-2-carbaldehyde (1,1.0 g,6.0 mmol) in N, N-dimethylformamide (5.0 mL) at room temperature were added cesium carbonate (0.58g, 1.79mmol) and (41- (bromomethyl) -4- (methoxymethyl) benzene (0.14g, 0.72mmol) and the reaction mixture was stirred at room temperature for 3 hours after completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (20 mL. Times.2), the combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure and the crude product was purified by CombiFlash using 12g of Redisp and 5% methanol in dichloromethane as eluent to give 1- (4- (methoxymethyl) benzyl) -1H-indole-2-carbaldehyde.
Synthesis of 1- (cyclopropylmethyl) -5, 6-difluoro-1H-indole-2-carbaldehyde (intermediate of example-32 &77)
Step 1a: preparation of 5, 6-difluoro-1- (phenylsulfonyl) -1H-indole (2)
To a solution of sodium hydride (0.26g, 13mmol) in DMF (10 mL) at 0 ℃ over 15 minutes was added dropwise a solution of 5, 6-difluoro-1H-indole (1, 0.52g, 13mmol) in DMF. Subsequently, a solution of benzenesulfonyl chloride in DMF (1.4g, 13mmol) was added at 0 ℃ and N at room temperature 2 Stirred under atmosphere for 2 hours. Ice-cold water (50 mL) was added to the reaction mixture, then the precipitate was filtered off and washed with ice-cold water to obtain a brown solid. (1g, 26% yield). MS (ESI): m/z 293.0 (M + H) + 。
And step 2b: preparation of 5, 6-difluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3)
To a solution of 5, 6-difluoro-1- (phenylsulfonyl) -1H-indole (2, 1g, 3.42mmol) in anhydrous THF (50 mL) at-78 deg.C was added lithium diisopropylamide 1M in THF (3.4 mL g, 6.84mmol) and stirred for 5 to 8 minutes, followed by N at-78 deg.C 2 Anhydrous DMF (0.5 mL, at-78 ℃ C. And stirring for 10 min) was added under atmosphere. Aqueous ammonium chloride (20 mL) was added to the reaction mixture, which was then extracted into EtOAc. The organic layer was treated with saturated NH 4 The Cl solution and brine were washed, dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a brown solid (0.7 g, 70%). MS (ESI): m/z 322.0 (M + H) + 。
And step 3c: preparation of 5, 6-difluoro-1H-indole-2-carbaldehyde (4)
To a stirred solution of 5, 6-difluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3, 0.8g, 2.49mmol) in THF (50 mL) was added TBAF (1M in THF) (9.15mL, 12.45mmol) at room temperature. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 15% to 25% ethyl acetate in hexane to give 5-fluoro-1H-indole-2-carbaldehyde as a sticky solid (0.4 g,88% yield), MS (ESI): c 9 H 5 F 2 Mass calculated value of NO, 181.145; m/z found 182 (M + H) + 。
And 4d: preparation of 1- (cyclopropylmethyl) -5, 6-difluoro-1H-indole-2-carbaldehyde (5)
To a stirred solution of 5,6-difluoro-1H-indole-2-carbaldehyde (4,0.3g, 1.65mmol) in DMF (20 mL) at room temperature was added potassium carbonate (0.68g, 4.97mmol) and (bromomethyl) cyclopropane (4 a,0.16mL, 1.82mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 3% to 7% ethyl acetate in hexane to give 1- (cyclopropylmethyl) -5, 6-difluoro-1H-indole-2-carbaldehyde as an off-white solid (0.2g, 48% yield).
MS(ESI)：C 13 H 11 F 2 Calculated mass NO of 235.23; m/z found value of 236.1[ m ] +H] + 。
Synthesis of 1- (cyclopropylmethyl) -4-fluoro-1H-indole-2-carbaldehyde (intermediate of example-80)
Step 1: preparation of 4-fluoro-1- (phenylsulfonyl) -1H-indole (2)
To a solution of sodium hydride (0.88g, 22.2 mmol) in DMF (50 mL) at 0 deg.C over 15 minutes was added dropwise a solution of 4-fluoro-1H-indole (1, 3.0g,22.2 mmol) in DMF. Benzenesulfonyl chloride in DMF (2.86mL, 22.2mmol) was added at 0 deg.C and at room temperature under N 2 Stirred under atmosphere for 2 hours. Ice-cold water (50 mL) was added to the reaction mixture, then the precipitate was filtered off and washed with ice-cold water to obtain a white solid. (7.0 g-crude).
Step 2: preparation of 4-fluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (3)
To a solution of 4-fluoro-1- (phenylsulfonyl) -1H-indole (2, 7.0g, 22.0mmol) in anhydrous THF (60 mL) at-78 deg.C was added lithium diisopropylamide 2M in THF (10.9mL, 22.0mmol), and stirred for 5 to 8 minutes, followed by addition of anhydrous DMF (2.5mL, 33.0mmol) at-78 deg.C, and N at-78 deg.C 2 Stirred under atmosphere for 10 minutes. Aqueous ammonium chloride (20 mL) was added to the reaction mixture, which was then extracted into EtOAc. The organic layer was treated with saturated NH 4 The Cl solution and brine were washed, dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a red liquid (6.80g, 88.31%).
And step 3: preparation of 4-fluoro-1H-indole-2-carbaldehyde (4)
To a solution of 4-fluoro-1- (phenylsulfonyl) -1H-indole-2-carbaldehyde (4,3.0g, 9.9mmol) in anhydrous THF (20 mL) was added tetrabutylammonium fluoride 1M in THF (14.8 mL), and the reaction mixture was stirred at room temperature for about 12 hours. The reaction mixture was quenched with water, and then extracted with ethyl acetate (50 mL × 3). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 5% to 10% ethyl acetate in hexane to give the product as a yellow solid. (yield: 99%,1.6 g). MS (ESI): c 9 H 6 The mass calculated value of FNO was 163.04; m/z found 164 (M + H) + 。
Step-4: preparation of 1- (cyclopropylmethyl) -4-fluoro-1H-indole-2-carbaldehyde (5)
To a stirred solution of 4-fluoro-1H-indole-2-carbaldehyde (4,1.6 g,9.877 mmol) in DMF (10 mL) was added potassium carbonate (6.8g, 49.38mmol) followed by (bromomethyl) cyclopropane (6,1.4 mL, 10.65mmol) and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (30 mL. Times.2). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude product. The crude residue was purified by gradient column chromatography using 5% to 10% ethyl acetate in hexane to give the product as a brown liquid. (yield: 47.6%,1 g).
MS(ESI)：C 13 H 12 The calculated mass value of FNO was 217.24; measured value of m/z is 218[ m ] +H] + 。
Synthesis of 7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (intermediate of example-87)
Step-1 a: synthesis of methyl 2-azidoacetate (2 a)
To a stirred solution of methyl 2-bromoacetate (1a, 20.0g,131.5 mmol) in N, N-dimethylformamide (40.0 mL) at 0 ℃ was added sodium azide (10.2g, 157.8mmol). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressureFollowed by concentration to obtain methyl 2-azidoacetate (2 a) as an oily liquid. Yield: 11.2g (74%). ELSD MS (ESI): 115.04; m/z found value of 116.10[ m ] +H] +1 。
Step-2 a: synthesis of methyl (Z) -2-azido-3- (3-chloro-4-fluorophenyl) acrylate (3 a)
To a stirred solution of methanol (25 mL) was added metallic sodium (1.09g, 47.46mmol) at room temperature, and allowed to stir at room temperature for 10 minutes. A solution of methyl 2-azidoacetate (2a, 2.50g, 15.80mmol) and 3-chloro-4-fluorobenzaldehyde (2b, 6.10g, 53.70mmol) in methanol (5.0 mL) was added at-15 ℃. The reaction mixture was stirred at-15 ℃ for 4 hours. After the reaction was complete, the reaction mixture was neutralized to pH 7 with 1N hydrogen chloride at 0 ℃. The precipitated solid was filtered and washed with water (10 mL. Times.2). The obtained compound was dried under vacuum to obtain methyl (Z) -2-azido-3- (3-chloro-4-fluorophenyl) acrylate (3 a) as a pale yellow solid. Yield: 1.8g (45%). MS (ESI): 255.02; the measured value of m/z is 256.25[ deg. ] M + H ] +1 . Step-3 a: synthesis of methyl 7-chloro-6-fluoro-1H-indole-2-carboxylate (4 a)
A stirred solution of methyl (Z) -2-azido-3- (3-chloro-4-fluorophenyl) acrylate (3a, 1.80g, 7.05mmol) in p-xylene (80.0 mL) was refluxed at 140 ℃ for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The crude product obtained was purified by CombiFlash using 40.0g RediSep column. The desired methyl 7-chloro-6-fluoro-1H-indole-2-carboxylate (4 a) was obtained in 2% ethyl acetate in hexane and methyl 5-chloro-6-fluoro-1H-indole-2-carboxylate (4 b) was obtained in 5% ethyl acetate in hexane. The desired fractions were concentrated to give methyl 7-chloro-6-fluoro-1H-indole-2-carboxylate (4 a) as a pale brown solid. Yield: 1.1g (crude). MS (Mass Spectrometry)(ESI): 227.01; the measured value of m/z is 228.01[ mu ] M + H] +1 。
Step-4 a: synthesis of (7-chloro-6-fluoro-1H-indol-2-yl) methanol (5 a)
To a stirred solution of methyl 7-chloro-6-fluoro-1H-indole-2-carboxylate (4a, 1.0g, 4.4mmol) in tetrahydrofuran (20.0 mL) at 0 deg.C was added 1.0M lithium aluminate hydrate in tetrahydrofuran (8.8mL, 8.80mmol). The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was diluted with ammonium chloride and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 40g RediSep column and 20% ethyl acetate in hexane as eluent to give (7-chloro-6-fluoro-1H-indol-2-yl) methanol (5 a) as a viscous solid. Yield: 8.24g (91%). MS (ESI): 199.02; m/z found value of 200.05[ mu ] M + H ] +1 。
Step-5 a: synthesis of 7-chloro-6-fluoro-1H-indole-2-carbaldehyde (6 a)
To a stirred solution of (7-chloro-6-fluoro-1H-indol-2-yl) methanol (5a, 0.80g, 4.00mmol) in dichloromethane (30.0 mL) was added persimmodineproodane (3.4 g, 8.00mmol) at room temperature. The reaction mixture was stirred at room temperature for 4 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with dichloromethane (20 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12.0g RediSep column and 2% to 5% ethyl acetate in hexane as eluent to give 7-chloro-6-fluoro-1H-indole-2-methanol (6 a) as a white solid. Yield: 0.63g (75%). MS (ESI): 197.0; the measured value of m/z is,is 198.12 2[ m ] +H] +1 。
Step-6 a: synthesis of 7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (7 a)
To a stirred solution of 7-chloro-6-fluoro-1H-indole-2-carbaldehyde (6 a,0.30g, 1.52mmol) in N, N-dimethylformamide (15.0 mL) was added cesium carbonate (1.40g, 4.56mmol) and (bromomethyl) cyclopropane (6 b,0.29mL, 3.04mmol) at room temperature. The reaction mixture was stirred at 60 ℃ for 30 minutes. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using a 12.0g red sepp column and 10% ethyl acetate in hexane as eluent to give 7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indole-2-carbaldehyde (7 a) as a viscous solid. Yield: 0.33g (88%). MS (ESI): 251.05; measured value of m/z is 252.25[ 2 ], [ M + H ] ] +1 。
Synthesis of 7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indole-2-carbaldehyde (intermediate of example-88)
To a stirred solution of 7-chloro-1H-indole-2-carbaldehyde (1a, 0.500g, 2.79mmol) in N, N-dimethylformamide (10.0 mL) was added cesium carbonate (2.7 g, 8.37mmol) and 5- (chloromethyl) pyrimidine hydrochloride (1b, 0.429g, 3.34mmol) at room temperature. The reaction mixture was stirred at room temperature for about 16 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (10 mL × 2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash using 12.0g Redisep and 30% ethyl acetate in hexane as eluent to give 7-chloro-1- (pyrimidine as a yellow solid-5-ylmethyl) -1H-indole-2-carbaldehyde (2 a). Yield: 0.260g (34%). MS (ESI): 271.10; measured value of m/z is 272.19[ m ] +H] +1 。
And (3) biological determination:
FP binding assay
Binding of the compound to the PAD4 enzyme was detected by FP assay. PAD4 enzyme was diluted to 1uM in assay buffer (100mM HEPES,50mM NaCl,1mM DTT,5% glycerol and 1mM CHAPS) and added to wells containing different concentrations of compound or DMSO vehicle (1%) in 384-well blanks. 10nM fluorescein-labeled probe (JPAD-00085) was added to the plate. The assay plates were incubated at room temperature for 60 min, and the FP read of the FP module (. Lamda.ex 485/lamda.em 535 nm) was then measured on the Pheastar. Computing IC Using XL-fit software model 205 50 (see: nat Chem biol.2015Mar;11 (3): 189-91).
Biochemical determination of ammonia release
Citrullination assay by ammonia release detection (Citrullination assay). PAD4 enzyme was diluted to 120nM in assay buffer (100mM HEPES,50mM NaCl,2mM DDT,0.6mg/mL BSA, pH 7.4) and added to wells containing different concentrations of compound or DMSO vehicle (1% final) in blank 384-well plates. After a pre-incubation of 60 min at room temperature, the reaction was initiated by addition of substrate (1.5 mM BAEE,50mM NaCl,350uM CaCl2, 2mM, pH 7.4 in 200mM HEPES). The reaction was stopped after 60 minutes by adding stop/detection buffer containing 50mM EDTA,2.6mM o-phthalaldehyde, and 2.6mM DTT. The assay was incubated at room temperature for 90 minutes and then fluorescence was measured on a Tecan reader (λ ex 405/λ em 460 nm). Computing IC Using XL-fit software model 205 50 . (see: nat Chem biol.2015Mar;11 (3): 189-91).
anti-PAD 4 activity:
table 1 below shows the activity of selected compounds of the present disclosure in the PAD4 assay described above. Compounds having activity designated "A" specify IC 50 <1uM; compounds having activity designated "B" specify IC 50 Is 1 to 10uM; and has a designation of Compounds with "C" activity specify IC 50 >10uM。
Table 1: PAD4 enzyme Activity
/>
/>
/>
nd = undetermined
Table 1 illustrates that most compounds (from examples 1 to 88) were found to be active against the PAD4 enzyme when evaluated by ammonia release biochemical assay and FP binding assay. IC (integrated circuit) 50 Values show the potency of the compounds to inhibit PAD4 enzyme activity. IC (integrated circuit) 50 The value represents how much of a particular drug or compound is required to inhibit a given biological process or component of a process, such as an enzyme. IC (integrated circuit) 50 Low values of (a) indicate high inhibitory potency of the test compound (examples 1 to 88 as described herein). However, in Table 1 above, the high effective forces are represented by "A", "B", and "C", where "A" has the smallest IC 50 The value, and thus the most efficient.
Biochemical ammonia release assay showed 62 of 88 compounds showed IC 50 The value < 1. Mu.M, which is indicated by "A". These 62 compounds are examples-1, 8 to 13, 15 to 28, 31 to 37, 39, 41, 46 to 51, 53, 55 to 57, 59 to 61, 63 to 67, 69 to 78 and 84 to 88.
In another aspect, the FP binding assay showed that 13 of the 23 test compounds were effective in inhibiting PAD4 enzyme activity. Examples 8 to 12, 14, 19, 63 to 65, 72, 73 and 77, respectively.
Thus, it can be concluded that examples-1, 8 to 13, 15 to 28, 31 to 37, 39, 41, 46 to 51, 53, 55 to 57, 59 to 61, 63 to 67, 69 to 78, and 84 to 87 were identified as potential drugs that could alleviate PAD4 enzyme activity and thus treat PAD4 mediated diseases, and could be developed.

Claims (20)

1. Compounds of formula (I), stereoisomers and pharmaceutically acceptable salts thereof,
wherein:
x is selected from O or S;
y is selected from O or N;
z is N;
a is CR 1 ；
B is CR 2 ；
n is 0 to 1;
R 1 and R 2 Independently selected from hydrogen or C 1-6 An alkyl group;
R 3 absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl, or SO 2 C 5-6 Aryl, wherein:
C 1-6 alkyl, (CO) C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution;
R 10 and R 11 Taken together, form a 5-to 6-membered monocyclic saturated heterocycle wherein:
said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s);
R 12 、R 13 、R 14 and R 15 Independent of each otherIs selected from hydrogen or C 1-6 An alkyl group; and is
R 16 Is a 5 to 10 membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from N or S, wherein,
the 5-to 10-membered bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl or C 1-6 alkyl-C 1-6 Heteroaryl of which C is 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, halogen, hydroxy, -CH 2 OH or-COOH.
2. A compound of formula (I), its stereoisomers and pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein:
x is selected from O or S;
y is selected from O or N;
z is N;
a is CR 1 ；
B is CR 2 ；
n is 0 to 1;
R 1 and R 2 Independently selected from hydrogen or C 1-6 An alkyl group;
R 3 absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl or SO 2 C 5-6 Aryl radical, wherein SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution;
R 10 and R 11 Are formed togetherA 5 to 6 membered monocyclic saturated heterocycle, wherein:
said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s);
R 12 、R 13 、R 14 and R 15 Independently selected from hydrogen or C 1-6 An alkyl group; and is provided with
R 16 Is a 5 to 10 membered bicyclic heteroaryl group having 1 to 5 heteroatoms selected from N or S, wherein,
The 5-to 10-membered bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl or C 1-6 alkyl-C 1-6 Heteroaryl of which C is 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, halogen, hydroxy, -CH 2 OH or-COOH.
3. A compound of formula (I), its stereoisomers and pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein:
x is selected from O or S;
y is selected from O or N;
z is N;
a is CR 1 ；
B is CR 2 ；
n is 0 to 1;
R 1 and R 2 Independently selected from hydrogen or C 1-6 An alkyl group;
R 3 absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl or SO 2 C 5-6 Aryl radical, wherein SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution;
R 10 and R 11 Taken together, form a 5-to 6-membered monocyclic saturated heterocycle wherein:
said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 2-4 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s); and
R 16 is a 5 to 10 membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from N or S, wherein,
The 5-to 10-membered bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl or C 1-6 alkyl-C 1-6 Heteroaryl of which C is 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heterocyclyl is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, halogen, hydroxy, -CH 2 OH or-COOH.
4. A compound of formula (I), its stereoisomers and pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein:
x is selected from O or S;
y is selected from O or N;
z is N;
a is CR 1 ；
B is CR 2 ；
n is 0 to 1;
R 1 and R 2 Independently is hydrogen;
R 3 absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl, SO 2 C 5-6 Aryl radicals or SO 2 C 1-6 Alkyl radical, wherein SO 2 C 1-6 Alkyl and SO 2 C 5-6 Aryl being optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution;
R 10 and R 11 Taken together, form a 5-to 6-membered monocyclic saturated heterocycle wherein:
said 5-to 6-membered monocyclic saturated heterocycle is optionally substituted with a substituent selected from amino, -NHC (O) CH = CHCH 2 N(CH 3 ) 2 Or C 1-6 Substituted with alkyl amino;
R 12 、R 13 、R 14 and R 15 Independently selected from hydrogen or C 1-6 An alkyl group; and
R 16 Is a 5 to 10 membered bicyclic heteroaryl having 1 to 2 heteroatoms selected from N or S, wherein:
the 5-to 10-membered bicyclic heteroaryl is optionally substituted with 1 to 3 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, halogen, hydroxy, -CH 2 OH or-COOH.
5. Compounds of formula (II), stereoisomers thereof and pharmaceutically acceptable salts thereof,
wherein:
x is selected from O or S;
y is selected from O or N;
z is N;
a is CR 1 ；
B is CR 2 ；
D is selected from N or CR 5 ；
E is CR 6 ；
F is CR 7 ；
G is CR 8 ；
n is 1 to 2;
R 1 、R 2 and R 9 Independently selected from hydrogen or C 1-6 An alkyl group;
R 5 、R 6 、R 7 and R 8 Independently selected from hydrogen, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 2-6 alkenyl-C 5-6 Aryl or C 1-6 A heteroaryl group;
R 3 absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl or SO 2 C 5-6 Aryl radical, wherein, C 1-6 Alkyl, (CO) C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution;
R 4 is selected from C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl or C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl is optionalSubstituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH or-COOH; and
R 10 and R 11 May together form a 5-to 6-membered monocyclic saturated heterocycle, wherein:
said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 。
6. Compounds of formula (III), stereoisomers thereof and pharmaceutically acceptable salts thereof,
wherein:
x is selected from O or S;
y is selected from O or N;
z is N;
n is 1 to 2;
R 1 、R 2 and R 9 Independently selected from hydrogen or C 1-6 An alkyl group;
R 5 、R 6 、R 7 and R 8 Independently selected from hydrogen, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 2-6 alkenyl-C 5-6 Aryl or C 1-6 (ii) a heteroaryl group, wherein,
R 3 absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl or SO 2 C 5-6 Aryl radical, wherein, C 1-6 Alkyl, (CO) C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution;
R 4 is selected from C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl or C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH or-COOH; and
R 10 and R 11 May together form a 5 to 6 membered monocyclic saturated heterocycle wherein:
said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 Is substituted with the substituent(s).
7. A compound of formula (I) as claimed in claim 1 or its stereoisomers and pharmaceutically acceptable salts thereof, selected from:
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-Aminopyrrolidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1-ethyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(2- (aminomethyl) piperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1-ethyl-1H-pyrrolo [2,3-b ] pyridin-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (1- (1- (cyclopropylmethyl) -1H-indol-2-yl) -8, 9-dihydro-7H-6-oxa-2, 9 a-diaza-benzo [ cd ] azulen-4-yl) methanone,
(R) - (3-Aminopyrrolidin-1-yl) (1- (1- (cyclopropylmethyl) -1H-indol-2-yl) -8, 9-dihydro-7H-6-oxa-2, 9 a-diaza-benzo [ cd ] azulen-4-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -7-methyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-4-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (3-ethylbenzo [ b ] thiophen-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-chlorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (2-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-dimethoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1-benzyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (6-methoxy-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (2-hydroxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyrazin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyrimidin-2-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridazin-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1-isobutyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-difluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- ((3-fluoropyridin-2-yl) methyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- ((3-fluoropyridin-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (4- (hydroxymethyl) benzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone trifluoroacetic acid, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable salt thereof,
(R, E) -N- (1- (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthene-7-carbonyl) piperidin-3-yl) -4- (dimethylamino) but-2-enamidotrifluoroacetic acid,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclobutylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) -2- (2- (7- (3-aminopiperidine-1-carbonyl) -3, 4-dihydro-5-oxa-1, 2a diazacenaphthen-2-yl) -1H-indol-1-yl) acetic acid,
(R) - (3-aminopiperidin-1-yl) (2- (1- (piperidin-4-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (oxetan-3-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- ((1-methylpiperidin-4-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (5-fluoro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (2, 2-difluoroethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (5-fluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- (4-fluorobenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (6-fluoro-1- (4-methoxybenzyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (4-fluorobenzyl) -6-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(3-aminopiperidin-1-yl) (2- (6-fluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclobutylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (5, 6-difluoro-1- (2-methoxyethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1-isobutyl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (2, 2-difluoroethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R, E) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-styryl-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- ((4-methylthiazol-2-yl) methyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-methoxy-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6- (hydroxymethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -3, 3-dimethyl-3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-3-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (5-bromo-1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5- (pyridin-3-yl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-2-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (2-fluorobenzyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (pyridin-4-ylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -6-methoxy-1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5-fluoro-1H-indol-2-yl) -6-methyl-5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (methylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -5, 6-difluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (6-cyclopropyl-2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (phenethylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -4-fluoro-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (6- ((4-chlorophenyl) sulfonyl) -2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- (cyclopropylsulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -6- ((2-ethoxy) sulfonyl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -7-methyl-1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanone,
(R) -1- (8- (3-aminopiperidine-1-carbonyl) -2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -4, 5-dihydro-6H-imidazo [1,5,4-de ] quinoxalin-6-yl) ethan-1-one,
(R) - (3-aminopiperidin-1-yl) (2- (1- (cyclopropylmethyl) -1H-indol-2-yl) -5, 6-dihydro-4H-imidazo [1,5,4-de ] quinoxalin-8-yl) methanethione,
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (cyclopropylmethyl) -6-fluoro-1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone, and
(R) - (3-aminopiperidin-1-yl) (2- (7-chloro-1- (pyrimidin-5-ylmethyl) -1H-indol-2-yl) -3, 4-dihydro-5-oxa-1, 2a-diazacenaphthen-7-yl) methanone.
8. A process for the preparation of a compound of formula (I) as claimed in any one of claims 1 to 4 and 7 or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, which process comprises reacting formula (IV) with R 16 C (O) H reaction:
wherein R of the formula (IV) 19 Selected from nitro or C 1-6 An alkoxy group; r 16 R of C (O) H 16 Is a 5 to 10 membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from N or S, wherein the 5 to 10 membered bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 alkyl-C 5-6 Aryl radical、C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl or C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, halogen, hydroxy, -CH 2 OH or-COOH; x of formula (I) is selected from O or S; y is selected from O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a n is 0 to 1; r 1 And R 2 Independently selected from hydrogen or C 1-6 An alkyl group; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl or SO 2 C 5-6 Aryl radical, wherein, C 1-6 Alkyl, (CO) C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution; r is 10 And R 11 Together form a 5-to 6-membered monocyclic saturated heterocycle, wherein said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s); r is 12 、R 13 、R 14 And R 15 Independently selected from hydrogen or C 1-6 An alkyl group; r is 16 Is a 5 to 10 membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from N or S, wherein the 5 to 10 membered bicyclic heteroaryl is optionally substituted with 1 to 5 substituents selected from: halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Haloalkyl, C 1-6 alkyl-C 5-6 Aryl radical, C 2-6 alkenyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic group, C 1-6 Heteroaryl or C 1-6 alkyl-C 1-6 Heteroaryl of which C is 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heteroaryl and C 1-6 alkyl-C 1-6 The heterocyclic group is optionally substituted by one or more groups selected from hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, halogen, hydroxy, -CH 2 OH or-COOH.
9. A process for preparing a compound of formula (II) as defined in any one of claims 1 to 5 and 7, or a stereoisomer thereof and pharmaceutically acceptable salts thereof, which process comprises reacting formula (IV) with formula (V):
wherein R of formula (IV) 19 Selected from nitro or C 1-6 An alkoxy group; x of formula (II) is selected from O or S; y is selected from O or N; z is N; a is CR 1 (ii) a B is CR 2 (ii) a D is selected from N or CR 5 (ii) a E is CR 6 (ii) a F is CR 7 (ii) a G is CR 8 (ii) a n is 1 to 2; r 1 、R 2 And R 9 Independently selected from hydrogen or C 1-6 An alkyl group; r 5 、R 6 、R 7 And R 8 Independently selected from hydrogen halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 2-6 alkenyl-C 5-6 Aryl and C 1-6 A heteroaryl group; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl or SO 2 C 5-6 Aryl radical, wherein, C 1-6 Alkyl, (CO) C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution; r 4 Is selected from C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl or C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH or-COOH; r is 10 And R 11 May together form a 5-to 6-membered monocyclic saturated heterocycle, wherein said 5-to 6-membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with a substituent of (1); d of formula (V) is selected from N or CR 5 (ii) a E is CR 6 (ii) a F is CR 7 (ii) a G is CR 8 ；R 9 Is hydrogen or C 1-6 An alkyl group; and R is 4 Is selected from C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic radicals or C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH or-COOH.
10. A process for preparing a compound of formula (III) as defined in any one of claims 6 to 7 or stereoisomers thereof and pharmaceutically acceptable salts thereof, which process comprises reacting formula (IV) with formula (VI):
wherein R of formula (IV) 19 Selected from nitro radicalsOr C 1-6 An alkoxy group; x of formula (III) is selected from O or S; y is O or N; z is N; n is 1 to 2; r 1 、R 2 And R 9 Independently selected from hydrogen or C 1-6 An alkyl group; r is 5 、R 6 、R 7 And R 8 Independently selected from hydrogen, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 2-6 alkenyl-C 5-6 Aryl or C 1-6 A heteroaryl group; r 3 Absent or selected from hydrogen, C 1-6 Alkyl radical, C 3-6 Cycloalkyl, C (O) C 1-6 Alkyl, SO 2 C 1-6 Alkyl, SO 2 C 3-6 Cycloalkyl or SO 2 C 5-6 Aryl radical, wherein, C 1-6 Alkyl, (CO) C 1-6 Alkyl, SO 2 C 5-6 Aryl and SO 2 C 1-6 Alkyl is optionally substituted by C 1-6 Alkoxy, halogen or C 5-6 Aryl substitution; r 4 Is selected from C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic radicals or C 1-6 alkyl-C 1-6 Heteroaryl of which C is 1-6 Alkyl radical C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH or-COOH; r 10 And R 11 May together form a 5 to 6 membered monocyclic saturated heterocycle, wherein said 5 to 6 membered monocyclic saturated heterocycle is optionally selected from amino, C 1-6 Alkylamino or-NHC (O) CH = CHCH 2 N(CH 3 ) 2 Substituted with the substituent(s); r of the formula (IV) 9 Is hydrogen or C 1-6 An alkyl group; r is 5 、R 6 、R 7 And R 8 Independently selected from hydrogen, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 2-6 alkenyl-C 5-6 Aryl or C 1-6 A heteroaryl group; and R 4 Is selected from C 1-6 Alkyl radical, C 1-6 Haloalkyl, C 1-6 Alkoxy radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclic radicals or C 1-6 alkyl-C 1-6 Heteroaryl of which C 1-6 Alkyl radical, C 1-6 alkyl-C 5-6 Aryl radical, C 1-6 alkyl-C 1-6 Heterocyclyl and C 1-6 alkyl-C 1-6 Heteroaryl is optionally substituted with one or more groups selected from: hydrogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-8 Cycloalkyl radical, C 5-6 Aryl radical, C 1-6 Heteroaryl, halogen, hydroxy, -CH 2 OH or-COOH.
11. A pharmaceutical composition comprising a compound of formula (I), formula (II) and formula (III), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7, and a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
12. The pharmaceutical composition of claim 11, wherein the composition is in a form selected from the group consisting of a tablet, a capsule, a powder, a syrup, a solution, an aerosol, and a suspension.
13. A compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for inhibiting one or more PAD in a cell.
14. Use of an effective amount of a compound of any one of claims 1 to 7 in the manufacture of a medicament for inhibiting one or more PAD families in a cell.
15. Use of a compound according to any one of claims 1 to 7 or a pharmaceutical composition according to any one of claims 11 or 12 for the manufacture of a medicament for the treatment of a PAD4 mediated disorder.
16. A compound as claimed in any one of claims 1 to 7 for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus and psoriasis.
17. Use of a compound according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 11 or 12 for the preparation of a medicament for the treatment and/or prophylaxis of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis, wherein the medicament is in combination with other clinically relevant or biological agents.
18. Use of a compound according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 11 or 12 for the manufacture of a medicament for the treatment and/or prevention of acid-induced lung injury, respiratory distress syndrome, allergen-induced asthma, allergic bronchopulmonary disease, chronic lung disease of premature infants, chronic obstructive pulmonary disease, colitis, cystic fibrosis, gouty arthritis, inflammatory bowel disease, inflammatory lung disease, inflammatory pain, juvenile rheumatoid arthritis, kidney disease, kidney injury caused by parasite infection, kidney transplant rejection prevention, lung injury, lupus nephritis, multiple sclerosis, muscular dystrophy, non-allergen-induced asthma, osteoarthritis, periodontitis, peritoneal endometriosis, psoriasis, lung disease, pulmonary fibrosis, suppurative arthritis, kidney disease, rheumatic disease, rheumatoid arthritis, sepsis, severe pain and ulcerative colitis, wherein the medicament is in combination with other clinically relevant or biological agents.
19. Use of a combination of a compound according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 11 or 12 in the manufacture of a medicament for the treatment of rheumatoid arthritis, wherein the medicament is in combination with other clinically relevant or biological agents.
20. Use of a combination of a compound according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 11 or 12 in the manufacture of a medicament for the treatment of cancer, wherein the medicament is in combination with other clinically relevant immunomodulators.
HK62020018519.2A 2017-09-22 2018-09-20 Heterocyclic compounds as pad inhibitors HK40028776B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201741033768 2017-09-22

Publications (2)

Publication Number Publication Date
HK40028776A HK40028776A (en) 2021-02-05
HK40028776B true HK40028776B (en) 2023-10-13

Family

ID=

Similar Documents

Publication Publication Date Title
CN111108105B (en) Heterocyclic compounds as PAD inhibitors
CN111225915B (en) Imidazopyridine compounds as PAD inhibitors
ES2924522T3 (en) Heteroaryl inhibitors of PAD4
JP2009526855A (en) Alphacarboline and its use
JP5126830B2 (en) Pyrrolo [3,2-c] pyridine derivative and method for producing the same
HK40028776B (en) Heterocyclic compounds as pad inhibitors
HK40028776A (en) Heterocyclic compounds as pad inhibitors
US20250302842A1 (en) Heterocyclic compounds useful for treatment of cancers
RU2782743C2 (en) Imidazopyridine compounds as pad inhibitors
RU2782743C9 (en) Imidazopyridine compounds as pad inhibitors
HK40036619A (en) Imidazo-pyridine compounds as pad inhibitors
HK40036619B (en) Imidazo-pyridine compounds as pad inhibitors
CN116217543A (en) Novel CCR3 inhibitor compound and application thereof
KR20080002935A (en) Pyrazolo [1,5-a] pyridine derivatives or pharmaceutically acceptable salts thereof
CA3008653A1 (en) Bruton&#39;s tyrosine kinase inhibitors